EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 98

Results Generated From:
Embase <1980 to 2023 Week 36>
Embase Weekly Updates (updates since 2023-09-01)

<1>
Accession Number
2026717571
Title
Outcomes Based on Angiographic vs Functional Significance of Complex
3-Vessel Coronary Disease: FAME 3 Trial.
Source
JACC: Cardiovascular Interventions. 16(17) (pp 2112-2119), 2023. Date of
Publication: 11 Sep 2023.
Author
Kobayashi Y.; Takahashi T.; Zimmermann F.M.; Otsuki H.; El Farissi M.;
Oldroyd K.G.; Wendler O.; Reardon M.J.; Woo Y.J.; Yeung A.C.; De Bruyne
B.; Pijls N.H.J.; Fearon W.F.
Institution
(Kobayashi) New York-Presbyterian Brooklyn Methodist Hospital, Weill
Cornell Medical College, Brooklyn, NY, United States
(Takahashi) Jacobi Medical Center, Albert Einstein College of Medicine,
Bronx, NY, United States
(Zimmermann, El Farissi, Pijls) Catharina Hospital, Eindhoven, Netherlands
(Otsuki, Woo, Yeung, Fearon) Stanford University School of Medicine and
Stanford Cardiovascular Institute, Stanford, CA, United States
(Oldroyd) University of Glasgow, Glasgow, United Kingdom
(Wendler) King's College Hospital, London, United Kingdom
(Reardon) Houston Methodist Hospital, Houston, TX, United States
(De Bruyne) Cardiovascular Center Aalst, Aalst, Belgium
(Fearon) VA Palo Alto Medical Systems, Palo Alto, CA, United States
Publisher
Elsevier Inc.
Abstract
Background: The functional SYNTAX score (FSS), which incorporates
functional information as assessed by fractional flow reserve (FFR), is a
better predictor of outcome after percutaneous coronary intervention (PCI)
in patients with less complex coronary artery disease (CAD).
 Objective(s): This study sought to test the prognostic value of the
FSS in patients with complex CAD eligible for coronary artery bypass
grafting (CABG). Method(s): The FAME 3 (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation 3) trial compared FFR-guided
PCI with CABG in patients with angiographic 3-vessel CAD. In this
prespecified substudy, the angiographic core laboratory calculated the
SYNTAX score (SS) and then the FSS by eliminating lesions that were not
significant based on FFR. Outcomes in the PCI patients based on the FSS
and the SS were compared to each other and to the patients treated with
CABG. Result(s): The FSS reclassified more than one-quarter of
patients from an SS >22 to an FSS <=22. In the 50% of PCI patients who had
an FSS <=22, the primary endpoint occurred at a similar rate to patients
treated with CABG (P = 0.77). The primary endpoint in patients without
functionally significant 3-vessel CAD was similar to the CABG group (P =
0.97). The rate of myocardial infarction and revascularization among all
deferred lesions was 0.5% and 3.2%, respectively. Conclusion(s): By
measuring the FSS, one can identify 50% of patients who have a similar
outcome at 1 year with PCI compared with CABG. Lesions deferred from PCI
based on FFR have a low event rate. Copyright © 2023 American
College of Cardiology Foundation

<2>
Accession Number
2026706502
Title
Heart Transplant and Donors After Circulatory Death: A
Clinical-Preclinical Systematic Review.
Source
Journal of Surgical Research. 292 (pp 222-233), 2023. Date of Publication:
December 2023.
Author
DiChiacchio L.; Goodwin M.L.; Kagawa H.; Griffiths E.; Nickel I.C.;
Stehlik J.; Selzman C.H.
Institution
(DiChiacchio, Goodwin, Kagawa, Griffiths, Nickel, Selzman) Division of
Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, United
States
(Stehlik) Division of Cardiology, University of Utah, Salt Lake City, UT,
United States
Publisher
Academic Press Inc.
Abstract
Introduction: Heart transplantation is the treatment of choice for
end-stage heart failure. There is a mismatch between the number of donor
hearts available and the number of patients awaiting transplantation.
Expanding the donor pool is critically important. The use of hearts
donated following circulatory death is one approach to increasing the
number of available donor hearts. Material(s) and Method(s): A
systematic review was performed according to the Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA) guidelines utilizing
Pubmed/MEDLINE and Embase. Articles including adult human studies and
preclinical animal studies of heart transplantation following donation
after circulatory death were included. Studies of pediatric populations or
including organs other than heart were excluded. Result(s): Clinical
experience and preclinical studies are reviewed. Clinical experience with
direct procurement, normothermic regional perfusion, and machine perfusion
are included. Preclinical studies addressing organ function assessment and
enhancement of performance of marginal organs through preischemic,
procurement, preservation, and reperfusion maneuvers are included.
Articles addressing the ethical considerations of thoracic transplantation
following circulatory death are also reviewed. Conclusion(s): Heart
transplantation utilizing organs procured following circulatory death is a
promising method to increase the donor pool and offer life-saving
transplantation to patients on the waitlist living with end-stage heart
failure. There is robust ongoing preclinical and clinical research to
optimize this technique and improve organ yield. There are also ongoing
ethical considerations that must be addressed by consensus before wide
adoption of this approach. Copyright © 2023 Elsevier Inc.

<3>
Accession Number
2026549343
Title
Evolution of the covered endovascular reconstruction of the aortic
bifurcation technique for complex aorto-iliac occlusive disease.
Source
Journal of Cardiovascular Surgery. 64(4) (pp 382-388), 2023. Date of
Publication: August 2023.
Author
Ruffino M.A.; Konings T.J.; Mees B.M.
Institution
(Ruffino) Department of Interventional Radiology, Ticino Vascular Center,
Institute of Imaging of Southern Switzerland, Lugano Regional Hospital,
Lugano, Switzerland
(Konings, Mees) Department of Surgery, Maastricht University Medical
Center, Maastricht, Netherlands
Publisher
Edizioni Minerva Medica
Abstract
INTRODUCTION: The covered endovascular reconstruction of aortic
bifurcation (CERAB) technique was introduced as a more anatomical and
physiological configuration of stents to overcome the limits of standard
endovascular technique with kissing stenting in terms of patency and
reintervention rates in the treatment of complex aorto-iliac occlusive
disease in particular when the aortic bifurcation is involved. The purpose
of this systematic review is to report the evolution of this technique
during recent years. EVIDENCE ACQUISITION: Data were retrieved from
retrospective studies and case series excluding letters, editorial, and
reviews conducted from 2000 to September 2022. EVIDENCE SYNTHESIS: The
literature analysis provided data on the evolution of CERAB technique and
the current evidence about clinical results. CONCLUSION(S): Since its
introduction in 2009, CERAB technique has grown as a safe and effective
endovascular therapeutic option for aortoiliac occlusive disease. Data
from prospective multicenter registries with dedicated stent grafts and
comparative trials are needed to validate the technique. Copyright
© 2023 EDIZIONI MINERVA MEDICA.

<4>
Accession Number
2026232417
Title
The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the
Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A
Meta-Analysis and Systematic Review.
Source
Cardiology Research. 14(4) (pp 250-260), 2023. Date of Publication: 2023.
Author
Rahman A.; Alqaisi S.; Saith S.E.; Alzakhari R.; Levy R.
Institution
(Rahman, Alqaisi) Department of Internal Medicine, Memorial Healthcare
System, Pembroke Pines, FL 33028, United States
(Saith) Cardiovascular Fellowship Program, Cardiovascular Disease at SUNY
Downstate Health Sciences University, Brooklyn, NY, United States
(Alzakhari) Cardiovascular Fellowship Program, University of Texas Medical
Branch Cardiovascular Disease Program, Galveston, TX, United States
(Levy) Department of Memorial Health Cardiology, Cardiovascular Disease at
Memorial Healthcare System, Pembroke Pines, FL 33028, United States
Publisher
Elmer Press
Abstract
Background: Since 2005, the cardioprotective effects of glucagonlike
peptide 1 receptor agonists (GLP-1 RAs) have garnered attention. The
cardioprotective effect could be an added benefit to the use of GLP-1 RA.
This systematic review and meta-analysis aimed at summarizing
observational studies that recruited type 2 diabetes individuals with
fewer cardiovascular (CV) events before enrolling in the research.
 Method(s): Systematically, the databases were searched for
observational studies reporting compound CV events and deaths in type 2
diabetics without having the risk of cardiovascular diseases (CVDs)
compared to other glucose-lowering agents. A meta-analysis was carried out
using random effects model to estimate the overall hazard ratio (HR) with
a 95% confidence interval (CI). Five studies were found eligible for the
systematic review including a total of 64,452 patients receiving either
liraglutide (three studies) or exenatide (two studies). Result(s):
The pooled HR for major adverse cardiac event (MACE) and extended MACE was
0.72 (95% CI: 0.65-0.93, I2 = 68%) and 0.93 (95% CI: 0.89-0.98, I2 = 29%),
respectively. The pooled HR for hospitalization due to heart failure (HHF)
and occurrence of HF was 0.84 (95% CI: 0.77-0.91, I2 = 79%) and 0.83 (95%
CI: 0.75-0.94, I2 = 95%), respectively. For stroke, GLP-1 RA was
associated with a significant risk reduction of 0.86 (95% CI: 0.75-0.98,
I2 = 81%). There was no significant myocardial infarction (MI) risk
reduction with GLP-1 RA. As for all-cause mortality, the pooled HR for the
occurrence of all-cause mortality was 0.82 (95% CI: 0.76-0.88, I2 = 0%).
The pooled HR for the occurrence of CV death was 0.75 (95% CI: 0.65-0.85,
I2 = 38%). GLP-1 RA therapy was associated with a significantly low risk
of MACE, extended MACE, all-cause mortality, and CV mortality. Except for
MACE, the heterogenicity among the studies was low. Conclusion(s): We
conclude that GLP-1 RA is associated with a low risk of CV events
composites and mortality. The findings support the cardioprotective effect
of GLP-1 RA. Copyright © Cardiol Res and Elmer Press IncTM

<5>
Accession Number
2025976062
Title
The impact of resource allocation during the COVID-19 pandemic on cardiac
surgical practice and patient outcomes: a systematic review.
Source
European Journal of Cardio-thoracic Surgery. 63(6) (no pagination), 2023.
Article Number: ezad230. Date of Publication: 01 Jun 2023.
Author
EL-Andari R.; Fialka N.M.; Nagendran J.
Institution
(EL-Andari, Nagendran) Division of Cardiac Surgery, Department of Surgery,
University of Alberta, Edmonton, AB, Canada
(Fialka) Faculty of Medicine and Dentistry, University of Alberta,
Edmonton, AB, Canada
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: The coronavirus disease 2019 (COVID-19) pandemic has shaken
the world and placed enormous strain on healthcare systems globally. In
this systematic review, we investigate the effect of resource allocation
on cardiac surgery programs and the impact on patients awaiting elective
cardiac surgery. METHOD(S): PubMed and Embase were systematically
searched for articles published from 1 January 2019 to 30 August 2022.
This systematic review included studies investigating the impact of the
COVID-19 pandemic on resource allocation and the subsequent influence on
cardiac surgery outcomes. A total of 1676 abstracts and titles were
reviewed and 20 studies were included in this review. RESULT(S):
During the COVID-19 pandemic, resources were allocated away from elective
cardiac surgery to help support the pandemic response. This resulted in
increased wait times for elective patients, increased rates of urgent or
emergent surgical intervention and increased rates of mortality or
complications for patients awaiting or undergoing cardiac surgery during
the pandemic. CONCLUSION(S): While the finite resources available
during the pandemic were often insufficient to meet the needs of all
patients as well as the influx of new COVID-19 patients, resource
allocation away from elective cardiac surgery resulted in prolonged wait
times, more frequent urgent or emergent surgeries and negative impacts on
patient outcomes. Understanding the impacts of delayed access to care with
regards to urgency of care, increased morbidity and mortality and
increased utilization of resources per indexed case needs to be considered
to navigate through pandemics to minimize the lingering effects that
continue to negatively impact patient outcomes. Copyright © 2023
European Association for Cardio-Thoracic Surgery. All rights reserved.

<6>
Accession Number
2024857845
Title
Optimal dose of neostigmine antagonizing cisatracurium-induced shallow
neuromuscular block in elderly patients: a randomized control study.
Source
BMC Anesthesiology. 23(1) (no pagination), 2023. Article Number: 269. Date
of Publication: December 2023.
Author
Cao M.; Huang H.; Tong J.; Ou Y.; Liao Y.
Institution
(Cao, Tong, Ou, Liao) Department of Anesthesiology, Third Xiangya
Hospital, Central South University, Hunan, Changsha 410013, China
(Huang) Department of Anesthesiology, The First Affiliated Hospital of
Xiamen University, Xiamen University, Xiamen, China
(Tong) Hunan Province Key Laboratory of Brain Homeostasis, Third Xiangya
Hospital, Central South University, Hunan, Changsha 410013, China
Publisher
BioMed Central Ltd
Abstract
Background: Residual neuromuscular block after using neuromuscular
blocking agents is a common and potentially harmful complication of
general anesthesia. Neostigmine is a widely used antagonist, but its
optimal dose for elderly patients is unclear. Objective(s): To
compare the optimal dosage and safety of neostigmine for reversing shallow
residual block in elderly patients after cisatracurium-induced
neuromuscular block. Method(s): A randomized controlled trial was
conducted in 196 elderly patients undergoing non-cardiac surgery under
general anesthesia with cisatracurium. Patients were assigned to receive
either no neostigmine (control group) or neostigmine at 20 microg/kg, 40
microg/kg or 50 microg/kg when train-of-four (TOF) ratio reached 0.2 at
the end of surgery. The primary outcome was the time to reach TOF ratio of
0.9 after administration. Secondary outcomes included TOF ratio at 10 min
after administration, postoperative nausea and vomiting, postoperative
cognitive impairment and post-anesthesia care unit (PACU) stay time.
 Result(s): The time to reach TOF ratio of 0.9 in the 20 microg/kg, 40
microg/kg and 50 microg/kg groups was significantly shorter than the
control group (H = 104.257, P < 0.01), and the time of 40 microg/kg group
and 50 microg/kg group was significantly shorter than the 20 microg/kg
group (P < 0.001). There was no significant difference between 40
microg/kg and 50 microg/kg groups (P = 0.249). The TOF ratio at 10 min
after administration showed similar results. There were no significant
differences among groups in postoperative nausea and vomiting,
postoperative cognitive impairment or post-operation hospital stay.
 Conclusion(s): Timely use of neostigmine after general anesthesia in
elderly patients can significantly shorten time of TOF value reaching 0.9,
among which 40 microg/kg dosage may be a more optimized choice. Trial
registration: this study was registered on chictr.org.cn
(ChiCTR2100054685, 24/12/2021). Copyright © 2023, BioMed Central
Ltd., part of Springer Nature.

<7>
Accession Number
2026639184
Title
Combined Effects of Continuous Positive Airway Pressure and Cycle
Ergometer in Early Rehabilitation of Coronary Artery Bypass Surgery
Patients.
Source
Journal of the College of Physicians and Surgeons Pakistan. 33(8) (pp
866-871), 2023. Date of Publication: August 2023.
Author
Bano A.; Aftab A.; Sahar W.; Haider Z.; Rashed M.I.; Shabbir H.M.
Institution
(Bano) Department of Physical Therapy, Capital Diagnostic Center,
Islamabad, Pakistan
(Aftab) Faculty of Pharmacy, Allied Health Sciences, University of
Sialkot, Sialkot, Pakistan
(Sahar) Department of Physical Therapy, The University of Lahore, Lahore,
Pakistan
(Haider) Department of Cardiac Surgery, Quaid-e-Azam Medical College,
Bahawalpur, Pakistan
(Rashed) Department of Medicine, DHQ, Toba Tek Singh, Pakistan
(Shabbir) Department of Physical Therapy, Islamabad Medical and Dental
College, Islamabad, Pakistan
Publisher
College of Physicians and Surgeons Pakistan
Abstract
Objective: To determine the combined effects of continuous positive airway
pressure (C-PAP) and physical exercise rehabilitation on a cycle ergometer
on postcoronary artery bypass surgery patients. Study Design:
Randomised controlled trial. Place and Duration of the Study: Rawalpindi
Institute of Cardiology, from December 2020 to May 2021. Methodology:
Patients, who underwent coronary artery bypass graft surgery, were divided
into two equal groups of each 51. The control group received standard
physiotherapy from the 1st postoperative day which included
breathing exercises, passive mobilisation in the sitting position, and
ambulation. The interventional group also had standard physiotherapy from
1st postoperative day; but also the 2nd to
4th postoperative day had additional dynamic exercises on cycle
ergometry in combination with CPAP (continuous positive airway pressure).
 Result(s): There was a significant improvement in functional capacity
measured by 6-minute walk test in the interventional group (p<0.001).
Length of hospital and ICU stay mean rank (68.88 and 58) were also
significantly decreased in the interventional group (p<0.001). There was
no improvement in maximum inspiratory pressure and maximum expiratory
pressure. One-minute sit-to-stand test was increased on 4th
postoperative day in the interventional group. There was no significant
difference observed in arterial blood gases between these two groups.
 Conclusion(s): Cycle ergometry combined with continuous positive
airway pressure (C-PAP) applied earlier on patients undergoing coronary
artery bypass grafting improves the functional capacity, decreases the ICU
and hospital length of stay and also improves lower limb muscle strength.
But no difference in respiratory muscle strength and arterial blood gases
was observed between the control and interventional groups. Copyright
© 2023 College of Physicians and Surgeons Pakistan. All rights
reserved.

<8>
Accession Number
2026723614
Title
The safety of immediate extubation, and factors associated with delayed
extubation, in cardiac surgical patients receiving fast-track cardiac
anesthesia: An integrative review.
Source
Canadian Journal of Respiratory Therapy. 59 (pp 8-19), 2023. Date of
Publication: June 2023.
Author
Tiganila R.; McCoy C.; Gilbert R.; Raco J.
Institution
(Tiganila) Human Nutrition and Functional Medicine Program, University of
Western States, Portland, OR, United States
(McCoy, Raco) Canadian Society of Respiratory Therapists, Ottawa, ON,
Canada
(Gilbert) School of Health Sciences, Dalhousie University, Halifax, NS,
Canada
Publisher
Canadian Society of Respiratory Therapists
Abstract
Background: Early extubation (EE), within 8 h of cardiac surgery, is
associated with improved resource utilization. Studies have demonstrated
that for patients receiving low-dose, fast-track opioid cardiac anesthesia
(FTCA) protocols, EE is as safe as conventional care. To date, it is
unclear when the earliest timepoints for safe extubation might be.
Additionally, some authors pointed out that certain patients receiving
FTCA protocols frequently experience delays during extubation attempts.
Understanding the factors associated with delayed extubation is crucial
for perioperative planning and resource management. This review seeks to
1) determine whether immediate extubation (IE) in the operating room is as
safe as EE and 2) identify factors associated with delayed extubation.
 Method(s): MEDLINE, Cochrane Library, EMBASE and CINAHL (up to March
2022) were searched. Studies pertaining to FTCA, IE, EE or factors
associated with delayed extubation were included. All authors extracted,
appraised and synthesized data. The primary outcome measures were
treatment results and factors associated with delayed extubation.
 Result(s): Six studies investigated treatment outcomes associated
with FTCA and IE. One randomized controlled trial reported that outcomes
associated with IE were comparable to those with EE. Five observational
studies reported incidence for 19 treatment outcomes associated with IE,
but no comparisons were made to EE. Six observational studies assessed
pre- and intraoperative factors associated with delayed extubation in FTCA
patients. In at least one study, 37 factors were investigated and 22 were
identified. The most frequently reported factors were pre-existing cardiac
insufficiency or renal disease, time on pump and cross-clamp time. Obesity
and stroke were investigated but were not associated with delayed
extubation. No study examined the influence of race, ethnicity or gender
on outcomes. Discussion and conclusion: Evidence pertaining to treatment
outcomes associated with FTCA and IE is weak. Observational studies cannot
determine causation. Large multicentre randomized control trials are
required to determine the safety of IE. Although numerous factors have
been associated with delayed extubation, several studies do not describe
how or which factors were selected for examination. Therefore, certain
factors may have yet to be evaluated. Future studies should
comprehensively define all factors under investigation. Copyright
© 2023 Canadian Society of Respiratory Therapists. All rights
reserved.

<9>
Accession Number
2025259787
Title
The impact of PECS II blockade in patients undergoing minimally invasive
cardiac surgery-a prospective, randomized, controlled, and triple-blinded
trial.
Source
Trials. 24(1) (no pagination), 2023. Article Number: 570. Date of
Publication: December 2023.
Author
Hoerner E.; Stundner O.; Naegele F.; Fiala A.; Bonaros N.; Mair P.;
Holfeld J.; Gasteiger L.
Institution
(Hoerner, Stundner, Fiala, Mair, Gasteiger) Department of Anaesthesiology
and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse
35, Innsbruck 6020, Austria
(Naegele, Bonaros, Holfeld) Department of Cardiac Surgery, Medical
University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria
Publisher
BioMed Central Ltd
Abstract
Background: Classic neuraxial techniques, such as thoracic epidural
anesthesia, or alternative approaches like the paravertebral block, are
not indicated in cardiac surgery due to increased bleeding risk. To
provide satisfactory analgesia without the need for excessive opioid use,
novel ultrasound techniques gained popularity and are of growing interest.
The pectoralis nerve block II (PECS II) has been shown to provide good
postoperative analgesia in modified radical mastectomy and might also be
suitable for minimally invasive cardiac surgery. Method(s): In a
single center, prospective, triple-blinded, two-group randomized trial, 60
patients undergoing elective, unilateral minimal invasive cardiac surgery
will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5%
(intervention group) or sodium chloride 0.9% (placebo group). The primary
outcome parameter is the overall opioid demand given as intravenous
morphine milligram equivalents (MME) during the first 24 h after
extubation. Secondary endpoints are the visual analog scale (VAS) 2, 4, 6,
8, 12, and 24 h after extubation, the Overall Benefit of Analgesia Score
(OBAS) after 24 h, the interval until extubation, and intensive care unit
(ICU) discharge within 24 h, as well as the length of hospital stay (LOS).
 Discussion(s): This prospective randomized, controlled, and
triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5%
helps to decrease the opioid demand in the first 24 h and increases
postoperative pain control after minimally invasive cardiac surgery. Trial
registration: www.clinicaltrialsregister.eu ; EudraCT Nr: 2021-005452-11;
Lukas Gasteiger MD, November 18, 2021. Copyright © 2023, BioMed
Central Ltd., part of Springer Nature.

<10>
Accession Number
2025228034
Title
Prognosis of coronary heart disease after percutaneous coronary
intervention: a bibliometric analysis over the period 2004-2022.
Source
European Journal of Medical Research. 28(1) (no pagination), 2023. Article
Number: 311. Date of Publication: December 2023.
Author
Tao S.; Tang X.; Yu L.; Li L.; Zhang G.; Zhang L.; Huang L.; Wu J.
Institution
(Tao, Yu, Zhang) Graduate School, Beijing University of Chinese Medicine,
Beijing, China
(Tang, Wu) Department of Cardiology, Beijing University of Chinese
Medicine Shenzhen Hospital (Longgang), Guangdong, Shenzhen, China
(Li) The First Hospital of Hebei Medical University, Hebei, Shijiazhuang,
China
(Zhang) Department of Oncology, Guang'anmen Hospital, China Academy of
Chinese Medical Sciences, Beijing, China
(Huang) Department of Integrative Cardiology, China-Japan Friendship
Hospital, Beijing, China
Publisher
BioMed Central Ltd
Abstract
Background: As the complexity and diversity of the percutaneous coronary
intervention (PCI) are being explored and reported, burgeoning research
has progressed in this field. However, there is no comprehensive analysis
available on PCI-related studies published in the literature. This study
aimed to analyze and visualize the changes of scientific output regarding
prognosis of coronary heart disease (CHD) after PCI over the past 20 years
and to reveal the knowledge domain and development trends in this field by
using CiteSpace software. Method(s): Relevant articles published over
the period 2004-2022 were retrieved from the Web of Science Core
Collection database. After manual selection, qualified documents were
included and recorded with the information of their title, abstract,
keyword, author, descriptor, citation, identifier, publishing year and
publishing organization. We transferred the data to CiteSpace V5.8.R2
(Version 5.8.R2) to draw knowledge maps and to conduct co-occurrence
analysis, cluster analysis, timeline analysis, burst term detection and
citation analysis. Result(s): A total of 14,699 literature records
were found relating prognosis of CHD after PCI in the past 20 years
(2004-2022), including 14,212 original articles and reviews, and they were
published in 153 different journals. Publication production has increased
annually and a total of 1182 authors, 796 institutes and 147 countries
have contributed to these publications. Moreover, the most representative
author was Gregg W Stone from the CardioVascular Research Foundation
(CVRF) with 368 publications, whose team mainly focused on exploring the
efficacy and safety of revascularization and the characteristics of
susceptible population. The global productivity ranking was led by the USA
with 3326 published papers, followed by Italy (n = 1355), Japan (n =
1080), China (n = 1075) and Germany (n = 937). And the keywords of these
publications were "percutaneous coronary intervention" (n = 2271),
"outcome" (n = 1756), "mortality" (n = 1730) and "impact" (n = 1334).
Other commonly-used words were "predictor" (n = 1324), "intervention" (n =
1310), "angioplasty" (n = 1299), "risk" (n = 1144), "acute myocardial
infarction" (n = 1136) and "artery disease" (n = 1098). Cluster analysis
showed that 15 high connected clusters were generated with a modularity Q
of 0.831 and a weighted mean silhouette of 0.9388 by applying the
log-likelihood ratio algorithm, and the top 5 clusters were #0 optical
coherence tomography, #1 dual antiplatelet therapy, #2 bleeding, #3
clopidogrel and #4 thrombus aspiration. Furthermore, the frontiers in the
field of prognosis of CHD after PCI mainly involved "decision making",
"reperfusion", "angioplasty", "balloon", "unstable angina", "dual
antiplatelet therapy", "cardiac surgical score", "restenosis",
"reperfusion", "thrombolytic therapy", etc. Conclusion(s): To sum up,
efficacy and safety of different types of stents, the risk factors of
restenosis and thrombotic events after PCI, early risk assessment, and
secondary prevention and complications of patients with CHD after PCI were
research hotspots and frontier topics in the area by bibliometric
analysis. The results could provide a comprehensive overview of the
research hotspots and frontier topics relating prognosis of CHD after PCI,
promoting a better understanding of the knowledge domain and development
trends in this field during the past 20 years. Copyright © 2023,
BioMed Central Ltd., part of Springer Nature.

<11>
Accession Number
2025244589
Title
Analgesic efficacy of erector spinae plane block versus paravertebral
block in lung surgeries-A non-inferiority randomised controlled trial.
Source
Acta Anaesthesiologica Scandinavica. (no pagination), 2023. Date of
Publication: 2023.
Author
Andrade Filho P.H.D.; Pereira V.E.; Sousa D.D.E.M.; Costa L.D.G.; Nunes
Y.P.; Taglialegna G.; de Paula-Garcia W.N.; Silva J.M.
Institution
(Andrade Filho, Sousa, Costa, Nunes, Silva) Department of Anaesthesiology,
Hospital do Servidor Publico Estadual de Sao Paulo, Sao Paulo, Brazil
(Andrade Filho, Silva) Postgraduate Programme in Anaesthesiology, Surgical
Sciences, and Perioperative Medicine, University of Sao Paulo Faculty of
Medicine (FMUSP), Sao Paulo, Brazil
(Pereira, Taglialegna, de Paula-Garcia) Orthopedics and Anaesthesiology
Department, Ribeirao Preto Medical School, University of Sao Paulo
(FMRP-USP), Ribeirao Preto, Brazil
Publisher
John Wiley and Sons Inc
Abstract
Background: Pain management plays an essential role in postoperative
recovery after lung surgeries. The Erector Spinae Plane Block (ESPB) is a
widely used regional anaesthesia technique; however, few clinical trials
have compared this block to active control in thoracic surgeries. This
study evaluated the non-inferiority of the analgesia provided by ESPB when
compared to paravertebral block (PVB) in lung surgeries. Method(s):
Randomised, active-controlled, blinded for patients and assessors,
non-inferiority trial. Patients who underwent unilateral lung surgeries
were divided into two groups according to the regional anaesthesia
technique-continuous ESPB or PVB at the T5 level. The primary outcome was
to assess pain using a numerical rating scale (NRS) with a test of the
interaction of three measures over 24 h postoperatively. An NRS score >= 7
was considered analgesia failure, and the prespecified non-inferiority
margin was 10%. Result(s): In the interim analysis that terminated
this study, 120 participants were enrolled. ESPB patients reported higher
mean NRS general values over 24 h, 4.6 +/- 3.2 in the ESPB group versus
3.9 +/- 2.9 in the PVB group, with a difference of -0.67 (-15.2%) and
95%CI: -1.29 to -0.05 (p =.02), demonstrating not non-inferiority. In
addition, the ESPB group presented higher NRS failure of analgesia over 24
h (p <.01) and required more postoperative opioids (p =.01 over 24 h).
There was no difference in patient satisfaction between groups.
 Conclusion(s): This trial demonstrated that a continuous erector
spinae plane block was not non-inferior to a continuous paravertebral
block for analgesia after lung surgery but resulted in higher levels of
postoperative pain and opioid consumption. Copyright © 2023 Acta
Anaesthesiologica Scandinavica Foundation.

<12>
Accession Number
642181967
Title
Minimally Invasive Versus Transcatheter Aortic Valve Replacement: An
Updated Meta-Analysis and Systematic Review.
Source
Innovations (Philadelphia, Pa.). (pp 15569845231197224), 2023. Date of
Publication: 02 Sep 2023.
Author
Ahmed A.; Varghese K.S.; Mathew J.; Huda S.; George J.; Mathew S.;
Abdelnasser O.A.; Awad A.K.; Mathew D.M.
Institution
(Ahmed, Varghese, Mathew, Huda, George, Mathew, Mathew) City University of
New York School of Medicine, NY, United States
(Awad, Abdelnasser) Faculty of Medicine, Ain Shams University, Cairo,
Egypt
(Awad) Faculty of Medicine, El-Galala University, Suez, Egypt
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Transcatheter aortic valve replacement (TAVR) has arisen as a
viable alternative to surgery. Similarly, minimally invasive surgical
aortic valve replacement (mini-SAVR), such as ministernotomy and
minithoracotomy, have also gained interest. We conducted a pairwise
meta-analysis to further investigate the efficacy of TAVR versus
mini-SAVR. METHOD(S): Medical databases were comprehensively searched
for studies comparing TAVR with a mini-SAVR modality, defined as minimally
invasive aortic surgery, ministernotomy, minithoracotomy, or
rapid-deployment or sutureless SAVR. Random-effects meta-analysis was
conducted using the generic inverse variance method. Primary outcomes
included 30-day mortality, midterm mortality, 30-day stroke, acute kidney
injury (AKI), paravalvular leak (PVL), new permanent pacemaker (PPM),
new-onset atrial fibrillation, and postintervention mean and peak valve
pressure gradients and were pooled as risk ratio (RR), mean difference
(MD), or hazard ratio (HR) with 95% confidence interval (CI).
 RESULT(S): A total of 5,071 patients (2,505 mini-SAVR vs 2,566 TAVR)
from 12 studies were pooled. Compared with TAVR, mini-SAVR showed
significantly lower rates of both 30-day (RR = 0.63, 95% CI: 0.42 to 0.96,
P = 0.03) and midterm mortality at 4 years of follow-up (HR = 0.76, 95%
CI: 0.67 to 0.87, P < 0.001). Furthermore, mini-SAVR was protective
against 30-day PVL (RR = 0.07, 95% CI: 0.04 to 0.13, P < 0.001) and new
PPM (RR = 0.25, 95% CI: 0.11 to 0.57, P < 0.001). Conversely, TAVR was
protective against 30-day AKI (RR = 1.67, 95% CI: 1.20 to 2.32, P = 0.002)
and postinterventional mean gradients (MD = 1.65, 95% CI: 0.25 to 3.05, P
= 0.02). No difference was observed for 30-day stroke (RR = 0.84, 95% CI:
0.56 to 1.24, P = 0.38), new-onset atrial fibrillation (RR = 1.79, 95% CI:
0.93 to 3.44, P = 0.08), or postinterventional peak gradients (MD = 3.24,
95% CI: -1.10 to 7.59, P = 0.14). CONCLUSION(S): Compared with TAVR,
mini-SAVR was protective against 30-day and midterm mortality, 30-day PVL,
and new permanent pacemaker, while TAVR patients had lower 30-day AKI.
Future randomized trials comparing the efficacy of mini-SAVR approaches
with TAVR are needed.

<13>
Accession Number
624628505
Title
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary
Intervention in ST-Segment Elevation Myocardial Infarction:
ATLANTIC-Morphine.
Source
American Journal of Cardiovascular Drugs. 19(2) (pp 173-183), 2019. Date
of Publication: 08 Apr 2019.
Author
Lapostolle F.; van't Hof A.W.; Hamm C.W.; Stibbe O.; Ecollan P.; Collet
J.-P.; Silvain J.; Lassen J.F.; Bolognese L.; Cantor W.J.; Cequier A.;
Chettibi M.; Goodman S.G.; Hammett C.J.; Huber K.; Janzon M.; Merkely B.;
Storey R.F.; ten Berg J.; Zeymer U.; Licour M.; Tsatsaris A.; Montalescot
G.; Bougherbal R.; Bouafia M.T.; Nibouche D.; Moklati A.; Benalia A.; Kaid
O.; Krim M.; Garraby P.; Jayasinghe R.; Rashford S.; Neunteufl T.; Brussee
H.; Alber H.; Weidinger F.; Brunner M.; Sipoetz J.; Prause G.; Baubin M.;
Sebald D.; Vijayaraghavan R.; Bata I.; Lavoie A.; Ravkilde J.; Jensen
L.O.; Christensen A.M.; Toftegaard M.; Kohler D.; Ducrocq G.; Danchin N.;
Henry P.; Livarek B.; Berthier R.; Hovasse T.; Garot P.; Payot L.; Benamer
H.; Esteve J.B.; Elhadad S.; Teiger E.; Bonnet J.L.; Paganelli F.; Cottin
Y.; Schiele F.; Thuaire C.; Cayla G.; Coste P.; Ohlmann P.; Cudraz E.B.;
Lantelme P.; Perret T.; Tron C.; De Labriolle A.; Aptecar E.; Beliard O.;
Varenne O.; Mahmoud R.E.; Filippi-Codaccioni E.; Angoulvant D.; Peycher
P.; Poitrineau O.; Tabone X.; Broche C.; Lambert Y.; Briole N.; Beruben
A.; Porcher N.; Auffray J.-P.; Freysz M.; Depardieu F.; Poubel D.; De La
Cousaye J.-E.; Bartier J.-C.; Jardel B.; Boulanger B.; Labourel H.; Soulat
L.-C.; Julie V.; Thicoipe M.; Capel O.; Carli P.; Tazarourte K.; Alcouffe
F.; Aboucaya D.; Aubert G.; Kierzek G.; Cahun-Giraud S.; Dengler T.;
Prondzinsky R.; Biever P.M.; Schafer A.; Seyfarth M.; Lemke B.; Werner G.;
Nef H.; Steiger H.; Leschke M.; Munzel T.; Orto M.C.D.; Loges C.; Schinke
M.; Koberne F.; Reiffen H.P.; Tiroch K.; Wierich D.; Kneussel M.; Little
S.; Sauer H.; Laufenberg-Feldmann R.; Ungi I.; Horvath I.; Edes I.; Martai
I.; Berti S.; Chiarella F.; Calabria P.; Fineschi M.; Galvani M.;
Valgimigli M.; Moretti L.; Tespili M.; Mando M.; Bermano F.; Biagioni R.;
Fabbri A.; Ricciardelli A.; Petroni M.R.; Vatteroni U.R.; Palumbo F.;
Willems F.F.; mafragi A.A.; Heestermans T.A.A.C.M.; Van Eck M.J.; Heutz
W.M.J.M.; Meppelder H.H.; Jong A.R.-D.; Van de Pas H.; Fillat A.C.; Tenas
M.S.; Ferrer J.M.; Penaranda A.S.; Ferrer J.A.; Del Blanco B.G.; Guardiola
F.M.; Nodar J.M.R.; Romo A.I.; Gonzalez N.V.; Nouche R.T.; De La Llera
L.D.; Garcia J.M.H.; Rivero-Crespo F.; Hernandez F.H.; Gomez J.L.Z.;
Farega X.J.; Fernandez G.A.; Toboso J.L.; Carrasco M.; Barreiro V.;
Vazquez J.A.I.; del Mar Ruiz Montero M.; Ortiz F.R.; Escudero G.G.;
Ingelmo V.S.-B.; Garcia A.L.; Oldgren J.; Calais F.; Kastberg R.; Bergsten
P.-A.; Blomberg H.; Thorn K.; Skoog G.; Zaman A.; Gerber R.; Ryding A.;
Spence M.; Swanson N.; Been M.; Grosser K.; Schofield P.; Mackin D.; Fell
P.; Foster T.Q.T.; McManus D.; Carson A.
Institution
(Lapostolle) SAMU 93 - UF Recherche-Enseignement-Qualite, Universite Paris
13, Sorbonne Paris Cite, Inserm U942, Hopital Avicenne, 125, rue de
Stalingrad, Bobigny 93009, France
(van't Hof) Department of Cardiology, Isala Clinics, Zwolle, Netherlands
(Hamm) Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad
Nauheim, Germany
(Stibbe) Service Medical d'Urgence, Brigade de Sapeurs-Pompiers de Paris,
Paris, France
(Ecollan, Collet, Silvain, Montalescot) Sorbonne Universite, ACTION Study
Group, Hopital Pitie-Salpetriere (AP-HP), 47 boul de l'Hopital, Paris
75013, France
(Lassen) Department of Cardiology B, Aarhus University Hospital, Skejby,
Aarhus N, Denmark
(Heutz) Regionale Ambulance Voor ziening Gelderland-Midden, Arnhem,
Netherlands
(Bolognese) Cardiovascular and Neurological Department, Azienda
Ospedaliera Arezzo, Arezzo, Italy
(Cantor) Southlake Regional Health Centre, University of Toronto,
Newmarket, ON, Canada
(Cequier) Heart Disease Institute, Hospital Universitario de Bellvitge,
University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
(Chettibi) Centre Hospito-universitaire Frantz Fanon, Blida, Algeria
(Goodman) Division of Cardiology, Canadian Heart Research Centre, St
Michael's Hospital, University of Toronto, Toronto, Canada
(Hammett) Department of Cardiology, Royal Brisbane and Women's Hospital,
Brisbane, QLD, Australia
(Huber) 3rd Department of Medicine, Cardiology and Intensive Care
Medicine, Wilhelminenhospital, Sigmund Freud University, Medical School,
Vienna, Austria
(Janzon) Department of Cardiology and Department of Medical and Health
Sciences, Linkoping University, Linkoping, Sweden
(Merkely) Heart and Vascular Center, Semmelweis University, Budapest,
Hungary
(Storey) Department of Infection, Immunity and Cardiovascular Disease,
University of Sheffield, Sheffield, United Kingdom
(ten Berg) Department of Cardiology, St Antonius Hospital Nieuwegein,
Nieuwegein, Netherlands
(Zeymer) Klinikum Ludwigshafen and Institut fur Herzinfarktforschung
Ludwigshafen, Ludwigshafen, Germany
(Licour, Tsatsaris) AstraZeneca, Rueil Malmaison, France
(van't Hof) Department of Cardiology, Maastricht University Medical
Center, Maastricht, Netherlands
Publisher
Adis
Abstract
Background: Morphine adversely impacts the action of oral adenosine
diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial
infarction (STEMI) patients, and is possibly associated with differing
patient characteristics. This retrospective analysis investigated whether
interaction between morphine use and pre-percutaneous coronary
intervention (pre-PCI) ST-segment elevation resolution in STEMI patients
in the ATLANTIC study was associated with differences in patient
characteristics and management. Method(s): ATLANTIC was an
international, multicenter, randomized study of treatment in the acute
ambulance/hospital setting where STEMI patients received ticagrelor 180 mg
+/- morphine. Patient characteristics, cardiovascular history, risk
factors, management, and outcomes were recorded. Result(s): Opioids
(97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were
no significant differences in age, sex or cardiovascular history, but more
morphine-treated patients had anterior myocardial infarction and left-main
disease. Time from chest pain to electrocardiogram and ticagrelor loading
was shorter with morphine (both p = 0.01) but not total ischemic time.
Morphine-treated patients more frequently received glycoprotein IIb/IIIa
inhibitors (p = 0.002), thromboaspiration and stent implantation (both p <
0.001). No significant difference between the two groups was found
regarding pre-PCI >= 70% ST-segment elevation resolution, death,
myocardial infarction, stroke, urgent revascularization and definitive
acute stent thrombosis. More morphine-treated patients had an absence of
pre-PCI Thrombolysis in Myocardial Infarction (TIMI) 3 flow (85.8% vs.
79.7%; p = 0.001) and more had TIMI major bleeding (1.1% vs. 0.1%; p =
0.02). Conclusion(s): Morphine-treatment was associated with
increased GP IIb/IIIa inhibitor use, less pre-PCI TIMI 3 flow, and more
bleeding. Judicious morphine use is advised with non-opioid analgesics
preferred for non-severe acute pain. Trial Registration:
clinicaltrials.gov identifier: NCT01347580. Copyright © 2018,
Springer Nature Switzerland AG.

<14>
Accession Number
2026624161
Title
Clinical Frailty Scale as a predictor of adverse outcomes following aortic
valve replacement: A systematic review and meta-analysis.
Source
Open Heart. 10(2) (no pagination), 2023. Article Number: e002354. Date of
Publication: 10 Aug 2023.
Author
Prendiville T.; Leahy A.; Gabr A.; Ahmad F.; Afilalo J.; Martin G.P.;
Mamas M.; Casserly I.P.; Mohamed A.; Saleh A.; Shanahan E.; O'Connor M.;
Galvin R.
Institution
(Prendiville) Department of Cardiology, Cork University Hospital, Cork,
Ireland
(Leahy, Gabr, Mohamed, Saleh, Shanahan, O'Connor) Department of Ageing and
Therapeutics, University Hospital Limerick, Limerick, Ireland
(Ahmad, Afilalo) Division of Cardiology, Centre of Clinical Epidemiology,
Jewish General Hospital, McGill University, Montreal, QC, Canada
(Martin) Division of Informatics Imaging and Data Science, Faculty of
Biology, Medicine and Health, University of Manchester, Manchester, United
Kingdom
(Mamas) Keele Cardiovascular Research Group, Centre for Prognosis
Research, Keele University, Keele, United Kingdom
(Casserly) Department of Cardiology, Mater Misericordiae University
Hospital, Dublin, Ireland
(Galvin) School of Allied Health, Faculty of Education and Health
Sciences, Ageing Research Centre, Health Research Institute, University of
Limerick, Limerick, Ireland
Publisher
BMJ Publishing Group
Abstract
Objectives Assessment of frailty prior to aortic valve intervention is
recommended in European and North American valvular heart disease
guidelines. However, there is a lack of consensus on how it is best
measured. The Clinical Frailty Scale (CFS) is a well-validated measure of
frailty that is relatively quick to calculate. This meta-analysis sought
to examine whether the CFS predicts mortality and morbidity following
either transcatheter aortic valve implantation (TAVI) or surgical aortic
valve replacement (SAVR). Methods Nine electronic databases were searched
systematically for data on clinical outcomes post-TAVI/SAVR, where
patients had undergone preoperative frailty assessment using the CFS. The
primary endpoint was 12-month mortality. TAVI and SAVR data were assessed
and reported separately. For each individual study, the incidence of
adverse outcomes was extracted according to a CFS score of 5-9 (ie, frail)
versus 1-4 (ie, non-frail), with meta-analysis performed using a random
effects model. Results Of 2612 records screened, nine were included in the
review (five TAVI, three SAVR and one which included both interventions).
Among 4923 TAVI patients, meta-analysis showed 12-month mortality rates of
19.1% for the frail cohort versus 9.8% for the non-frail cohort (RR 2.53
(1.63 to 3.95), p<0.001, I 2 =83%). For the smaller cohort of SAVR
patients (n=454), mortality rates were 20.3% versus 3.9% for the frail and
non-frail cohorts, respectively (RR 5.08 (2.31 to 11.15), p<0.001, I 2
=5%). Conclusions Frailty, as determined by the CFS, was associated with
an increased mortality risk in the 12 months following either TAVI or
SAVR. These data would support its use in the preoperative assessment of
elderly patients undergoing aortic valve interventions. Copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC
BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<15>
Accession Number
2026466995
Title
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic
ketoacidosis: A meta summary of case reports.
Source
World Journal of Diabetes. 14(8) (pp 1314-1322), 2023. Date of
Publication: 15 Aug 2023.
Author
Juneja D.; Nasa P.; Jain R.; Singh O.
Institution
(Juneja, Singh) Institute of Critical Care Medicine, Max Super Speciality
Hospital, Saket, New Delhi 110017, India
(Nasa) Department of Critical Care Medicine, NMC Specialty Hospital, Dubai
7832, United Arab Emirates
(Nasa) Department of Internal Medicine, College of Medicine and Health
Sciences, Al Ain, Abu Dhabi 15551, United Arab Emirates
(Jain) Department of Critical Care Medicine, Mahatma Gandhi Medical
College and Hospital, Rajasthan, Jaipur 302022, India
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are commonly
prescribed to manage patients with diabetes mellitus. These agents may
rarely lead to the development of euglycemic diabetic ketoacidosis (EDKA),
which may complicate the disease course of these patients. AIM To analyze
the demographic profile, predisposing factors, symptomology, clinical
interventions and outcomes of patients presenting with EDKA secondary to
SGLT2i use by reviewing the published case reports and series. METHODS We
performed a systematic search of PubMed, Science Direct, Google Scholar
and Reference Citation Analysis databases using the terms "canagliflozin"
OR "empagliflozin" OR "dapagliflozin" OR "SGLT2 inhibitors" OR
"Sodium-glucose cotransporter-2" AND "euglycemia" OR "euglycemic diabetic
ketoacidosis" OR "metabolic acidosis". The inclusion criteria were: (1)
Case reports or case series with individual patient details; and (2)
Reported EDKA secondary to SGLT2i. Furthermore, the data were filtered
from the literature published in the English language and on adults (> 18
years). We excluded: (1) Conference abstracts; and (2) Case reports or
series which did not have individual biochemical data. All the case
reports and case series were evaluated. The data extracted included
patient demographics, clinical symptomatology, clinical interventions,
intensive care unit course, need for organ support and outcomes. RESULTS
Overall, 108 case reports and 17 cases series with 169 unique patients
that met all the inclusion criteria were included. The majority of
patients were females (54.4%, n = 92), and the commonly reported symptoms
were gastrointestinal (nausea/vomiting 65.1%, abdominal pain 37.3%) and
respiratory (breathlessness 30.8%). One hundred and forty-nine (88.2%)
patients had underlying type II diabetes, and the most commonly involved
SGLT-2 inhibitor reported was empagliflozin (46.8%). A triggering factor
was reported in most patients (78.7%), the commonest being acute severe
infection (37.9%), which included patients with sepsis, coronavirus
disease 2019, other viral illnesses, and acute pancreatitis. 61.5% were
reported to require intensive unit care, but only a minority of patients
required organ support in the form of invasive mechanical ventilation
(13%), vasopressors (6.5%) or renal replacement therapy (5.9%). The
overall mortality rate was only 2.4%. CONCLUSION Patients on SGLT2i may
rarely develop EDKA, especially in the presence of certain predisposing
factors, including severe acute infections and following major surgery.
The signs and symptoms of EDKA may be similar to that of DKA but with
normal blood sugar levels, which may make the diagnosis challenging.
Outcomes of EDKA are good if recognized early and corrective actions are
taken. Hence, physicians managing such patients must be aware of this
potential complication and must educate their patients accordingly to
ensure early diagnosis and management. Copyright © The Author(s)
2023. Published by Baishideng Publishing Group Inc. All rights reserved.

<16>
Accession Number
2025917545
Title
A prospective study comparing short versus standard dual antiplatelet
therapy in patients with acute myocardial infarction: design and rationale
of the TARGET-FIRST trial.
Source
EuroIntervention. 19(3) (pp 240-247), 2023. Date of Publication: June
2023.
Author
Tarantini G.; Smits P.C.; Lhermusier T.; Honton B.; Range G.; Piot C.;
Lemesle G.; Ruiz-Nodar J.M.; Godin M.; Cambero M.M.; Motreff P.; Cuisset
T.; Bouchez D.; Poezevara Y.; Cayla G.
Institution
(Tarantini) Department of Cardiac, Thoracic, Vascular Sciences and Public
Health, University of Padua, Padua, Italy
(Smits) Maasstad Ziekenhuis, Rotterdam, Netherlands
(Lhermusier) CHU de Toulouse, Pole Cardiovasculaire et Metabolique,
Toulouse, France
(Honton) Department of Interventional Cardiology, Clinique Pasteur,
Toulouse, France
(Range) Service de Cardiologie, Centre Hospitalier de Chartres, Hopital
Louis Pasteur, Le Coudray, France
(Piot) Service/Pole de Cardiologie, Clinique du Millenaire, Montpellier,
France
(Lemesle) Heart and Lung Institute, University Hospital of Lille, Lille,
France
(Lemesle) Institut Pasteur of Lille, Inserm, U1011, Lille, France
(Lemesle) FACT (French Alliance for Cardiovascular Trials), Paris, France
(Ruiz-Nodar) Servicio de Cardiologia, Hospital General Universitario de
Alicante, Alicante, Spain
(Godin) Service Cardiologie, Clinique Saint Hilaire, Rouen, France
(Cambero) Tergooi MC, Blaricum, Netherlands
(Motreff) Service/Pole Cardiologie, Hopital Gabriel-Montpied,
Clermont-Ferrand, France
(Cuisset) Service de Cardiologie, University Hospital La Timone,
Marseille, France
(Bouchez, Poezevara) MicroPort CRM, Clinical Affairs, Clamart, France
(Cayla) Service de Cardiologie, CHU de Nimes, Universite de Montpellier,
Nimes, France
Publisher
Europa Group
Abstract
Based on the latest knowledge and technological advancements, it is still
debatable whether a modern revascularisation approach in the setting of
acute myocardial infarction (AMI), including complete revascularisation
(in patients with significant non-culprit lesions) with newer-generation
highly biocompatible drug-eluting stents, requires prolonged dual
antiplatelet therapy (DAPT). TARGET-FIRST (ClinicalTrials. gov:
NCT04753749) is a prospective, open-label, multicentre, randomised
controlled study comparing short (one month) DAPT versus standard (12
months) DAPT in a population of patients with non-ST/ST-segment elevation
myocardial infarction, completely revascularised at index or staged
procedure (within 7 days), using Firehawk, an abluminal in-groove
biodegradable polymer rapamycin-eluting stent. The study will be conducted
at approximately 50 sites in Europe. After a mandatory 30-40 days of DAPT
with aspirin and P2Y<inf>12</inf> inhibitors (preferably potent
P2Y<inf>12</inf> inhibitors), patients are randomised (1:1) to 1)
immediate discontinuation of DAPT followed by P2Y<inf>12</inf> inhibitor
monotherapy (experimental arm), or 2) continued DAPT with the same regimen
(control arm), up until 12 months. With a final sample size of 2,246
patients, the study is powered to evaluate the primary endpoint
(non-inferiority of short antiplatelet therapy in completely
revascularised patients) for net adverse clinical and cerebral events. If
the primary endpoint is met, the study is powered to assess the main
secondary endpoint (superiority of short DAPT in terms of major or
clinically relevant non-major bleeding). TARGET-FIRST is the first
randomised clinical trial to investigate the optimisation of antiplatelet
therapy in patients with AMI after achieving complete revascularisation
with an abluminal in-groove biodegradable polymer rapamycin-eluting stent
implantation. Copyright © Europa Digital & Publishing 2023. All
rights reserved.

<17>
Accession Number
2025826099
Title
Vascular endothelial growth factor-D plasma levels and VEGFD genetic
variants are independently associated with outcomes in patients with
cardiovascular disease.
Source
Cardiovascular Research. 119(7) (pp 1596-1605), 2023. Date of Publication:
01 Jun 2023.
Author
Davidsson P.; Eketjall S.; Eriksson N.; Walentinsson A.; Becker R.C.;
Cavallin A.; Bogstedt A.; Collen A.; Held C.; James S.; Siegbahn A.;
Stewart R.; Storey R.F.; White H.; Wallentin L.
Institution
(Davidsson, Eketjall, Walentinsson, Cavallin, Bogstedt) Translational Sci.
and Exp. Med. Res. and Early Development, Cardiovascular, Renal and
Metabolism, BioPharmaceuticals R&d, AstraZeneca Gothenburg, Pepparedsleden
1, Molndal 431 83, Sweden
(Eriksson, Held, James, Siegbahn, Wallentin) Uppsala Clinical Research
Center, Uppsala University, Dag Hammarskjolds vag 38, Uppsala 751 85,
Sweden
(Becker) Division of Cardiovascular Health and Disease, Heart, Lung and
Vascular Institute, University of Cincinnati, College of Medicine, 231
Albert Sabin Way ML 0542, Cincinnati, OH 45267, United States
(Collen) Projects Cardiovascular, Renal and Metabolism, BioPharmaceuticals
R&d, AstraZeneca, Gothenburg, Pepparedsleden 1, Molndal 431 83, Sweden
(Held, James, Siegbahn, Wallentin) Department of Medical Sciences
Cardiology, Uppsala University, Akademiska Sjukhuset, Uppsala 751 85,
Sweden
(Siegbahn) Clinical Chemistry, Uppsala University, Akademiska Sjukhuset,
Uppsala 751 85, Sweden
(Stewart, White) Green Lane Cardiovascular Service, Auckland City
Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand
(Storey) Department of Infection Immunity and Cardiovascular Disease,
University of Sheffeld, Beech Hill Road, Sheffield S10 2RX, United Kingdom
Publisher
Oxford University Press
Abstract
Aims: The vascular endothelial growth factor (VEGF) family is involved in
pathophysiological mechanisms underlying cardiovascular (CV) diseases. The
aim of this study was to investigate the associations between circulating
VEGF ligands and/or soluble receptors and CV outcome in patients with
acute coronary syndrome (ACS) and chronic coronary syndrome (CCS).
 Methods and Results: Levels of VEGF biomarkers, including bFGF,
Flt-1, KDR (VEGFR2), PlGF, Tie-2, VEGF-A, VEGF-C, and VEGF-D, were
measured in the PLATO ACS cohort (n = 2091, discovery cohort).
Subsequently, VEGF-D was also measured in the STABILITY CCS cohort (n =
4015, confirmation cohort) to verify associations with CV outcomes.
Associations between plasma VEGF-D and outcomes were analysed by multiple
Cox regression models with hazard ratios (HR [95% CI]) comparing the upper
vs. the lower quartile of VEGF-D. Genome-wide association study (GWAS) of
VEGF-D in PLATO identified SNPs that were used as genetic instruments in
Mendelian randomization (MR) meta-analyses vs. clinical endpoints. GWAS
and MR were performed in patients with ACS from PLATO (n = 10 013) and
FRISC-II (n = 2952), and with CCS from the STABILITY trial (n = 10 786).
VEGF-D, KDR, Flt-1, and PlGF showed significant association with CV
outcomes. VEGF-D was most strongly associated with CV death (P = 3.73e-05,
HR 1.892 [1.419, 2.522]). Genome-wide significant associations with VEGF-D
levels were identified at the VEGFD locus on chromosome Xp22. MR analyses
of the combined top ranked SNPs (GWAS P-values; rs192812042, P = 5.82e-20;
rs234500, P = 1.97e-14) demonstrated a significant effect on CV mortality
[P = 0.0257, HR 1.81 (1.07, 3.04) per increase of one unit in log VEGF-D].
 Conclusion(s): This is the first large-scale cohort study to
demonstrate that both VEGF-D plasma levels and VEGFD genetic variants are
independently associated with CV outcomes in patients with ACS and CCS.
Measurements of VEGF-D levels and/or VEGFD genetic variants may provide
incremental prognostic information in patients with ACS and
CCS. Copyright © 2023 The Author(s). Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved.

<18>
Accession Number
2025062969
Title
The Effects of Exercise Training on Exercise Capacity and Vascular
Function after Transcatheter Aortic Valve Implantation-A Pilot Study.
Source
Journal of Cardiovascular Development and Disease. 10(8) (no pagination),
2023. Article Number: 343. Date of Publication: August 2023.
Author
Vitez L.; Bunc M.; Jug B.
Institution
(Vitez, Bunc) Department of Cardiology, Division of Internal Medicine,
University Medical Centre Ljubljana, Ljubljana 1000, Slovenia
(Vitez, Bunc, Jug) Faculty of Medicine, University of Ljubljana, Ljubljana
1000, Slovenia
(Jug) Department of Vascular Diseases, Division of Internal Medicine,
University Medical Centre Ljubljana, Ljubljana 1000, Slovenia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Transcatheter aortic valve implantation (TAVI) improves event-free
survival in patients with severe aortic stenosis, but patients' exercise
capacity remains poor after the procedure. Therefore, we sought to compare
the effects of a supervised center-based exercise training program and
unsupervised exercise routine on exercise capacity and vascular function
in patients after TAVI. Patients were randomized to either center-based
exercise training (12-24 sessions of combined aerobic and low-weight
resistance training twice weekly for 8-12 weeks) or an unsupervised
home-based exercise routine (initial appraisal with detailed
recommendations and monthly follow-up). Exercise capacity (cardiopulmonary
testing) and vascular function (ultrasonographic measurement of
flow-mediated vasodilation (FMD) and arterial stiffness) were assessed at
the baseline and after the study period. We included 23 patients (mean age
of 81 years, 61% women), with higher-than-expected drop-out rates (41%)
because of the coronavirus-19 pandemic outbreak. Exercise capacity
improved over time, irrespective of the intervention group: 0.09 mL/min/kg
increase in peak oxygen uptake (95% CI [0.01-0.16]; p = 0.02), 8.2 Watts
increase in workload (95% CI [0.6-15.8]; p = 0.034), and 47 s increase in
cumulative exercise time (95% CI [5.0-89.6]; p = 0.029). A between-group
difference in change over time (treatment effect) was detected only for
FMD (4.49%; 95% CI [2.35; 6.63], p < 0.001), but not for other outcome
variables. Both supervised and unsupervised exercise training improve
exercise capacity and vascular function in patients after TAVI, with
supervised exercise training possibly yielding larger improvements in
vascular function, as determined by FMD. Copyright © 2023 by the
authors.

<19>
Accession Number
2025014121
Title
Management of priming fluids in cardiopulmonary bypass for adult cardiac
surgery: network meta-analysis.
Source
Annals of Medicine. 55(2) (no pagination), 2023. Article Number: 2246996.
Date of Publication: 2023.
Author
Xian-Yu C.-Y.; Xu J.-B.; Ma Y.-T.; Deng N.-J.; Tao Y.-T.; Li H.-J.; Gao
T.-Y.; Yang J.-Y.; Zhang C.
Institution
(Xian-Yu, Ma, Deng, Tao, Li, Gao, Zhang) Center for Evidence-Based
Medicine and Clinical Research, Taihe Hospital, Hubei University of
Medicine, Hubei, Shiyan, China
(Xu) Department of Emergency, Renmin Hospital, Hubei University of
Medicine, Hubei, Shiyan, China
(Yang) Department of Anesthesia Surgery, Zhongnan Hospital of Wuhan
University, Wuhan University, Hubei, Wuhan, China
Publisher
Taylor and Francis Ltd.
Abstract
Background: Cardiopulmonary bypass (CPB) is frequently employed for
cardiac surgery, and selecting a suitable priming fluid is a prerequisite
for CPB. Currently, the commonly used priming fluids in clinics are
classified as crystalloids and colloids, including balanced crystalloids,
albumin, dextran, gelatin and hydroxyethyl starch (HES). This network
meta-analysis compared the effects of eight fluids used during CPB in
adults to determine optimal priming fluid during CPB surgery.
 Method(s): Randomised controlled trials assessing priming fluids for
CPB in adult cardiac surgery published before 13 April 2023 were searched
across Ovid MEDLINE(R) ALL, OVID EMbase, and Cochrane Central Register of
Controlled Trials. Various priming fluids were classified into eight
categories, including balanced crystalloids, 0.9% NaCl, iso-oncotic human
albumin, hyperoncotic human albumin, HES with molecular weight 130k, HES
with molecular weight 200k, gelatin and dextran. Result(s): The NMA
of platelet counts revealed no significant differences in any result. In
direct comparison results, only the comparison of HES with molecular
weight 130k vs. gelatin (standard mean difference = -0.40, 95% confidence
interval [95%CI: -0.63, -0.16) revealed a significant difference.
According to the SUCRA, balanced crystalloids had the highest platelet
count, followed by gelatin, and HES with a molecular weight of 130k had
the lowest platelet, followed by HES with a molecular weight of 200k.
 Conclusion(s): Patients using dextran have a low mortality rate and a
short mean CPB time, the use of balanced crystalloids is beneficial in
terms of platelet count, and HES with molecular weight 130k is beneficial
for postoperative urine volume at 24h. However, all priming fluids have
pros and cons quite, and the optimal choice of priming fluids remains
unsupported by current evidences. When performing CPB surgery, the type of
priming fluid should be selected according to the actual situation in CPB
for adult cardiac surgery. Copyright © 2023 The Author(s).
Published by Informa UK Limited, trading as Taylor & Francis Group.

<20>
Accession Number
2016536944
Title
Outcomes of cardiac surgical procedures performed by trainees versus
consultants: A systematic review with meta-analysis.
Source
Journal of Thoracic and Cardiovascular Surgery. 166(2) (pp 612-627.e35),
2023. Date of Publication: August 2023.
Author
Escorel Neto A.C.; Sa M.P.; Van den Eynde J.; Rotbi H.; Do-Nguyen C.C.;
Olive J.K.; Cavalcanti L.R.P.; Torregrossa G.; Sicouri S.; Ramlawi B.;
Hussein N.
Institution
(Escorel Neto, Cavalcanti) Division of Cardiovascular Surgery of Pronto
Socorro Cardiologico de Pernambuco - PROCAPE, Recife, Brazil
(Escorel Neto, Cavalcanti) University of Pernambuco - UPE, Recife, Brazil
(Sa, Torregrossa, Ramlawi) Department of Cardiothoracic Surgery, Lankenau
Heart Institute, Main Line Health, Wynnewood, PA, United States
(Sa, Sicouri, Ramlawi) Department of Cardiac Surgery Research, Lankenau
Institute for Medical Research, Wynnewood, PA, United States
(Van den Eynde) Department of Cardiovascular Diseases, Unit of Cardiac
Surgery, University Hospitals Leuven, Leuven, Belgium
(Rotbi) Faculty of Medicine, Radboud University, Nijmegen, Netherlands
(Rotbi) Radboud Institute for Health Sciences, Department of Physiology,
Radboud University Medical Center, Nijmegen, Netherlands
(Do-Nguyen) Department of Cardiac Surgery, University of Michigan, Ann
Arbor, Mich, United States
(Olive) Division of Cardiovascular and Thoracic Surgery, Department of
Surgery, Duke University Medical Center, Durham, NC, United States
(Hussein) Department of Congenital Cardiac Surgery, Yorkshire Heart
Centre, Leeds General Infirmary, Leeds, United Kingdom
Publisher
Elsevier Inc.
Abstract
Objectives: Cardiac surgery is highly demanding and the ideal teaching
method to reach competency is widely debated. Some studies have shown that
surgical trainees can safely perform full operations with equivocal
outcomes compared with their consultant colleagues while under
supervision. We aimed to compare outcomes after cardiac surgery with
supervised trainee involvement versus consultant-led procedures.
 Method(s): We systematically reviewed databases (PubMed/MEDLINE,
Embase, the Cochrane Central Register of Controlled Trials,
ClinicalTrials.gov, Google Scholar) and reference lists of relevant
articles for studies that compared outcomes of cardiac surgery performed
by trainees versus consultants. Primary end points included: operative
mortality, coronary events, neurological/renal complications, reoperation,
permanent pacemaker implantation, and sternal complications. Secondary
outcomes included cardiopulmonary bypass and aortic cross-clamp times and
intensive care/in-hospital length of stay. Random effects meta-analysis
was performed. Result(s): Thirty-three observational studies that
reported on a total of 81,616 patients (trainee: 20,154; consultant:
61,462) were included. There was a difference favoring trainees in terms
of operative mortality in the main analysis and in an analysis restricted
to propensity score-matched samples, whereas other outcomes were not
consistently different in both analyses. Overall cardiopulmonary bypass
and aortic cross-clamp times were longer in the trainee group but did not
translate in longer intensive care unit or hospital stay.
 Conclusion(s): In the right conditions, good outcomes are possible in
cardiac surgery with trainee involvement. Carefully designed training
programs ensuring graduated hands-on operative exposure as primary
operator with appropriate supervision is fundamental to maintain
high-quality training in the development of excellent cardiac
surgeons. Copyright © 2021

<21>
Accession Number
2014931813
Title
Evaluation of a tummy time intervention to improve motor skills in infants
after cardiac surgery.
Source
Cardiology in the Young. 32(8) (pp 1210-1215), 2022. Date of Publication:
27 Aug 2022.
Author
Uzark K.; Smith C.; Yu S.; Lowery R.; Tapley C.; Romano J.C.; Butcher J.
Institution
(Uzark, Romano) Department of Cardiac Surgery, University of Michigan Mott
Children's Hospital, Ann Arbor, MI, United States
(Uzark, Smith, Yu, Lowery, Tapley, Romano, Butcher) Department of
Pediatrics, University of Michigan Mott Children's Hospital, Ann Arbor,
MI, United States
Publisher
Cambridge University Press
Abstract
Background: Infants who require open heart surgery are at increased risk
for developmental delays including gross motor impairments which may have
implications for later adaptive skills and cognitive performance. We
sought to evaluate the feasibility and efficacy of a tummy time
intervention to improve motor skill development in infants after cardiac
surgery. Method(s): Infants <4 months of age who underwent cardiac
surgery were randomly assigned to tummy time with or without outpatient
reinforcement or standard of care prior to hospital discharge. The Alberta
Infant Motor Scale (AIMS) was administered to each infant prior to and 3
months after discharge. Groups were compared, and the association between
parent-reported tummy time at home and change in motor scores at follow-up
was examined. Result(s): Parents of infants (n = 64) who had cardiac
surgery at a median age of 5 days were randomly assigned to tummy time
instruction (n = 20), tummy time + outpatient reinforcement (n = 21) or
standard of care (n = 23). Forty-nine (77%) returned for follow-up. At
follow-up, reported daily tummy time was not significantly different
between groups (p = 0.17). Fifteen infants had <15 minutes of tummy time
daily. Infants who received >15 minutes of tummy time daily had a
significantly greater improvement in motor scores than infants with <15
minutes of tummy time daily (p = 0.01). Conclusion(s): In infants
following cardiac surgery, <15 minutes of tummy time daily is associated
with increased motor skill impairment. Further research is needed to
elucidate the best strategies to optimise parental compliance with tummy
time recommendations. Copyright © The Author(s), 2021. Published
by Cambridge University Press.

<22>
Accession Number
2026706578
Title
Utility of Brain Injury Biomarkers in Children With Congenital Heart
Disease Undergoing Cardiac Surgery.
Source
Pediatric Neurology. 148 (pp 44-53), 2023. Date of Publication: November
2023.
Author
Kuhn J.E.; Pareja Zabala M.C.; Chavez M.M.; Almodovar M.; Mulinari L.A.;
Sainathan S.; de Rivero Vaccari J.P.; Wang K.K.; Munoz Pareja J.C.
Institution
(Kuhn) University of Miami Miller School of Medicine, Miami, FL, United
States
(Pareja Zabala) Department of Pediatrics Medical College of Wisconsin,
Milwaukee, WI, United States
(Chavez) Knowledge and Research Evaluation Unit, Mayo Clinic College of
Medicine and Science, Rochester, MN, United States
(Almodovar) Division of Pediatric Cardiology, Department of Pediatrics,
University of Miami Miller School of Medicine, Miami, FL, United States
(Mulinari, Sainathan) Division of Pediatric Cardiothoracic Surgery,
Department of Surgery, University of Miami Miller School of Medicine,
Miami, FL, United States
(de Rivero Vaccari, Munoz Pareja) Department of Neurological Surgery and
the Miami Project to Cure Paralysis, University of Miami Miller School of
Medicine, Miami, FL, United States
(Wang) Department of Emergency Medicine, Morehouse University, School of
Medicine, Atlanta, GA, United States
(Wang) Center for Neurotrauma, Multiomics & Biomarkers (CNMB), Morehouse
University, School of Medicine, Atlanta, GA, United States
(Munoz Pareja) Division of Pediatric Critical Care, Department of
Pediatrics, University of Miami Miller School of Medicine, Miami, FL,
United States
Publisher
Elsevier Inc.
Abstract
Background: Congenital heart disease (CHD) affects roughly 40,000 children
annually. Despite advancements, children undergoing surgery for CHD are at
an increased risk for adverse neurological outcomes. At present, there is
no gold standard for the diagnosis of cerebral injury during the
perioperative period. Objective(s): To determine the utility of brain
injury biomarkers in children undergoing cardiac surgery. Method(s):
We searched PUBMED, EMBASE, LILACS, EBSCO, ClinicalTrials.gov, Cochrane
Databases, and OVID interface to search MEDLINE through July 2021 and
assessed the literature following the snowball method. The search terms
used were "congenital heart disease," "cardiopulmonary bypass,"
"biomarkers," "diagnosis," "prognosis," and "children." No language or
publication date restrictions were used. Papers studying inflammatory and
imaging biomarkers were excluded. The risk of bias, strengths, and
limitations of the study were reported. Study was registered in PROSPERO
ID: CRD42021258385. Result(s): A total of 1449 articles were
retrieved, and 27 were included. Eight neurological biomarkers were
examined. Outcomes assessed included prognosis of poor neurological
outcome, mortality, readmission, and diagnosis of brain injury. Results
from these studies support that significant perioperative elevations in
brain injury biomarkers in cerebrospinal fluid and serum, including S100B,
GFAP, NSE, and activin A, may be diagnostic of real-time brain injury and
serve as an independent predictor of adverse neurological outcomes in
patients with CHD undergoing cardiopulmonary bypass. Conclusion(s):
There are limited homogeneous data in the field, limiting the
generalizability and comparability of the results. Further large-scale
longitudinal studies addressing neurological biomarkers in children
undergoing CHD corrective surgery are required to support the routine use
of neuronal biomarkers in this population. Copyright © 2023
Elsevier Inc.

<23>
Accession Number
2024905598
Title
Myocardial injury after non-cardiac surgery and per operative fibrin
metabolism in patients undergoing hip-fracture surgery: an observational
study.
Source
Scandinavian Journal of Clinical and Laboratory Investigation. 83(5) (pp
299-308), 2023. Date of Publication: 2023.
Author
Wahlstrom K.L.; Ekeloef S.; Gogenur I.; Munster A.-M.B.
Institution
(Wahlstrom, Ekeloef, Gogenur) Center for Surgical Science, Department of
Surgery, Zealand University Hospital, Koge, Denmark
(Gogenur) Institute for Clinical Medicine, Copenhagen University, Denmark
(Munster) Unit for Thrombosis Research, Department of Regional Health
Research, University of Southern Denmark, Odense, Denmark
(Munster) Department of Clinical Biochemistry, Regional Hospital West
Jutland, Holstebro, Denmark
Publisher
Taylor and Francis Ltd.
Abstract
Myocardial injury after non-cardiac surgery (MINS) is associated with a
2-3-fold increased risk of subsequent major cardiovascular events and
postoperative mortality. The pathological mechanism behind MINS is not
fully uncovered. We hypothesized that patients with MINS following hip
fracture surgery would have an altered haemostatic balance pre- and
postoperative compared with patients without MINS. This was investigated
in a prospective single-centre observational study including patients
consecutively. The outcomes were changes in thrombin generation,
fibrinogen/fibrin turnover, tissue plasminogen activator, plasminogen
activator inhibitor-1 and fibrin structure measurements in patients
developing MINS and patients who did not. Outcomes were measured
preoperatively and two hours postoperatively. Seventy-two patients were
included whereof 26 (36%) patients developed MINS. D-dimer delta values
were significantly higher in patients developing MINS than in patients who
did not (p = 0.01). After adjusting for age, sex, smoking, alcohol abuse,
atrial fibrillation, anticoagulant medication preoperative CRP,
preoperative creatinine and duration of surgery, the association remained
significant (p = 0.04). There were no significant changes in thrombin
generation, in markers of fibrinogen/fibrin turnover besides D-dimer, or
in fibrin structure measurements pre- and postoperatively between patients
with and without MINS. As such, a relationship between the coagulative and
fibrinolytic activity and MINS cannot be ruled out in patients with MINS
after hip fracture surgery.Registration: The study was an observational
sub-study to a multicentre randomised clinical trial registered at
ClinicalTrials.gov (NCT02344797). Copyright © 2023 Medisinsk
Fysiologisk Forenings Forlag (MFFF).

<24>
Accession Number
642169652
Title
USING PRE-OPERATIVE LOW INTENSITY VESTIBULAR SHOCKWAVE THERAPY REDUCES
OPIOID USE POST-VESTIBULECTOMY.
Source
Journal of Sexual Medicine. Conference: International Society for the
Study of Women's Sexual Health Annual Meeting, ISSWSH 2021. Dallas, TX
United States. 20(3) (pp ii6), 2023. Date of Publication: June 2023.
Author
Stearns H.; Uloko M.; Gagnon C.; Goldstein I.
Institution
(Stearns, Uloko, Gagnon) San Diego Sexual Medicine, United States
(Goldstein) Alvarado Hospital, United States
Publisher
Oxford University Press
Abstract
Introduction: Surgeons performing complete vestibulectomy for
neuro-proliferative vestibulodynia need to consider two competing
post-operative interests: accomplishing acute pain relief in the early
postoperative period; reducing risks of persistent post-operative opioid
use. Data support that measures to decrease overall post-operative opioid
use will decrease future opioid-related adverse events including opioid
abuse and addiction. Sexual medicine providers are thus motivated to
identify strategies such as pre-operative low intensity shockwave therapy
(LISWT) to decrease opioid use in these vestibulectomy patients. To date,
only one study has been published assessing the effect of pre-operative
LISWT on surgical outcome. Dumfarth at al reported in a prospective
randomized study that pre-operative LISWT significantly improved lower
extremity wound healing compared to controls in patients undergoing vein
harvesting for coronary artery bypass graft surgery. While Dumfarth et al
did not directly assess post-operative pain, pre-operative LISWT was
associated with statistically significantly increased satisfactory
healing, reduced disturbance of healing and reduced minor skin infections,
all consistent with less post-operative pain. It was hypothesized that
pre-operative LISWT improved wound healing via enhanced blood supply and
angiogenesis through expression of vascular endothelial growth factor
(VEGF) and nitric oxide synthesis, and via anti-inflammatory action
downregulating necrosis factor B activation thereby lowering inflammatory
cytokines. Objective(s): We wished to see if pre-operative LISWT
would reduce opioid use in women undergoing complete vestibulectomy. The
objective of this study was to compare the use of opioids following
vestibulectomy when LISWT with Urogold 100TM MTS was applied just prior to
surgery versus no shockwave. LISWT is a non-invasive, non-pharmacologic,
non-surgical treatment strategy with low morbidity that is FDA-cleared for
pain amelioration in the US as non-significant risk in humans, Urogold
100TMMTS provides unfocused electrohydraulic shockwaves with a unique
parabolic reflector. Method(s): Patients scheduled for surgery were
required to present to the hospital 4 days before surgery for a COVID- 19
test. On that day and each subsequent day until surgery, based on the
patient's availability, the patient presented to the office for
approximately 2400 shocks to the vestibule. This is a descriptive study of
the patients' post-operative experiences with pain. Result(s): To
date 4 women have undergone LISWT just prior to surgery. At the time of
surgery Exparel was delivered to the site, allowing them 24-36 hours of
anesthesia to the area so they could travel home easily. Patients were
prescribed Percocet to be take every 4 hours as needed. Post-op patients
routinely use this opioid 4-6 times a day for multiple days, causing
constipation among themany side effects.The women who underwent LISWT
immediately prior to surgery have experienced decreased levels of pain
post-operatively such that they are using 1/2 tab of Percocet at bedtime
or twice a day, thus decreasing opioid use with all of its potential side
effects. Conclusion(s): Performing LISWT using Urogold 100TMMTS may
reduce the need for opioid medications after total vestibulectomy with
vaginal advancement flap as itmaymediate pain after the surgical
procedure.

<25>
Accession Number
2026613001
Title
Extrathoracic Against Intrathoracic Vascular Accesses for Transcatheter
Aortic Valve Replacement: A Systematic Review With Meta-Analysis.
Source
American Journal of Cardiology. 203 (pp 473-483), 2023. Date of
Publication: 15 Sep 2023.
Author
Abellan C.; Antiochos P.; Fournier S.; Skali H.; Shah P.; Maurizi N.;
Eeckhout E.; Roguelov C.; Monney P.; Tzimas G.; Kirsch M.; Muller O.; Lu
H.
Institution
(Abellan) Service of Internal Medicine, Lausanne University Hospital and
University of Lausanne, Switzerland, Lausanne, Switzerland
(Antiochos, Fournier, Maurizi, Eeckhout, Roguelov, Monney, Tzimas, Muller,
Lu) Service of Cardiology, Lausanne University Hospital and University of
Lausanne, Switzerland, Lausanne, Switzerland
(Skali, Shah, Lu) Division of Cardiovascular Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, Massachusetts, United States
(Kirsch) Service of Cardiovascular Surgery, Lausanne University Hospital
and University of Lausanne, Lausanne, Switzerland
Publisher
Elsevier Inc.
Abstract
Alternative vascular accesses to transfemoral access for transcatheter
aortic valve replacement (TAVR) can be divided into intrathoracic
(IT)-transapical and transaortic- and extrathoracic (ET)-transcarotid,
transsubclavian, and transaxillary. This study aimed to compare the
outcomes and safety of IT and ET accesses for TAVR as alternatives to
transfemoral access. A systematic review with meta-analysis was performed
by searching PubMed/MEDLINE and EMBASE databases for all studies comparing
IT-TAVR with ET-TAVR published until April 2023. Outcomes included
in-hospital or 30-day all-cause mortality (ACM), 1-year ACM, postoperative
and 30-day complications. A total of 18 studies with 6,800 IT-TAVR
patients and 5,032 ET-TAVR patients were included. IT accesses were
associated with a significantly higher risk of in-hospital or 30-day ACM
(relative risk 1.99, 95% confidence interval 1.67 to 2.36, p <0.001), and
1-year ACM (relative risk 1.31, 95% confidence interval 1.21 to 1.42, p
<0.001). IT-TAVR patients presented more often with postoperative
life-threatening bleeding, 30-day new-onset atrial fibrillation or
flutter, and 30-day acute kidney injury needing renal replacement therapy.
The risks of postoperative permanent pacemaker implantation and
significant paravalvular leak were lower with IT-TAVR. ET-TAVR patients
were more likely to be directly discharged home. There was no
statistically significant difference regarding the 30-day risk of stroke.
Compared with ET-TAVR, IT-TAVR was associated with higher risks of
in-hospital or 30-day ACM, 1-year ACM and higher risks for some critical
postprocedural and 30-day complications. Our results suggest that ET-TAVR
could be considered as the first-choice alternative approach when
transfemoral access is contraindicated. Copyright © 2023 The
Author(s)

<26>
Accession Number
2025199654
Title
Sternomanubrial reduction with plating for fully displaced sternal
fracture: A systematic review.
Source
Clinical Case Reports. 11(9) (no pagination), 2023. Article Number: e7740.
Date of Publication: September 2023.
Author
Samat S.H.; Yelleswarapu K.; Zakharov K.
Institution
(Samat) Department of Surgery, Michigan State University, Lansing, MI,
United States
(Yelleswarapu) Michigan State University College of Osteopathic Medicine,
East Lansing, MI, United States
(Zakharov) Thoracic and Cardiac Surgery, Sparrow Hospital, Lansing, MI,
United States
Publisher
John Wiley and Sons Inc
Abstract
Key Clinical Message: Sternal fractures are commonly due to blunt force
trauma and reduction is an invasive surgical procedure typically indicated
for refractory pain sternal instability. There were various modalities
used for treatment and fixation of the sternal fractures. Sternal
displacement fractures are traumatic injuries that may require surgical
correction. Copyright © 2023 The Authors. Clinical Case Reports
published by John Wiley & Sons Ltd.

<27>
Accession Number
2025198372
Title
The analgesic efficacy of erector spinae plane block versus paravertebral
block in thoracic surgeries: a meta-analysis.
Source
Frontiers in Medicine. 10 (no pagination), 2023. Article Number: 1208325.
Date of Publication: 2023.
Author
Fenta E.; Kibret S.; Hunie M.; Tamire T.; Mekete G.; Tiruneh A.; Fentie
Y.; Dessalegn K.; Teshome D.
Institution
(Fenta, Kibret, Hunie, Tamire, Mekete, Tiruneh, Fentie, Dessalegn,
Teshome) Department of Anesthesia, College of Health Sciences, Debre Tabor
University, Debre Tabor, Ethiopia
Publisher
Frontiers Media SA
Abstract
Background: Acute postoperative pain after thoracic surgery might lead to
chronic postsurgical pain (PSP), which lowers quality of life. The
literature suggests thoracic paravertebral block (PVB) as a pain
management approach. The ESPB (erector spinae plane block) is regarded to
be an effective PVB alternative. The analgesic efficacy of the two
analgesic therapies is controversial. The purpose of this study is to
compare the analgesic efficacy of ESPB and PVB in preventing acute PSP.
 Method(s): We searched relevant articles in PubMed, Cochrane Library,
Embase, Web of Science, and Google Scholar databases. The primary outcome
was postoperative pain score, with secondary outcomes including analgesic
consumption, the frequency of rescue analgesia, and postoperative nausea
and vomiting. Result(s): This meta-analysis included ten RCTs with a
total of 670 patients. PVB significantly lowered the pain scores at
movement at 12 h following surgery as compared to the ESPB. The PVB group
used much less opioids within 24 h after surgery compared to the ESPB
group. However, there were no significant differences between the groups
in terms of postoperative rescue analgesia or in the incidence of
postoperative nausea and vomiting (p > 0.05). Conclusion(s): PVB
produced superior analgesia than ESPB in patients who underwent thoracic
surgeries. In addition, PVB demonstrated greater opioid sparing effect by
consuming much less opioids. Systematic review registration: This trial is
registered on PROSPERO, number CRD42023412159. Copyright © 2023
Fenta, Kibret, Hunie, Tamire, Mekete, Tiruneh, Fentie, Dessalegn and
Teshome.

<28>
Accession Number
2026520629
Title
Hormonal changes in the first 24 postoperative hours after cardiac
surgical procedures.
Source
Physiology International. (no pagination), 2023. Date of Publication:
2023.
Author
Szecsi B.; Toth K.; Szabo A.; Eke C.; Szentgroti R.; Dohan O.; Benke K.;
Radovits T.; Polos M.; Merkely B.; Gal J.; Szekely A.
Institution
(Szecsi, Toth, Eke, Szentgroti) Doctoral School of Theoretical and
Translational Medicine, Semmelweis University, Budapest, Hungary
(Szabo, Gal, Szekely) Department of Anesthesiology and Intensive Therapy,
Semmelweis University, Budapest, Hungary
(Dohan) Department of Internal Medicine and Oncology, Semmelweis
University, Budapest, Hungary
(Benke, Radovits, Polos, Merkely) Heart and Vascular Centre, Semmelweis
University, Budapest, Hungary
(Szekely) Department of Oxiology and Emergency Care, Semmelweis
University, Budapest, Hungary
Publisher
Akademiai Kiado ZRt.
Abstract
Background: Hormone level changes after heart surgeries are a widely
observed phenomenon due to neurohormonal feedback mechanisms that may
affect postoperative morbidity and mortality. The current study aimed to
analyze the changes in thyroid and sex hormones in the first 24
postoperative hours after heart surgery. Method(s): This prospective,
observational study (registered on ClinicalTrials.gov: NCT03736499;
09/11/2018) included 49 patients who underwent elective cardiac surgical
procedures at a tertiary heart center between March 2019 and December
2019. Thyroid hormones, including thyroid-stimulating hormone (TSH),
triiodothyronine (T3), and thyroxine (T4), and sex hormones, including
prolactin (PRL) and total testosterone, were measured preoperatively and
at 24 h postoperatively. Result(s): Significant decreases in serum
TSH (P < 0.001), T3 (P < 0.001) and total testosterone (P < 0.001) levels
were noted, whereas T4 (P = 0.554) and PRL (P = 0.616) did not
significantly change. Intensive care unit (ICU) hours (P < 0.001),
mechanical ventilation (P < 0.001) and Vasoactive-Inotropic Score (VIS) (P
= 0.006) were associated with postoperative T3 level. ICU hours were
associated with postoperative T4 level (P = 0.028). Postoperative and
delta testosterone levels were in connection with lengths of stay in ICU
(P = 0.032, P = 0.010 respectively). Model for End-Stage Liver Disease
(MELD) scores were associated with thyroid hormone levels and serum
testosterone. Conclusion(s): T3 may represent a marker of
nonthyroidal illness syndrome and testosterone may reflect hepatic
dysfunction. In addition, PRL may act as a stress hormone in female
patients. Copyright © 2023 The Author(s).

<29>
Accession Number
642176552
Title
Rationale and design of the ULYSS trial: A randomized multicenter
evaluation of the efficacy of early Impella CP implantation in acute
coronary syndrome complicated by cardiogenic shock.
Source
American heart journal. (no pagination), 2023. Date of Publication: 30
Aug 2023.
Author
Delmas C.; Laine M.; Schurtz G.; Roubille F.; Coste P.; Leurent G.;
Hraiech S.; Pankert M.; Gonzalo Q.; Dabry T.; Letocart V.; Loubiere S.;
Resseguier N.; Bonello L.
Institution
(Delmas) Intensive Cardiac Care Unit, Rangueil University Hospital, 31059
Toulouse, France; INSERM U1048, I2MC, Toulouse, France; REICATRA, Institut
Saint Jacques, 31059 Toulouse, France
(Laine, Bonello) Aix-Marseille Universite, F-13385 Marseille, France;
Intensive Care Unit, Department of Cardiology, Assistance
Publique-Hopitaux de Marseille, Hopital Nord, F-13385 Marseille, France;
Mediterranean Association for Research and Studies in Cardiology (MARS
Cardio), Marseille, France
(Schurtz) Intensive Cardiac Care Unit, Lille University Hospital, Lille,
France
(Roubille) PhyMedExp, Universite de Montpellier, INSERM, CNRS, Cardiology
Department, CHU de Montpellier, France
(Coste) Cardiology Department, Bordeaux University Hospital, Pessac,
France
(Leurent) Intensive Cardiac Care Unit, Cardiology Department, Rennes
University Hospital, Rennes, France
(Hraiech) Medical Intensive Care Unit, Assistance Publique-Hopitaux de
Marseille, Hopital Nord, Marseille F-13385, France
(Pankert) Cardiology Department, CH Avignon, France
(Gonzalo) Cardiology Department, CH Toulon, France
(Dabry) Cardiology Department, CH Aix en Provence, France
(Letocart) Department of Cardiology, CHU Nantes, l'institut du thorax,
Nantes, France
(Loubiere, Resseguier) Department of Epidemiology and Health Economics,
APHM, Marseille, France; CEReSS-Health Service Research and Quality of
Life Center, School of Medicine Aix-Marseille University Marseille France
Publisher
NLM (Medline)
Abstract
Despite 20 years of improvement in acute coronary syndromes care, patients
with acute myocardial infarction complicated by cardiogenic shock (AMICS)
remains a major clinical challenge with a stable incidence and mortality.
While intra-aortic balloon pump (IABP) did not meet its expectations,
percutaneous mechanical circulatory supports (pMCS) with higher
hemodynamic support, large availability and quick implementation may
improve AMICS prognosis by enabling early hemodynamic stabilization and
unloading. Both interventional and observational studies suggested a
clinical benefit in selected patients of the IMPELLA CP device within in a
well-defined therapeutic strategy. While promising, these preliminary
results are challenged by others suggesting a higher rate of complications
and possible poorer outcome. Given these conflicting data and its high
cost, a randomized clinical trial is warranted to delineate the benefits
and risks of this new therapeutic strategy. The ULYSS trial is a
prospective randomized open label, 2 parallel multicenter clinical trial
that plans to enroll patients with AMICS for whom an emergent percutaneous
coronary intervention (PCI) is intended. Patients will be randomized to an
experimental therapeutic strategy with pre-PCI implantation of an IMPELLA
CP device on top of standard medical therapy or to a control group
undergoing PCI and standard medical therapy. The primary objective of this
study is to compare the efficacy of this experimental strategy by a
composite endpoint of death, need to escalate to ECMO, long-term left
ventricular assist device or heart transplantation at 1 month. Among
secondary objectives one-year efficacy, safety and cost effectiveness will
be assessed. Copyright © 2023. Published by Elsevier Inc.

<30>
Accession Number
642176487
Title
Glutamate infusion reduces myocardial dysfunction after coronary artery
bypass grafting according to NT-proBNP: summary of two randomized
controlled trials (GLUTAMICS I-II).
Source
The American journal of clinical nutrition. (no pagination), 2023. Date
of Publication: 30 Aug 2023.
Author
Holm J.; Vanky F.; Svedjeholm R.
Institution
(Holm, Vanky, Svedjeholm) Department of Thoracic and Vascular Surgery,
Dept of Health, Medicine and Caring Sciences, Unit of Cardiovascular
Medicine, Linkoping University, Sweden
Publisher
NLM (Medline)
Abstract
BACKGROUND: Glutamate is reported to enhance recovery of oxidative
metabolism and contractile function of the heart after ischemia. The
effect appears to be blunted in diabetic hearts. Elevated plasma
N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial
dysfunction. In the GLUTAmate for Metabolic Intervention in Coronary
Surgery (GLUTAMICS) II trial the proportion of patients with diabetes had
almost doubled to 47% compared to the cohort used for sample size
estimation, and a significant effect on postoperative NT-proBNP rise was
only observed in patients without diabetes. OBJECTIVE(S): Our aim was
to summarize pooled NT-proBNP results from the GLUTAMICS trials and
address the impact of diabetes. METHOD(S): Data from two prospective,
randomized, double-blind multicenter trials with similar inclusion
criteria and endpoints were pooled. Patients underwent CABG +/- valve
procedure and had left ventricular ejection fraction <=0.30 or EuroSCORE
II >= 3.0 with at least one cardiac risk factor. Intravenous infusion of
0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was started 10-20
minutes before reperfusion and continued for 150 minutes. The primary
endpoint was the difference between preoperative and day-3 postoperative
NT-proBNP levels. RESULT(S): 451 patients, 224 receiving glutamate
and 227 controls, fulfilled inclusion criteria. Glutamate was associated
with a reduced primary endpoint (5344 +/- 5104 ng/L vs. 6662 +/- 5606
ng/L; p=0.01). Postoperative mortality <=30days was 0.9% vs. 3.5%
(p=0.11), and stroke <=24 h was 0.4% vs. 2.6% (p=0.12). No adverse events
related to glutamate were detected. A significant interaction regarding
the primary endpoint was only detected between glutamate and
insulin-treated diabetes (p = 0.04). Among patients without
insulin-treated diabetes, the primary endpoint was 5047 +/- 4705 ng/L vs.
7001 +/- 5830 ng/L (p=0.001). CONCLUSION(S): Infusion of glutamate
reduced postoperative rise in NT-proBNP after CABG in medium to high-risk
patients. A significantly blunted effect was observed only in
insulin-treated diabetes patients. CLINICAL TRIAL REGISTRATION:
NCT02592824,
https://clinicaltrials.gov/ct2/show/NCT02592824. Copyright © 2023
The Author(s). Published by Elsevier Inc. All rights reserved.

<31>
Accession Number
608827005
Title
Effect of Pre-Hospital Ticagrelor during the First 24 h after Primary
Percutaneous Coronary Intervention in Patients with ST-Segment Elevation
Myocardial Infarction the ATLANTIC-H24 Analysis.
Source
JACC: Cardiovascular Interventions. 9(7) (pp 646-656), 2016. Date of
Publication: 11 Apr 2016.
Author
Montalescot G.; Van 'T Hof A.W.; Bolognese L.; Cantor W.J.; Cequier A.;
Chettibi M.; Collet J.-P.; Goodman S.G.; Hammett C.J.; Huber K.; Janzon
M.; Lapostolle F.; Lassen J.F.; Licour M.; Merkely B.; Salhi N.; Silvain
J.; Storey R.F.; Ten Berg J.M.; Tsatsaris A.; Zeymer U.; Vicaut E.; Hamm
C.W.; Bougherbal R.; Bouafia M.T.; Nibouche D.; Moklati A.; Benalia A.;
Kaid O.; Krim M.; Garrahy P.; Jayasinghe R.; Rashford S.; Neunteufl T.;
Brussee H.; Alber H.; Weidinger F.; Brunner M.; Sipoetz J.; Prause G.;
Baubin M.; Sebald D.; Vijayaraghavan R.; Bata I.; Lavoie A.; Ravkilde J.;
Jensen L.O.; Christensen A.Mo.; Toftegaard M.; Kohler D.; Ducrocq G.;
Danchin N.; Henry P.; Livarek B.; Berthier R.; Hovasse T.; Garot P.; Payot
L.; Benamer H.; Esteve J.B.; Elhadad S.; Teiger E.; Bonnet J.L.; Paganelli
F.; Cottin Y.; Schiele F.; Thuaire C.; Cayla G.; Coste P.; Ohlmann P.;
Cudraz E.B.; Lantelme P.; Perret T.; Tron C.; De Labriolle A.; Aptecar E.;
Beliard O.; Varenne O.; El Mahmoud R.; Filippi-Codaccioni E.; Angoulvant
D.; Peycher P.; Poitrineau O.; Tabone X.; Ecollan P.; Broche C.; Lambert
Y.; Briole N.; Beruben A.; Porcher N.; Auffray J.-P.; Freysz M.; Depardieu
F.; Poubel D.; De La Cousaye J.-E.; Bartier J.-C.; Jardel B.; Boulanger
B.; Labourel H.; Soulat L.-C.; Julie V.; Thicoipe M.; Capel O.; Stibbe O.;
Carli P.; Tazarourte K.; Alcouffe F.; Aboucaya D.; Aubert G.; Kierzek G.;
Cahun-Giraud S.; Dengler T.; Prondzinsky R.; Biever P.M.; Schafer A.;
Seyfarth M.; Lemke B.; Werner G.; Nef H.; Steiger H.; Leschke M.; Munzel
T.; Dell Orto M.C.; Loges C.; Schinke M.; Koberne F.; Reiffen H.P.; Tiroch
K.; Wierich D.; Kneussel M.; Little S.; Sauer H.; Laufenberg-Feldmann R.;
Ungi I.; Horvath I.; Edes I.; Martai I.; Berti S.; Chiarella F.; Calabria
P.; Fineschi M.; Galvani M.; Valgimigli M.; Moretti L.; Tespili M.; Mando
M.; Bermano F.; Biagioni R.; Fabbri A.; Ricciardelli A.; Petroni M.R.;
Vatteroni U.R.; Palumbo F.; Willems F.F.; Al Mafragi A.; Heestermans
T.A.A.C.M.; Van Eck M.J.; Heutz W.M.J.M.; Meppelder H.H.; Jong A.R.-D.;
Van De Pas H.; Fillat A.C.; Tenas M.S.; Ferrer J.M.; Penaranda A.S.;
Ferrer J.A.; Del Blanco B.G.; Guardiola F.M.; Ruiz Nodar J.M.; Romo A.I.;
Gonzalez N.V.; Nouche R.T.; De La Llera L.D.; Hernandez Garcia J.M.;
Rivero-Crespo F.; Hernandez F.H.; Zamorano Gomez J.L.; Farega X.J.;
Fernandez G.A.; Toboso J.L.; Carrasco M.; Barreiro V.; Iglesias Vazquez
J.A.; Montero M.D.M.R.; Ortiz F.R.; Escudero G.G.; Ingelmo V.S.-B.; Garcia
A.L.; Oldgren J.; Calais F.; Kastberg R.; Bergsten P.-A.; Blomberg H.;
Thorn K.; Skoog G.; Zaman A.; Gerber R.; Ryding A.; Spence M.; Swanson N.;
Been M.; Grosser K.; Schofield P.; Mackin D.; Fell P.; Quinn T.; Foster
T.; McManus D.; Carson A.
Institution
(Montalescot, Collet, Silvain) Universite Paris 6, ACTION Study Group,
Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire
Pitie-Salpetriere, INSERM UMRS 1166, 47 Boulevard de lHopital, Paris
75013, France
(Van 'T Hof) Department of Cardiology, Isala Clinics, Zwolle, Netherlands
(Bolognese) Cardiovascular and Neurological Department, Azienda
Ospedaliera Arezzo, Arezzo, Italy
(Cantor) Southlake Regional Health Centre, University of Toronto,
Newmarket, ON, Canada
(Cequier) Heart Disease Institute, Hospital Universitario de Bellvitge,
University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
(Chettibi) Centre Hospito-Universitaire Frantz Fanon, Blida, Algeria
(Goodman) Canadian Heart Research Centre, Division of Cardiology, St.
Michael's Hospital, University of Toronto, Toronto, Canada
(Hammett) Department of Cardiology, Royal Brisbane and Women's Hospital,
Brisbane, QLD, Australia
(Huber) 3rd Department of Medicine, Cardiology and Intensive Care
Medicine, Wilhelminenhospital, Vienna, Austria
(Janzon) Department of Cardiology, Linkoping University, Linkoping, Sweden
(Lapostolle) SAMU 93 Hopital Avicenne, Bobigny, France
(Lassen) Department of Cardiology B, Aarhus University Hospital, Aarhus N,
Denmark
(Licour, Tsatsaris) AstraZeneca, Rueil Malmaison, France
(Merkely) Heart and Vascular Center, Semmelweis University, Budapest,
Hungary
(Salhi) AstraZeneca, Luton, United Kingdom
(Storey) Department of Cardiovascular Science, University of Sheffield,
Sheffield, United Kingdom
(Ten Berg) Department of Cardiology, St. Antonius Hospital Nieuwegein,
Nieuwegein, Netherlands
(Zeymer) Klinikum Ludwigshafen, Institut fur Herzinfarktforschung
Ludwigshafen, Ludwigshafen, Germany
(Vicaut) Unite de Recherche Clinique, Universite Paris 7, Hopital
Lariboisiere, ACTION Study Group, Paris, France
(Hamm) Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim,
Germany
Publisher
Elsevier Inc.
Abstract
Objectives The aim of this landmark exploratory analysis,
ATLANTIC-H24, was to evaluate the effects of pre-hospital
ticagrelor during the first 24 h after primary percutaneous coronary
intervention (PCI) in the ATLANTIC (Administration of Ticagrelor in the
cath Lab or in the Ambulance for New ST elevation myocardial infarction to
open the Coronary artery) study. Background The ATLANTIC trial in patients
with ongoing ST-segment elevation myocardial infarction showed that
pre-hospital ticagrelor was safe but did not improve pre-PCI coronary
reperfusion compared with in-hospital ticagrelor. We hypothesized that the
effect of pre-hospital ticagrelor may not have manifested until after PCI
due to the rapid transfer time (31 min). Methods The
ATLANTIC-H24 analysis included 1,629 patients who underwent
PCI, evaluating platelet reactivity, Thrombolysis In Myocardial Infarction
flow grade 3, >=70% ST-segment elevation resolution, and clinical
endpoints over the first 24 h. Results Following PCI, largest
between-group differences in platelet reactivity occurred at 1 to 6 h;
coronary reperfusion rates numerically favored pre-hospital ticagrelor,
and the degree of ST-segment elevation resolution was significantly
greater in the pre-hospital group (median, 75.0% vs. 71.4%; p = 0.049). At
24 h, the composite ischemic endpoint was lower with pre-hospital
ticagrelor (10.4% vs. 13.7%; p = 0.039), as were individual endpoints of
definite stent thrombosis (p = 0.0078) and myocardial infarction (p =
0.031). All endpoints except death (1.1% vs. 0.2%; p = 0.048) favored
pre-hospital ticagrelor, with no differences in bleeding events.
Conclusions The effects of pre-hospital ticagrelor became apparent after
PCI, with numerical differences in platelet reactivity and immediate
post-PCI reperfusion, associated with reductions in ischemic endpoints,
over the first 24 h, whereas there was a small excess of mortality.
(Administration of Ticagrelor in the cath Lab or in the Ambulance for New
ST elevation myocardial infarction to open the Coronary artery [ATLANTIC,
NCT01347580]) Copyright © 2016 American College of Cardiology
Foundation.

<32>
Accession Number
2026377808
Title
3-Year Outcome in Patients With Combined Precapillary and Postcapillary
Pulmonary Hypertension: Results From PADN-5 Trial.
Source
JACC: Heart Failure. Part 2. 11(8) (pp 1135-1146), 2023. Date of
Publication: August 2023.
Author
Zhang H.; Kan J.; Zhang J.; Xie D.; Li X.; Zhou W.; Dong J.; Gu H.; Han
Y.; Chen S.-L.
Institution
(Zhang, Kan, Zhang, Zhou, Chen) Division of Cardiology, Nanjing First
Hospital, Nanjing Medical University, Nanjing, China
(Xie, Li) Division of Cardiology, Nanjing Cardiovascular Hospital,
Nanjing, China
(Dong, Gu) Division of Pulmonology, Anzhen Hospital, Capital Medical
University, Beijing, China
(Han) Division of Cardiology, Shenyang Northern Hospital, Shenyang, China
Publisher
Elsevier Inc.
Abstract
Background: Long-term benefits of pulmonary artery denervation (PADN) for
patients with combined precapillary and postcapillary pulmonary
hypertension (CpcPH) secondary to left heart failure are unknown.
 Objective(s): The authors sought to report the 3-year clinical
results of PADN for patients with CpcPH. Method(s): A total of 98
patients with CpcPH, defined as having mean pulmonary arterial pressure of
>=25 mm Hg, pulmonary capillary wedge pressure of >15 mm Hg, and pulmonary
vascular resistance of >3.0 WU, were randomly assigned to receive the sham
+ sildenafil or PADN. The primary endpoint was the occurrence of clinical
worsening defined as cardiopulmonary death, rehospitalization or
heart/lung transplantation at 3-year follow-up. Changes in the 6-minute
walk distance and N-terminal pro-B-type natriuretic peptide served as
secondary points. Result(s): At the 3-year follow-up, clinical
worsening was reported in 49 (50.0%) patients, with 31 (62.0%) in the sham
+ sildenafil group and 18 (37.5%) in the PADN group (HR: 2.13 [95% CI:
1.19-3.81]; P = 0.011), largely driven by a higher rate of
rehospitalization in the sham + sildenafil group (56.2% vs 35.4%; HR: 1.96
[95% CI: 1.07-3.58]; P = 0.029) by Cox proportional hazards regression. At
the end of the study, cardiopulmonary-related deaths occurred in 16
(32.0%) patients in the sham and 9 (18.8%) (P = 0.167) patients in the
PADN group. PADN also resulted in a more profound increase in the 6-minute
walk distance and reduction in N-terminal pro-B-type natriuretic peptide.
 Conclusion(s): PADN is associated with significant improvements in
exercise capacity, cardiac function, and clinical outcomes. Further study
without approved drugs for pulmonary arterial hypertension is required to
confirm the benefits of PADN for patients with CpcPH. (Pulmonary Arterial
Denervation in Patients With Pulmonary Hypertension Associated With the
Left Heart Failure [PADN-5]; NCT02220335) Copyright © 2023
American College of Cardiology Foundation

<33>
Accession Number
2025758813
Title
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous
Coronary Intervention.
Source
Journal of the American College of Cardiology. 82(5) (pp 401-410), 2023.
Date of Publication: 01 Aug 2023.
Author
Lee S.-J.; Joo J.H.; Park S.; Kim C.; Choi D.-W.; Hong S.-J.; Ahn C.-M.;
Kim J.-S.; Kim B.-K.; Ko Y.-G.; Choi D.; Jang Y.; Nam C.-M.; Hong M.-K.
Institution
(Lee, Hong, Ahn, Kim, Kim, Ko, Choi, Hong) Severance Hospital, Yonsei
University College of Medicine, Seoul, South Korea
(Joo, Nam) Department of Preventive Medicine, Yonsei University College of
Medicine, Seoul, South Korea
(Joo, Park) Graduate School of Public Health, Yonsei University, Seoul,
South Korea
(Kim) Ewha Womans University College of Medicine, Seoul Hospital, Seoul,
South Korea
(Choi) Cancer Big Data Center, National Cancer Center, Goyang, South Korea
(Jang) CHA University College of Medicine, Seongnam, South Korea
Publisher
Elsevier Inc.
Abstract
Background: The RACING (randomized comparison of efficacy and safety of
lipid-lowering with statin monotherapy versus statin/ezetimibe combination
for high-risk cardiovascular diseases) trial examined the effects of
combination therapy with moderate-intensity statin and ezetimibe in
patients with atherosclerotic cardiovascular disease compared with
high-intensity statin monotherapy. Objective(s): This observational
study was conducted to evaluate the impact of 2 treatment strategies used
in the RACING trial in clinical practice. Method(s): After stabilized
inverse probability of treatment weighting, a total of 72,050 patients who
were prescribed rosuvastatin after drug-eluting stent implantation were
identified from a nationwide cohort database: 10,794 patients with
rosuvastatin 10 mg plus ezetimibe 10 mg (combination lipid-lowering
therapy) and 61,256 patients with rosuvastatin 20 mg monotherapy. The
primary endpoint was the 3-year composite event of cardiovascular death,
myocardial infarction, coronary artery revascularization, hospitalization
for heart failure treatment, or nonfatal stroke in accordance with the
RACING trial. Result(s): Combination lipid-lowering therapy was
associated with a lower occurrence of the primary endpoint (11.6% vs 15.2%
for those with high-intensity statin monotherapy; HR: 0.75; 95% CI:
0.70-0.79; P < 0.001). Compared with high-intensity statin monotherapy,
combination lipid-lowering therapy was associated with fewer
discontinuations of statin (6.5% vs 7.6%; HR: 0.85; 95% CI: 0.78-0.94: P <
0.001) and a lower occurrence of new-onset diabetes requiring medication
(7.7% vs 9.6%; HR: 0.80; 95% CI: 0.72-0.88; P < 0.001).
 Conclusion(s): In clinical practice, combination lipid-lowering
therapy with ezetimibe and moderate-intensity statin was associated with
favorable clinical outcomes and drug compliance in patients treated with
drug-eluting stent implantation. (CONNECT DES Registry;
NCT04715594) Copyright © 2023 American College of Cardiology
Foundation

<34>
Accession Number
2025142558
Title
How European Research Projects Can Support Vaccination Strategies: The
Case of the ORCHESTRA Project for SARS-CoV-2.
Source
Vaccines. 11(8) (no pagination), 2023. Article Number: 1361. Date of
Publication: August 2023.
Author
Azzini A.M.; Canziani L.M.; Davis R.J.; Mirandola M.; Hoelscher M.; Meyer
L.; Laouenan C.; Giannella M.; Rodriguez-Bano J.; Boffetta P.; Mates D.;
Malhotra-Kumar S.; Scipione G.; Stellmach C.; Rinaldi E.; Hasenauer J.;
Tacconelli E.
Institution
(Azzini, Canziani, Davis, Mirandola, Tacconelli) Infectious Diseases
Division, Department of Diagnostics and Public Health, University of
Verona, Verona 37134, Italy
(Hoelscher) Division of Infectious Diseases and Tropical Medicine, Medical
Center of the University of Munich (LMU), Munich 80802, Germany
(Hoelscher) German Center for Infection Research (DZIF), Partner Site
Munich, Munich 80802, Germany
(Meyer) Centre de Recherche en Epidemiologie et Sante des Population,
Institut National de la Sante et de la Recherche Medicale (INSERM),
Universite Paris-Saclay, Le Kremlin-Bicetre 94270, France
(Laouenan) INSERM, IAME, UMR 1137, Universite Paris Cite, Paris 75018,
France
(Laouenan) Departement d'Epidemiologie Biostatistiques e Recherche
Clinique, AP-HP, Hospital Bichat, Paris 75018, France
(Giannella) Infectious Diseases Unit, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy
(Giannella, Boffetta) Department of Medical and Surgical Sciences,
University of Bologna, Bologna 40138, Italy
(Rodriguez-Bano) Infectious Diseases and Microbiology Unit, Hospital
Universitario Virgen Macarena, Department of Medicine, Biomedicines
Institute of Sevilla-CSIC, University of Sevilla, Sevilla 41004, Spain
(Rodriguez-Bano) Centro de Investigacion Biomedica en Red en Enfermedades
Infecciosas, Instituto de Salud Carlos III, Madrid 28029, Spain
(Boffetta) Stony Brook Cancer Center, Stony Brook University, Stony Brook,
NY 10041, United States
(Mates) National Institute of Public Health, Bucharest 050463, Romania
(Malhotra-Kumar) Laboratory of Medical Microbiology, Vaccine & Infectious
Disease Institute, University of Antwerp, Antwerp 2000, Belgium
(Scipione) Supercomputing Applications and Innovation Department, Cineca
Consorzio Interuniversitario, Bologna 40033, Italy
(Stellmach, Rinaldi) Berlin Institute of Health at Charite,
Universitatsmedizin Berlin, Berlin 10117, Germany
(Hasenauer) Life and Medical Sciences Institute, University of Bonn, Bonn
53113, Germany
(Hasenauer) Institute of Computational Biology, Helmholtz Center
Munich-German Research Center for Environmental Health, Neuherberg 85764,
Germany
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
ORCHESTRA ("Connecting European Cohorts to Increase Common and Effective
Response To SARS-CoV-2 Pandemic") is an EU-funded project which aims to
help rapidly advance the knowledge related to the prevention of the
SARS-CoV-2 infection and the management of COVID-19 and its long-term
sequelae. Here, we describe the early results of this project, focusing on
the strengths of multiple, international, historical and prospective
cohort studies and highlighting those results which are of potential
relevance for vaccination strategies, such as the necessity of a vaccine
booster dose after a primary vaccination course in hematologic cancer
patients and in solid organ transplant recipients to elicit a higher
antibody titer, and the protective effect of vaccination on severe
COVID-19 clinical manifestation and on the emergence of post-COVID-19
conditions. Valuable data regarding epidemiological variations, risk
factors of SARS-CoV-2 infection and its sequelae, and vaccination efficacy
in different subpopulations can support further defining public health
vaccination policies. Copyright © 2023 by the authors.

<35>
Accession Number
2023426207
Title
Edge-to-Edge Transcatheter Mitral Valve Repair Using PASCAL vs. MitraClip:
A Systematic Review and Meta-Analysis.
Source
Journal of Clinical Medicine. 12(10) (no pagination), 2023. Article
Number: 3579. Date of Publication: May 2023.
Author
Hosseini K.; Soleimani H.; Nasrollahizadeh A.; Jenab Y.; Karlas A.;
Avgerinos D.V.; Briasoulis A.; Kuno T.; Doulamis I.; Kampaktsis P.N.
Institution
(Hosseini, Soleimani, Nasrollahizadeh, Jenab) Cardiac Primary Prevention
Research Center, Cardiovascular Diseases Research Institute, Tehran
University of Medical Sciences, Tehran 1419733141, Iran, Islamic Republic
of
(Hosseini, Soleimani, Nasrollahizadeh, Jenab) Tehran Heart Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran 1419733141, Iran, Islamic Republic of
(Soleimani) Non-Communicable Diseases Research Center, Endocrinology and
Metabolism Population Sciences Institute, Tehran University of Medical
Sciences, Tehran 1411713139, Iran, Islamic Republic of
(Karlas) Institute for Biological and Medical Imaging, Helmholtz Zentrum
Munchen, Neuherberg 85764, Germany
(Karlas) Department for Vascular and Endovascular Surgery, Rechts der Isar
Hospital, Technical University of Munich, Munich 81675, Germany
(Avgerinos) Onassis Cardiac Surgery Center, Athens 17674, Greece
(Briasoulis) Medical School, National and Kapodistrian University of
Athens, Athens 11527, Greece
(Kuno) Department of Medicine, Montefiore Medical Center, New York, NY
10461, United States
(Doulamis) Department of Surgery, The Johns Hopkins Hospital, School of
Medicine, Baltimore, MD 21287, United States
(Kampaktsis) Division of Cardiology, Columbia University Irving Medical
Center, New York, NY 10032, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Transcatheter edge-to-edge repair (TEER) of the mitral valve
(MV) can be performed using the PASCAL or MitraClip devices. Few studies
offer a head-to-head outcome comparison of these two devices.
 Material(s) and Method(s): PubMed, EMBASE, Cochrane Library,
Clinicaltrials.gov and WHO's International Clinical Trials Registry
Platform, from 1 January 2000 until 1 March 2023, were searched. Study
protocol details were registered in the International Prospective Register
of Systematic Reviews (PROSPERO ID: CRD42023405400). Randomized Controlled
Trials and observational studies reporting head-to-head clinical
comparison of PASCAL and MitraClip devices were eligible for selection.
Patients with severe functional or degenerative mitral regurgitation (MR)
who had undergone TEER of the MV with either PASCAL or MitraClip devices
were included in the meta-analysis. Data from six studies (five
observational and one randomized clinical trial) were extracted and
analyzed. The main outcomes were a reduction in MR to 2+ or less,
improvement of New York Heart Association (NYHA) and 30-day all-cause
mortality. Peri-procedural mortality, success rate and adverse events were
also compared. Result(s): Data from 785 and 796 patients that
underwent TEER using PASCAL and MitraClip, respectively, were analyzed.
Thirty-day all-cause mortality (Risk ratio [RR] = 1.51, 95% CI 0.79-2.89),
MR reduction to maximum 2+ (RR = 1.00, 95% CI 0.98-1.02) and NYHA
improvement (RR = 0.98, 95% CI 0.84-1.15) were similar in both device
groups. Both devices had high and similar success rates (96.9% and 96.7%
for the PASCAL and MitraClip group, respectively, p value = 0.91). MR
reduction to 1+ or less at discharge was similar in both device groups (RR
= 1.06, 95% CI 0.95-1.19). Composite peri-procedural and in-hospital
mortality was 0.64% and 1.66% in the PASCAL and MitraClip groups,
respectively (p value = 0.094). Rates of peri-procedural cerebrovascular
accidents were 0.26% in PASCAL and 1.01% in MitraClip (p value = 0.108).
 Conclusion(s): Both PASCAL and MitraClip devices have high success
and low complication rates for TEER of the MV. PASCAL was not inferior to
MitraClip in reducing the MR level at discharge. Copyright © 2023
by the authors.

<36>
Accession Number
2023061741
Title
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic
surgery for lung cancer: A randomized, noninferiority trial.
Source
American Journal of Hematology. 98(8) (pp 1185-1195), 2023. Date of
Publication: August 2023.
Author
Zhao M.; Bao Y.; Jiang C.; Chen L.; Xu L.; Liu X.; Yang Y.; Jiang G.; Li
J.; She Y.; Chen Q.; Shen L.; Chen C.
Institution
(Zhao, Bao, Jiang, Chen, Liu, Li, Yang, Jiang, She, Chen, Shen, Chen)
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji
University School of Medicine, Shanghai, China
(Xu) Department of Ultrasound, Shanghai Pulmonary Hospital, Tongji
University School of Medicine, Shanghai, China
(Li) Clinical Research Center, Ruijin Hospital, Shanghai Jiaotong
University School of Medicine, Shanghai, China
(Shen) Department of Infectious Diseases, Shanghai Key Laboratory of
Infectious Diseases and Biosafety Emergency Response, National Medical
Center for Infectious Diseases, Huashan Hospital, Fudan University,
Shanghai, China
Publisher
John Wiley and Sons Inc
Abstract
The benefit of rivaroxaban in thromboprophylaxis after oncologic lung
surgery remains unknown. To evaluate the efficacy and safety of
rivaroxaban, patients who underwent thoracic surgery for lung cancer were
enrolled, and randomly assigned to rivaroxaban or nadroparin groups in a
1:1 ratio; anticoagulants were initiated 12-24 h after surgery and
continued until discharge. Four hundred participants were required
according to a noninferiority margin of 2%, assuming venous
thromboembolism (VTE) occurrence rates of 6.0% and 12.6% for patients in
the rivaroxaban and nadroparin groups, respectively. The primary efficacy
outcome was any VTE during the treatment and 30-day follow-up periods. The
safety outcome was any on-treatment bleeding event. Finally, 403 patients
were randomized (intention-to-treat [ITT] population), with 381 included
in per-protocol (PP) population. The primary efficacy outcomes occurred in
12.5% (25/200) of the rivaroxaban group and 17.7% (36/203) of the
nadroparin group (absolute risk reduction, -5.2%; 95% confidence interval
[CI], [-12.2-1.7]), indicating the noninferiority of rivaroxaban in ITT
population. Sensitivity analysis was performed in the PP population and
yielded similar results, confirming the noninferiority of rivaroxaban. In
the safety analysis population, the incidence of any on-treatment bleeding
events did not differ significantly between the groups (12.2% for
rivaroxaban vs. 7.0% for nadroparin; relative risk [RR], 1.9; 95% CI,
[0.9-3.7]; p =.08), including major bleeding (9.7% vs. 6.5%; RR, 1.6 [95%
CI, 0.9-3.7]; p =.24), and nonmajor bleeding (2.6% vs. 0.5%; RR, 5.2 [95%
CI, 0.6-45.2]; p =.13). Rivaroxaban for thromboprophylaxis after oncologic
lung surgery was shown to be noninferior to nadroparin. Copyright
© 2023 Wiley Periodicals LLC.

<37>
Accession Number
2026170784
Title
Clinical outcomes following tricuspid transcatheter edge-to-edge repair
with PASCAL: A meta-analysis.
Source
International Journal of Cardiology. 389 (no pagination), 2023. Article
Number: 131194. Date of Publication: 15 Oct 2023.
Author
Badwan O.; Mirzai S.; Skoza W.; Hawk F.; Braghieri L.; Persits I.;
Krishnaswamy A.; Puri R.; Kapadia S.R.
Institution
(Badwan, Mirzai, Skoza, Braghieri, Persits) Department of Internal
Medicine, Cleveland Clinic, Cleveland, OH, United States
(Hawk) Division of Cardiovascular Medicine, University of South Florida
College of Medicine, Tampa, FL, United States
(Krishnaswamy, Puri, Kapadia) Department of Cardiovascular Medicine,
Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH,
United States
Publisher
Elsevier Ireland Ltd
Abstract
Background: Patients with severe tricuspid regurgitation (TR) exhibit high
morbidity and mortality. Tricuspid transcatheter edge-to-edge repair
(T-TEER) is a rapidly evolving strategy to address the unmet clinical need
of severe TR therapies. Objective(s): Organize the current body of
evidence on outcomes following use of the PASCAL (Edwards Lifesciences)
system for T-TEER. Method(s): For this meta-analysis, we searched the
MEDLINE/PubMed, Embase, and Cochrane databases for keywords ["tricuspid"]
and ["transcatheter" or "edge-to-edge"] and ["PASCAL" or "leaflet repair"
or "valve repair"] from the database inception until January 11, 2023.
Primary outcomes of interest were procedural success, mortality, New York
Heart Association (NYHA) functional class, 6-min walking distance (6MWD),
and TR severity. Result(s): A total of 549 patients undergoing PASCAL
or PASCAL Ace T-TEER were included. The mean age ranged from 71.0 to 80.3
years, with 25.0 to 63.6% females. The follow-up duration ranged from 30
days to 1 year. The success rate was 83.5% (409/490). There was
improvement in symptoms based on NYHA classification (at 1- to 6-months;
NYHA >=3 RR 0.27 [95% CI 0.19-0.39]; p < 0.001) and 6MWD (at 1-month;
50.96 [95% CI 32.34-69.59]; p < 0.001) post-procedure. On imaging, there
was improvement in TR severity post-procedure (at 1- to 12-months; >=
severe TR 0.21 [95% CI 0.14-0.31]; p < 0.001), which remained significant
with each study removed. Conclusion(s): PASCAL for T-TEER is
associated with high procedural success rates along with improvements in
NYHA functional class, TR severity, 6MWD, and patient-reported
outcomes. Copyright © 2023

<38>
Accession Number
2025197275
Title
Cardiovascular events risk in patients with systemic autoimmune diseases:
a prognostic systematic review and meta-analysis.
Source
Clinical Research in Cardiology. (no pagination), 2023. Date of
Publication: 2023.
Author
Asenjo-Lobos C.; Gonzalez L.; Bulnes J.F.; Roque M.; Munoz Venturelli P.;
Rodriguez G.M.
Institution
(Asenjo-Lobos, Munoz Venturelli) Centro de Estudios Clinicos, Instituto de
Ciencias e Innovacion en Medicina (ICIM), Facultad de Medicina Clinica
Alemana Universidad de Desarrollo, Santiago, Chile
(Gonzalez) Centro de Imagenes Biomedicas, Departamento de Radiologia,
Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago,
Chile
(Gonzalez) Instituto Milenio de Ingenieria e Inteligencia Artificial para
la Salud, iHEALTH, Pontificia Universidad Catolica de Chile, Santiago,
Chile
(Bulnes, Rodriguez) Division de Enfermedades Cardiovasculares, Pontificia
Universidad Catolica de Chile, Santiago, Chile
(Roque) Iberoamerican Cochrane Centre, Sant Pau Biomedical Research
Institute (IIB-Sant Pau), Barcelona, Spain
(Munoz Venturelli) Faculty of Medicine, The George Institute for Global
Health, University of New South Wales, Sydney, NSW, Australia
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Chronic inflammation is considered a risk factor for the
development of atherosclerosis and cardiovascular (CV) events. We seek to
assess the risk of CV events in patients with Systemic autoimmune diseases
(SAD), such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis
(RA), Psoriasis (Ps) and Ankylosing Spondylitis (AS), compared with the
general population. Methods and Results: A systematic search of
MEDLINE from inception up to May 2021 was performed. Observational studies
including individuals with and without autoimmune diseases (SLE, RA, Ps,
AS), which reported a measure of association and variability for the
effect of SAD on CV events, were included. The random effects
meta-analysis was performed using the Hartung-Knapp-Sidik-Jonkman approach
to obtain the pooled estimates. Cardiovascular Events including CV
mortality, non-fatal myocardial infarction (MI), non-fatal stroke and
coronary revascularization were the main outcomes evaluated. Fifty-four
studies were selected, with a total of 24,107,072 participants. The
presence of SAD was associated with an increased risk of CV mortality (HR
1.49 [95% CI 1.10-2.03]), non-fatal MI (HR 1.42 [95% CI 1.23-1.62]), and
non-fatal stroke (HR 1.47 [95% CI 1.28-1.70]). RA, SLE, and Ps
(particularly with arthritis) were significantly associated with a higher
risk of MI and stroke. SAD was also associated with an increased risk of
Major Adverse Cardiovascular Events (MACE) (HR 1.45 [95% CI 1.16-1.83]).
 Conclusion(s): Patients with SAD present an increased risk of CV
morbidity and mortality, which should be considered when establishing
therapeutic strategies. These findings support the role of systemic
inflammation in the development of atherosclerosis-driven disease.
Graphical abstract: [Figure not available: see fulltext.]. Copyright
© 2023, The Author(s), under exclusive licence to Springer-Verlag
GmbH Germany.

<39>
Accession Number
2024564686
Title
Aortic Thrombosis in Patients on Mechanical Circulatory Support: A
Systematic Literature Review.
Source
Heart Lung and Circulation. 32(8) (pp 926-937), 2023. Date of Publication:
August 2023.
Author
Guglin M.; Rao R.A.
Institution
(Guglin, Rao) Indiana University School of Medicine, Division of
Cardiovascular Disease, Krannert Institute of Cardiology, Indianapolis,
IN, United States
Publisher
Elsevier Ltd
Abstract
Background: Aortic valve (AV) thrombosis is an uncommon but ominous
complication in patients managed with mechanical circulatory support (MCS)
devices. In this systematic review, we summarised the data on clinical
presentations and outcomes in such patients. Method(s): We searched
articles on PubMed and Google Scholar, reporting at least one adult
patient with aortic thrombosis on MCS support and where the individual
patient data could be extracted. We grouped the patients by the type of
MCS (temporary or durable), and the type of the AV (prosthetic, surgically
modified, or native) Results: We identified reports on six patients with
aortic thrombus on short-term MCS, and on 41 patients on durable left
ventricular assist devices (LVADs). On temporary MCS, AV thrombus
typically causes no symptoms and is found incidentally pre- or
intra-operatively. For those with durable MCS, the occurrence of aortic
thrombus forming on prosthetic or surgically modified valves appears to be
more related to the intervention on the valve, rather than from the
presence of LVAD. The mortality in this group was 18%. In patients with
native AV on durable LVAD support, 60% of patients presented with acute
myocardial infarction, acute stroke, or acute heart failure, and mortality
in this cohort was 45%. In terms of management, heart transplantation was
most successful. Conclusion(s): While the outcomes of aortic
thrombosis were good in patients where temporary MCS was used in the
setting of aortic valve surgery, patients with native AV who develop this
complication on durable LVAD have high morbidity and mortality. Cardiac
transplantation should be strongly considered in eligible candidates
because other therapies provide inconsistent results. Copyright ©
2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons
(ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)

<40>
Accession Number
2023701863
Title
Comparison of endovenous laser ablation and cyanoacrylate embolization in
the non-invasive treatment of superficial venous insufficiency in terms of
patient satisfaction.
Source
Phlebology. 38(7) (pp 436-444), 2023. Date of Publication: August 2023.
Author
ER Z.C.; Ikbali Afsar F.; Atilgan K.; Onuk B.E.
Institution
(ER) Cardiovascular Surgery, Bozok Universitesi Tip Fakultesi, Yozgat Mer,
Turkey
(Ikbali Afsar) Cardiovascular Surgery, 29 Mayis Devlet Hastanesi, Ankara,
Turkey
(Atilgan, Onuk) Cardiovascular Surgery, TOBB ETU Hospital, Ankara, Turkey
Publisher
SAGE Publications Ltd
Abstract
Objective: Ablation with n-butyl cyanoacrylate is a clinically newer
technique than endovenous laser ablation and other interventional
techniques in the treatment of chronic venous insufficiency (CVI). The aim
of this study was to compare the endovenous laser ablation (EVLA) and
n-butyl cyanoacrylate (NBCA) interventional techniques in terms of
benefit, effectiveness, and patient satisfaction. Material(s) and
Method(s): The study was conducted at Yozgat City Hospital and Bozok
University Research Hospital Cardiovascular Surgery clinics between
November 2016 and February 2021. A total of 260 symptomatic patients with
130 randomized cases in each intervention group were included. NBCA
patients constituted Group 1 and EVLA patients Group 2. The saphenous vein
was evaluated by color Doppler ultrasonography (CDUS) of the lower
extremity. Patients with saphenous veins over 5.5 mm in diameter and a
saphenous-femoral reflux time of 2 s or longer were included in the study.
The patients were asked about their satisfaction and symptoms in the first
postoperative week during an outpatient clinic follow-up with CDUS
investigation at the first and sixth months. Result(s): Although vena
saphenous magna (VSM) closure results were similar with the two methods,
satisfaction rates were found to be higher with the NBCA procedure.
 Conclusion(s): Comparison of the new methods used in the treatment of
CVI revealed similar VSM closure rates in the two methods, but the
satisfaction rate was higher with the NBCA technique in this
study. Copyright © The Author(s) 2023.

<41>
Accession Number
2026661192
Title
A Systematic Review of the Design, Method of Implantation and Early
Clinical Outcomes of Transcatheter Tricuspid Prostheses.
Source
Reviews in Cardiovascular Medicine. 24(8) (no pagination), 2023. Article
Number: 231. Date of Publication: 2023.
Author
Sazzad F.; Zhu Y.; Leo H.L.; Nah J.H.; Ang H.Y.; Lee C.N.; Hon J.K.F.
Institution
(Sazzad, Nah, Lee, Hon) Department of Surgery, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore 117597, Singapore
(Zhu, Leo, Ang, Lee) Department of Biomedical Engineering, College of
Design and Engineering, National University of Singapore, Singapore
117583, Singapore
(Lee, Hon) Department of Cardiac, Thoracic and Vascular Surgery, National
University Hospital, Singapore 119074, Singapore
Publisher
IMR Press Limited
Abstract
Background: Intervention for tricuspid regurgitation (TR) tends to happen
concurrently with and is addressed during mitral valve surgery. Isolated
TR interventions, however, are not unusual and are becoming more common.
The purpose of this study was to provide a general overview of the
transcatheter tricuspid valve implantation (TTVI) devices, taking into
account the several design variations, and to unify the implantation
technique, existing clinical results, and potential future directions for
TR replacement therapy. Method(s): The major databases, namely Pubmed
via Medline, Embase, and Cochrane library, were systematically searched
from the date of conception until 10 February 2023, in accordance with the
preferred reporting items for systematic reviews and meta-analyses
(PRISMA) standards. Result(s): Eleven studies were isolated from a
total cohort of 5842 publications. All the transcatheter tricuspid
prostheses were circular in design yet categorized into annular tricuspid
valve implantation (ATVI) and caval valve implantation (CAVI) groups.
Bleeding (25.2%), severe access site and vascular issues requiring
intervention (5.8%), device migration or embolization (3.6%), and
paravalvular leak (38%) are among the early TTVI-related complications
that have been observed. The CAVI group experienced 3 of 28 bleeding cases
and 2 of 4 device migration cases. Conclusion(s): Following the
intervention with a transcatheter tricuspid prosthesis, this review
discovered an early favorable outcome and a general improvement in heart
failure symptoms. However, there was a lot of variation in their design,
implantation technique, and early clinical outcomes. Understanding the
design variations, difficulty of implantation and learning from this
review's key findings could help with the future development of
catheter-based tricuspid valves. Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022312142.
 Copyright © 2023 The Author(s).

<42>
Accession Number
2026600273
Title
expanding restrictive transfusion evidence in surgical practice: a
multicentre, prospective cohort study.
Source
Blood Transfusion. 20(5) (pp 382-394), 2022. Date of Publication:
September 2022.
Author
Wang L.; Wang Z.; Huang Y.; Wang Y.; Liu Z.; Xin S.; Lei G.; Han W.; Xue
F.; Chen Y.; Wu P.; Jiang J.; Yu X.
Institution
(Wang, Wang, Han, Xue, Chen, Wu, Jiang) Department of Epidemiology and
Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of
Medical Sciences, School of Basic Medicine, Peking Union Medical College,
Beijing, China
(Huang, Yu) Anaesthesiology Department, Peking Union Medical College
Hospital, Chinese Academy of Medical Sciences, Beijing, China
(Wang) Orthopaedics Department, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences, Beijing, China
(Liu) Clinical Transfusion Research Centre, Institute of Blood
Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
(Xin) Vascular and Thyroid Surgery Department, the First Hospital of China
Medical University, Shenyang, China
(Lei) Orthopaedics Department, Xiangya Hospital, Central South University,
Changsha, China
(Yu) Nephrology Department, Peking Union Medical College Hospital, Chinese
Academy of Medical Sciences, Beijing, China
Publisher
Edizioni SIMTI
Abstract
Background - Findings of observational studies investigating the impact of
transfusions are at odds with those of randomised controlled trials,
raising concern that observational studies may be inappropriate to inform
transfusion decisions. We examined whether observational data could
replicate evidence from randomised controlled trials on restrictive
transfusion in cardiac and orthopaedic surgery, and be generalised to
broader specialties as well as to a lower haemoglobin transfusion
threshold (7 g/dL). Material and methods - A multicentre, prospective
cohort study was performed at three representative regional hospitals in
China between 2015 and 2016. Participants were surgical inpatients (>=18
years; hospital stay >=24 h) in six specialties: cardiac, cerebral,
vascular (CCV), and orthopaedic, general, thoracic (non-CCV). Patients
with a stable haemoglobin (7-10 g/dL) constituted the primary analytic
sample, while patients with >=500 mL intra-operative bleeding were
analysed separately to avoid haemoglobin instability. The association of
transfusion with surgical outcomes (death, in-hospital complications) was
evaluated. Results - The transfusion rate was 10.7% in 36,607 patients
(mean age, 52.5+/-14.3 years; 52.3% female). After restriction,
stratification, and propensity score matching to reduce patients'
heterogeneity, transfusion was unrelated to death (CCV: odds ratio
[OR]=0.74, 95% confidence interval [CI]: 0.16-3.39; non-CCV: OR 0.83, 95%
CI: 0.36-1.94) and the composite complication (CCV: OR 1.31, 95% CI:
0.63-2.72; non-CCV: OR=1.24, 95% CI: 0.81-1.90). The results were
consistent in subgroups (elderly, coronary heart disease, malignant
tumour, severe illness) and applicable to patients with significant
bleeding after restoration of a stable haemoglobin. Discussion -
Transfusion at a stable haemoglobin concentration of 7-10 g/dL did not
alter surgical outcomes. Our results show the feasibility of observational
data to expand restrictive transfusion to broader specialties and a lower
transfusion threshold in surgical practice. Copyright © 2022
Edizioni SIMTI. All rights reserved.

<43>
[Use Link to view the full text]
Accession Number
2026583464
Title
The Use of Intraoperative Transit Time Flow Measurement for Coronary
Artery Bypass Surgery: Systematic Review of the Evidence and Expert
Opinion Statements.
Source
Circulation. 144(14) (pp 1160-1171), 2021. Date of Publication: 05 Oct
2021.
Author
Gaudino M.; Sandner S.; Di Giammarco G.; Di Franco A.; Arai H.; Asai T.;
Bakaeen F.; Doenst T.; Fremes S.E.; Glineur D.; Kieser T.M.; Lawton J.S.;
Lorusso R.; Patel N.; Puskas J.D.; Tatoulis J.; Taggart D.P.; Vallely M.;
Ruel M.
Institution
(Gaudino, Di Franco) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York, United States
(Sandner) Division of Cardiac Surgery, Department of Surgery, Medical
University of Vienna, Austria
(Di Giammarco) Cardiac Surgery Unit, University of Chieti, Italy
(Arai) The Department of Cardiovascular Surgery, Tokyo Medical and Dental
University Graduate School of Medical and Dental Sciences, Japan
(Asai) Department of Cardiovascular Surgery, Juntendo University, Tokyo,
Japan
(Bakaeen) Department of Thoracic and Cardiovascular Surgery, Heart,
Vascular and Thoracic Institute, Cleveland Clinic, OH, United States
(Doenst) Department of Cardiothoracic Surgery,
Friedrich-Schiller-University Jena, University Hospital, Germany
(Fremes) Division of Cardiac Surgery, Schulich Heart Centre, Department of
Surgery, Sunnybrook Health Sciences Centre, University of Toronto,
Ontario, Canada
(Glineur) Division of Cardiac Surgery, University of Ottawa Heart
Institute, Ontario, Canada
(Ruel) University of Ottawa Heart Institute, Division of Cardiac Surgery,
Ontario, Canada
(Kieser) Department of Cardiac Sciences, Libin Cardiovascular Institute,
University of Calgary, Canada
(Lawton) Division of Cardiac Surgery, Department of Surgery, Johns Hopkins
University, Baltimore, MD, United States
(Lorusso) Department of Cardio-Thoracic Surgery, CARIM School for
Cardiovascular Diseases, Heart and Vascular Centre, Maastricht University
Medical Centre, Netherlands
(Patel) Department of Cardiovascular and Thoracic Surgery, Lenox Hill
Hospital/Northwell Health, New York, United States
(Puskas) Department of Cardiovascular Surgery, Mount Sinai Morningside
Hospital, New York, United States
(Tatoulis) Royal Melbourne Hospital, University of Melbourne, Melbourne,
VIC, Australia
(Taggart) Nuffield Department of Surgical Sciences, University of Oxford,
John Radcliffe Hospital, United Kingdom
(Vallely) Division of Cardiac Surgery, The Ohio State University Wexner
Medical Center, Columbus, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Transit time flow measurement (TTFM) allows quality control in coronary
artery bypass grafting but remains largely underused, probably because of
limited information and the lack of standardization. We performed a
systematic review of the evidence on TTFM and other methods for quality
control in coronary artery bypass grafting following PRISMA standards and
elaborated expert recommendations by using a structured process. A panel
of 19 experts took part in the consensus process using a 3-step modified
Delphi method that consisted of 2 rounds of electronic voting and a final
face-to-face virtual meeting. Eighty percent agreement was required for
acceptance of the statements. A 2-level scale (strong, moderate) was used
to grade the statements based on the perceived likelihood of a clinical
benefit. The existing evidence supports an association between TTFM
readings and graft patency and postoperative clinical outcomes, although
there is high methodological heterogeneity among the published series. The
evidence is more robust for arterial, rather than venous, grafts and for
grafts to the left anterior descending artery. Although TTFM use increases
the duration and the cost of surgery, there are no data to quantify this
effect. Based on the systematic review, 10 expert statements for TTFM use
in clinical practice were formulated. Six were approved at the first round
of voting, 3 at the second round, and 1 at the virtual meeting. In
conclusion, although TTFM use may increase the costs and duration of the
procedure and requires a learning curve, its cost/benefit ratio seems
largely favorable, in view of the potential clinical consequences of graft
dysfunction. These consensus statements will help to standardize the use
of TTFM in clinical practice and provide guidance in clinical
decision-making. Copyright © 2021 Lippincott Williams and
Wilkins. All rights reserved.

<44>
[Use Link to view the full text]
Accession Number
2026583462
Title
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney
Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized
Clinical Study.
Source
Circulation. 144(14) (pp 1133-1144), 2021. Date of Publication: 05 Oct
2021.
Author
Thielmann M.; Corteville D.; Szabo G.; Swaminathan M.; Lamy A.; Lehner
L.J.; Brown C.D.; Noiseux N.; Atta M.G.; Squiers E.C.; Erlich S.;
Rothenstein D.; Molitoris B.; Mazer C.D.
Institution
(Thielmann) Department of Thoracic and Cardiovascular Surgery, West-German
Heart and Vascular Center Essen, University Duisburg-Essen, Germany
(Corteville) Sands Constellation Heart Institute, Rochester Regional
Health, Rochester, NY, United States
(Szabo) Central German Heart Center University Hospital Halle (Saale),
University Clinic and Polyclinic for Cardiac Surgery, Halle, Germany
(Swaminathan) Division of Cardiothoracic Anesthesiology and Critical Care
Medicine, Duke University Medical Center, Durham, NC, United States
(Lamy) David Braley Cardiac, Vascular and Stroke Research Institute,
McMaster University, Hamilton, ON, Canada
(Lehner) Department of Nephrology and Medical Intensive Care, Charite
Universitatsmedizin, Berlin, Germany
(Brown) New Brunswick Heart Centre, The Saint John Regional Hospital, NB,
Canada
(Noiseux) Division of Cardiac Surgery, University of Montreal Hospital
Center, CHUM Research Center, Montreal, QC, Canada
(Atta) Division of Nephrology, Johns Hopkins School of Medicine,
Baltimore, MD, United States
(Squiers) Coastal Vista Consulting LLC, Half Moon Bay, CA, United States
(Erlich, Rothenstein) Quark Pharmaceuticals, Inc, Newark, CA, United
States
(Molitoris) Nephrology Division, Department of Medicine, Indiana
University School of Medicine, Indiana Center for Biological Microscopy,
Indianapolis, United States
(Mazer) Li Ka Shing Knowledge Institute of St. Michael's Hospital,
Institute of Medical Sciences, Departments of Anesthesia and Physiology,
University of Toronto, ON, Canada
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Acute kidney injury (AKI) affects up to 30% of patients
undergoing cardiac surgery, leading to increased in-hospital and long-term
morbidity and mortality. Teprasiran is a novel small interfering RNA that
temporarily inhibits p53-mediated cell death that underlies AKI.
 Method(s): This prospective, multicenter, double-blind, randomized,
controlled phase 2 trial evaluated the efficacy and safety of a single 10
mg/kg dose of teprasiran versus placebo (1:1), in reducing the incidence,
severity, and duration of AKI after cardiac surgery in high-risk patients.
The primary end point was the proportion of patients who developed AKI
determined by serum creatinine by postoperative day 5. Other end points
included AKI severity and duration using various prespecified criteria. To
inform future clinical development, a composite end point of major adverse
kidney events at day 90, including death, renal replacement therapy, and
>=25% reduction of estimated glomerular filtration rate was assessed. Both
serum creatinine and serum cystatin-C were used for estimated glomerular
filtration rate assessments. Result(s): A total of 360 patients were
randomly assigned in 41 centers; 341 dosed patients were 73+/-7.5 years of
age (mean+/-SD), 72% were men, and median European System for Cardiac
Operative Risk Evaluation score was 2.6%. Demographics and surgical
parameters were similar between groups. AKI incidence was 37% for
teprasiran- versus 50% for placebo-treated patients, a 12.8% absolute risk
reduction, P=0.02; odds ratio, 0.58 (95% CI, 0.37-0.92). AKI severity and
duration were also improved with teprasiran: 2.5% of teprasiran- versus
6.7% of placebo-treated patients had grade 3 AKI; 7% teprasiran- versus
13% placebo-treated patients had AKI lasting for 5 days. No significant
difference was observed for the major adverse kidney events at day 90
composite in the overall population. No safety issues were identified with
teprasiran treatment. Conclusion(s): The incidence, severity, and
duration of early AKI in high-risk patients undergoing cardiac surgery
were significantly reduced after teprasiran administration. A phase 3
study with a major adverse kidney event at day 90 primary outcome that has
recently completed enrollment was designed on the basis of these findings
(NCT03510897). Registration: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT02610283. Copyright © 2021 Lippincott Williams and
Wilkins. All rights reserved.

<45>
[Use Link to view the full text]
Accession Number
2026583460
Title
No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After
Coronary Artery Bypass Grafting Surgery: Multicenter Randomized,
Controlled Trial.
Source
Circulation. 144(14) (pp 1120-1129), 2021. Date of Publication: 05 Oct
2021.
Author
Tian M.; Wang X.; Sun H.; Feng W.; Song Y.; Lu F.; Wang L.; Wang Y.; Xu
B.; Wang H.; Liu S.; Liu Z.; Chen Y.; Miao Q.; Su P.; Yang Y.; Guo S.; Lu
B.; Sun Z.; Liu K.; Zhang C.; Wu Y.; Xu H.; Zhao W.; Han C.; Zhou X.; Wang
E.; Huo X.; Hu S.
Institution
(Tian, Wang, Sun, Feng, Song, Lu, Wang, Yang, Guo, Sun, Liu, Zhang, Wu,
Xu, Zhao, Han, Zhou, Wang, Huo, Hu) Department of Surgery, Chinese Academy
of Medical Sciences & Peking Union Medical College, Beijing, China
(Wang) Medical Research & Biometrics Center, Chinese Academy of Medical
Sciences & Peking Union Medical College, Beijing, China
(Xu) Department of Cardiology, Chinese Academy of Medical Sciences &
Peking Union Medical College, Beijing, China
(Lu) Department of Radiology, Chinese Academy of Medical Sciences & Peking
Union Medical College, Beijing, China
(Miao) National Center for Cardiovascular Disease, China & Fuwai Hospital,
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, China
(Wang) Beijing Hospital, China
(Liu) The Second Hospital of Hebei Medical University, China
(Liu) TEDA International Cardiovascular Hospital, Chinese Academy of
Medical Sciences & Peking Union Medical College, Tianjin, China
(Chen) Peking University People's Hospital, Beijing, China
(Su) Beijing Chaoyang Hospital, Capital Medical University, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Vein graft occlusion is deemed a major challenge in coronary
artery bypass grafting. Previous studies implied that the no-touch
technique for vein graft harvesting could reduce occlusion rate compared
with the conventional approach; however, evidence on the clinical benefit
and generalizability of the no-touch technique is scare. Method(s):
From April 2017 to June 2019, we randomly assigned 2655 patients
undergoing coronary artery bypass grafting at 7 hospitals in a 1:1 ratio
to receive no-touch technique or conventional approach for vein
harvesting. The primary outcome was vein graft occlusion on computed
tomography angiography at 3 months and the secondary outcomes included
12-month vein graft occlusion, recurrence of angina, and major adverse
cardiac and cerebrovascular events. The generalized estimate equation
model was used to account for the cluster effect of grafts from the same
patient. Result(s): During the follow-up, 2533 (96.0%) participants
received computed tomography angiography at 3 months after coronary artery
bypass grafting and 2434 (92.2%) received it at 12 months. The no-touch
group had significantly lower rates of vein graft occlusion than the
conventional group both at 3 months (2.8% versus 4.8%; odds ratio, 0.57
[95% CI, 0.41-0.80]; P<0.001) and 12 months (3.7% versus 6.5%; odds ratio,
0.56 [95% CI, 0.41-0.76]; P<0.001). Recurrence of angina was also less
common in the no-touch group at 12 months (2.3% versus 4.1%; odds ratio,
0.55 [95% CI, 0.35-0.85]; P<0.01). Rates of major adverse cardiac and
cerebrovascular events were of no significant difference between the 2
groups. The no-touch technique was associated with higher rates of leg
wound surgical interventions at 3-month follow-up (10.3% versus 4.3%; odds
ratio, 2.55 [95% CI, 1.85-3.52]; P<0.001). Conclusion(s): Compared
with the conventional vein harvesting approach in coronary artery bypass
grafting, the no-touch technique significantly reduced the risk of vein
graft occlusion and improved patient prognosis. Registration: URL:
https://www.clinicaltrials.gov; Unique identifier:
NCT03126409. Copyright © 2021 Lippincott Williams and Wilkins.
All rights reserved.

<46>
Accession Number
2026230770
Title
Evaluation of stable angina by coronary computed tomographic angiography
versus standard of care: A systematic review and meta-analysis.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2023. Date of
Publication: 2023.
Author
Palicherla A.; Ismayl M.; Thandra A.; Budoff M.; Shaikh K.
Institution
(Palicherla, Ismayl) Internal Medicine, Creighton University School of
Medicine, Omaha, NE, United States
(Thandra) Interventional Cardiology, Creighton University School of
Medicine, Omaha, NE, United States
(Budoff) David Geffen School of Medicine at UCLA, Los Angeles, United
States
(Shaikh) University of Tennessee, Knoxville, United States
Publisher
Elsevier Inc.
Abstract
Introduction: There is limited data comparing Coronary Computed Tomography
Angiography (CCTA) versus the usual Standard of care (SOC) in patients
with suspected stable coronary artery disease (CAD). We aimed to perform a
systematic review and meta-analysis to compare CCTA versus SOC in patients
with stable CAD. Method(s): We searched multiple databases for
randomized controlled trials (RCTs) comparing CCTA with SOC, which
included various functional testing approaches for evaluating stable CAD.
We used a random-effects model to calculate risk ratios (RRs) with 95 %
confidence intervals (CIs). Outcomes included all-cause mortality,
myocardial infarction (MI), hospitalization for unstable angina (UA),
invasive angiography, revascularization, percutaneous coronary
intervention (PCI), and coronary artery bypass grafting (CABG).
 Result(s): We identified 6 RCTs with 19,881 patients with stable CAD,
of which 9995 underwent CCTA, and 9886 underwent SOC. There were no
significant differences between CCTA and SOC in terms of all-cause
mortality (RR: 0.91; 95 % CI: 0.70-1.19; p = 0.50), MI (RR: 0.78; 95 % CI:
0.58-1.05; p = 0.11), hospitalizations for UA (RR: 1.20; 95 % CI:
0.95-1.51;p = 0.12), invasive angiography (RR: 0.71; 95 % CI: 0.32-1.61; p
= 0.42), revascularization (RR:1.25; 95 % CI: 0.83-1.89; p = 0.29), PCI
(RR: 1.20; 95 % CI: 0.78-1.85; p = 0.40), and CABG rates (RR: 0.89; 95 %
CI: 0.530-1.49; p = 0.65). Conclusion(s): In patients with stable
CAD, CCTA is associated with similar outcomes compared to the usual
Standard of care. Given its potential to quickly rule out severe
obstructive disease, its ability to provide non-invasive physiology and
identify non-obstructive CAD with plaque information makes it an
attractive addition to the available armamentarium to evaluate chest
pain. Copyright © 2023 Elsevier Inc.

<47>
Accession Number
642166645
Title
Transcatheter aortic valve implantation versus surgical aortic valve
replacement in patients at low to intermediate surgical risk: rationale
and design of the randomised DEDICATE Trial.
Source
EuroIntervention : journal of EuroPCR in collaboration with the Working
Group on Interventional Cardiology of the European Society of Cardiology.
(no pagination), 2023. Date of Publication: 01 Sep 2023.
Author
Seiffert M.; Vonthein R.; Baumgartner H.; Borger M.A.; Choi Y.-H.; Falk
V.; Frey N.; Hagendorff A.; Hagl C.; Hamm C.; Konig I.R.; Landmesser U.;
Massberg S.; Reichenspurner H.; Thiele H.; Twerenbold R.; Vens M.; Walther
T.; Ziegler A.; Cremer J.; Blankenberg S.
Institution
(Seiffert, Twerenbold, Ziegler, Blankenberg) Department of Cardiology,
University Heart and Vascular Center Hamburg, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
(Seiffert, Twerenbold, Ziegler, Blankenberg) Centre for Population Health
Innovation (POINT), University Heart and Vascular Center Hamburg,
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Seiffert, Konig, Reichenspurner, Twerenbold, Cremer, Blankenberg) DZHK
(German Centre for Cardiovascular Research) partner site
Hamburg/Kiel/Lubeck, Hamburg, Germany
(Vonthein, Konig, Vens) Institute of Medical Biometry and Statistics,
University of Lubeck, Lubeck, Germany
(Baumgartner) Department of Cardiology III - Adult Congenital and Valvular
Heart Disease, University Hospital Muenster, Muenster, Germany
(Borger) Department of Cardiac Surgery, Heart Center Leipzig at University
of Leipzig, Leipzig, Germany
(Choi) Department of Cardiac Surgery, Kerckhoff-Klinik, Bad Nauheim,
Germany
(Choi, Hamm, Walther) DZHK (German Centre for Cardiovascular Research)
partner site Rhine-Main, Rhine-Main, Germany
(Falk) Department of Cardiothoracic and Vascular Surgery, Berlin, Germany
(Falk, Landmesser) DZHK (German Centre for Cardiovascular Research)
partner site Berlin, Berlin, Germany
(Falk) Department of Health Sciences & Technology, ETH Zurich,
Translational Cardiovascular Technology, Zurich, Switzerland
(Frey) Department of Cardiology, Angiology, Pneumology, Heidelberg
University Hospital, Heidelberg, Germany
(Frey) DZHK (German Centre for Cardiovascular Research) partner site
Heidelberg/Mannheim, Heidelberg, Germany
(Hagendorff) Department of Cardiology, University of Leipzig, Leipzig,
Germany
(Hagl, Massberg) Department of Cardiac Surgery, University Hospital
Munich, Ludwig-Maximilians-University Munich, Munich, Germany
(Hagl) DZHK (German Centre for Cardiovascular Research) partner site
Munich Heart Alliance, Munich, Germany
(Hamm) University of Giessen, Campus Kerckhoff and Medical Clinic I,
Giessen, Germany
(Landmesser) Department of Cardiology, Angiology and Intensive Care
Medicine, Germany and Charite Universitatsmedizin Berlin, Berlin, Germany
(Massberg) Department of Cardiology, University Hospital Munich,
Ludwig-Maximilians-University Munich, Munich, Germany
(Reichenspurner) Department of Cardiovascular Surgery, University Heart
and Vascular Center Hamburg, Hamburg, Germany
(Thiele) Department of Cardiology, Heart Center Leipzig at University of
Leipzig, Germany and Leipzig Heart Science, Leipzig, Germany
(Walther) Department of Thoracic and Cardiovascular Surgery, University
Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main,
Germany
(Ziegler) Medizincampus Davos, Davos, Switzerland
(Ziegler) School of Mathematics, Statistics and Computer Science,
University of KwaZulu-Natal, Pietermaritzburg, South Africa
(Cremer) Department of Cardiovascular Surgery, University Hospital of
Schleswig-Holstein, Kiel, Germany
Publisher
NLM (Medline)
Abstract
Transcatheter aortic valve implantation (TAVI) has become the preferred
treatment option for patients with severe aortic stenosis at increased
risk for surgical aortic valve replacement (SAVR) and for older patients
irrespective of risk. However, in younger, low-risk patients for whom both
therapeutic options, TAVI and SAVR, are applicable, the optimal treatment
strategy remains controversial, as data on long-term outcomes remain
limited. The DEDICATE-DZHK6 Trial is an investigator-initiated,
industry-independent, prospective, multicentre, randomised controlled
trial investigating the efficacy and safety of TAVI compared to SAVR in
low- to intermediate-risk patients aged 65 years or older. To evaluate
both treatment strategies, approximately 1,404 patients determined
eligible for both TAVI and SAVR by the interdisciplinary Heart Team were
randomised to TAVI or SAVR. Broad inclusion and strict exclusion criteria
targeted an all-comers patient population. Procedures were performed
according to local best practice with contemporary routine medical
devices. The primary endpoints are a composite of mortality or stroke at 1
year and 5 years in order to incorporate midterm efficacy results and
complement early safety data. Primary outcomes will be tested sequentially
for non-inferiority and superiority. The DEDICATE-DZHK6 Trial has been
designed to mirror clinical reality for the treatment of severe aortic
stenosis and provide unique information on overall outcomes after TAVI and
SAVR that can be directly applied to clinical routines. Its results will
help further define optimal treatment strategies for low- to
intermediate-risk patients in whom both TAVI and SAVR are currently
advisable.

<48>
Accession Number
642166414
Title
Red Blood Cell Transfusion Guided by Hemoglobin Only or Integrating
Perfusion Markers in Patients Undergoing Cardiac Surgery: A Systematic
Review and Meta-Analysis With Trial Sequential Analysis.
Source
Journal of cardiothoracic and vascular anesthesia. (no pagination), 2023.
Date of Publication: 09 Aug 2023.
Author
Putaggio A.; Tigano S.; Caruso A.; La Via L.; Sanfilippo F.
Institution
(Putaggio) School of Anesthesia and Intensive Care, University Magna
Graecia, Catanzaro, Italy
(Tigano, Caruso) School of Anesthesia and Intensive Care, University of
Catania, Catania, Italy
(La Via) University Hospital Policlinico, G. Rodolico - San Marco,
Catania, Italy
(Sanfilippo) University Hospital Policlinico, G. Rodolico - San Marco,
Catania, Italy; Department of Surgery and Medical-Surgical Specialties,
University of Catania, Catania, Italy
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Strategies for red blood cell (RBC) transfusion in patients
undergoing cardiac surgery have been traditionally anchored to hemoglobin
(Hb) targets. A more physiologic approach would consider markers of organ
hypoperfusion. DESIGN: The authors conducted a systematic review and
meta-analysis with trial sequential analysis of randomized controlled
trials (RCTs). SETTING: Cardiac surgery. PARTICIPANTS: Adult patients.
INTERVENTION: RBC transfusion targeting only Hb levels compared with
strategies combining Hb values with markers of organ hypoperfusion.
MEASUREMENTS AND MAIN RESULTS: Primary outcomes were the number of RBC
units transfused, the number of patients transfused at least once, and the
average number of transfusions. Secondary outcomes were postoperative
complications, intensive care (ICU) and hospital lengths of stay, and
mortality. Only 2 RCTs were included (n = 257 patients), and both used
central venous oxygen saturation (ScvO2) as a marker of organ
hypoperfusion (cut-off: <70% or <=65%). A transfusion protocol combining
Hb and ScvO2 reduced the overall number of RBC units transfused (risk
ratio [RR]: 1.57 [1.33-1.85]; p < 0.0001, I2 = 0%), and the number of
patients transfused at least once (RR: 1.33 [1.16-1.53]; p < 0.0001, I2 =
41%), but not the average number of transfusions (mean difference [MD]:
0.18 [-0.11 to 0.47]; p = 0.24, I2 = 66%), with moderate certainty of
evidence. Mortality (RR: 1.29, [0.29-5.77]; p = 0.73, I2 = 0%), ICU
length-of-stay (MD: -0.06 [-0.58 to 0.46]; p = 0.81, I2 = 0%), hospital
length-of-stay (MD: -0.05 [-1.49 to 1.39];p = 0.95, I2 = 0%), and all
postoperative complications were not affected. CONCLUSION(S): In
adult patients undergoing cardiac surgery, a restrictive protocol
integrating Hb values with a marker of organ hypoperfusion (ScvO2) reduces
the number of RBC units transfused and the number of patients transfused
at least once without apparent signals of harm. These findings were
preliminary and warrant further multicentric research. Copyright
© 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

<49>
Accession Number
642166200
Title
Pulmonary Vasodilator and Inodilator Drugs in Cardiac Surgery: A
Systematic Review With Bayesian Network Meta-Analysis.
Source
Journal of cardiothoracic and vascular anesthesia. (no pagination), 2023.
Date of Publication: 01 Aug 2023.
Author
Sardo S.; Tripodi V.F.; Guerzoni F.; Musu M.; Cortegiani A.; Finco G.
Institution
(Sardo, Guerzoni, Musu, Finco) Department of Medical Sciences and Public
Health, University of Cagliari, Monserrato, Italy
(Tripodi) Department of Human Pathology, Unit of Anesthesia and Intensive
Care, University Hospital of Messina, Messina, Italy
(Cortegiani) Department of Surgical Oncological and Oral Science,
University of Palermo, Palermo, Italy; Department of Anesthesia, Intensive
Care, and Emergency, University Hospital "Policlinico Paolo Giaccone",
Palermo, Italy
Publisher
NLM (Medline)
Abstract
OBJECTIVE: The authors performed a systematic review to evaluate the
effect of pharmacologic therapy on pulmonary hypertension in the
perioperative setting of elective cardiac surgery (PROSPERO
CRD42023321041). DESIGN: Systematic review of randomized controlled trials
with a Bayesian network meta-analysis. SETTING: The authors searched
biomedical databases for randomized controlled trials on the perioperative
use of inodilators and pulmonary vasodilators in adult cardiac surgery,
with in-hospital mortality as the primary outcome and duration of
ventilation, length of stay in the intensive care unit, stage 3 acute
kidney injury, cardiogenic shock requiring mechanical support, and change
in mean pulmonary artery pressure as secondary outcomes. PARTICIPANTS:
Twenty-eight studies randomizing 1,879 patients were included.
INTERVENTIONS: Catecholamines and noncatecholamine inodilators, arterial
pulmonary vasodilators, vasodilators, or their combination were considered
eligible interventions compared with placebo or standard care.
MEASUREMENTS AND MAIN RESULTS: Ten studies reported in-hospital mortality
and assigned 855 patients to 12 interventions. Only inhaled prostacyclin
use was supported by a statistically discernible improvement in mortality,
with a number-needed-to-treat estimate of at least 3.3, but a wide
credible interval (relative risk 1.26 x 10-17 - 0.7). Inhaled prostacyclin
and nitric oxide were associated with a reduction in intensive care unit
stay, and none of the included interventions reached a statistically
evident difference compared to usual care or placebo in the other
secondary clinical outcomes. CONCLUSION(S): Inhaled prostacyclin was
the only pharmacologic intervention whose use is supported by a
statistically discernible improvement in mortality in the perioperative
cardiac surgery setting as treatment of pulmonary hypertension. However,
available evidence has significant limitations, mainly the low number of
events and imprecision. Copyright © 2023 The Author(s). Published
by Elsevier Inc. All rights reserved.

<50>
Accession Number
642162022
Title
Lipoprotein(a) and calcific aortic valve disease: current evidence and
future directions.
Source
Current opinion in clinical nutrition and metabolic care. (no
pagination), 2023. Date of Publication: 29 Aug 2023.
Author
Lan N.S.R.; Khan Z.; Watts G.F.
Institution
(Lan, Watts) Departments of Cardiology and Internal Medicine, Royal Perth
Hospital
(Lan, Watts) School of Medicine, University of Western Australia, Perth,
WA, Australia
(Khan) Department of Cardiology, Barts Heart Centre, London, United
Kingdom
(Khan) University of South Wales, Cardiff, United Kingdom
Publisher
NLM (Medline)
Abstract
PURPOSE OF REVIEW: Calcific aortic valve disease (CAVD), the most common
cause of aortic stenosis (AS), is characterized by slowly progressive
fibrocalcific remodelling of the valve cusps. Once symptomatic, severe AS
is associated with poor survival unless surgical or transcatheter valve
replacement is performed. Unfortunately, no pharmacological interventions
have been demonstrated to alter the natural history of CAVD.
Lipoprotein(a) [Lp(a)], a low-density lipoprotein-like particle, has been
implicated in the pathophysiology of CAVD. RECENT FINDINGS: The mechanisms
by which Lp(a) results in CAVD are not well understood. However, the
oxidized phospholipids carried by Lp(a) are considered a crucial mediator
of the disease process. An increasing number of studies demonstrate a
causal association between plasma Lp(a) levels and frequency of AS and
need for aortic valve replacement, which is independent of inflammation,
as measured by plasma C-reactive protein levels. However, not all studies
show an association between Lp(a) and increased progression of
calcification in individuals with established CAVD. SUMMARY:
Epidemiologic, genetic, and Mendelian randomization studies have
collectively suggested that Lp(a) is a causal risk factor for CAVD.
Whether Lp(a)-lowering can prevent initiation or slow progression of CAVD
remains to be demonstrated. Copyright © 2023 Wolters Kluwer
Health, Inc. All rights reserved.

<51>
Accession Number
2026562206
Title
Comparative effects of off-pump and multiple cardiopulmonary bypass
strategies in coronary artery bypass grafting surgery: Protocol for a
systematic review and network meta-analysis.
Source
BMJ Open. 13(6) (no pagination), 2023. Article Number: e072545. Date of
Publication: 06 Jun 2023.
Author
Tan J.; Gao S.; Li Y.; Li X.; Du L.; Ji B.
Institution
(Tan, Li, Du) Department of Anesthesiology, Sichuan University, Sichuan,
Chengdu, China
(Gao, Ji) Department of Cardiopulmonary Bypass, Fuwai Hospital, Chinese
Academy of Medical Sciences and Peking Union Medical College, Beijing,
Xicheng, China
(Li) Department of Cardiac Surgery, Lanzhou University Second Hospital,
Gansu, Lanzhou, China
Publisher
BMJ Publishing Group
Abstract
Introduction Multiple revascularisation strategies with or without cardiac
arrest have been developed to minimise the negative effects of
cardiopulmonary bypass interventions during coronary artery bypass
grafting (CABG) surgery. Several observational and randomised studies have
evaluated the efficacy of these interventions. This study aims to compare
the efficacy and safety of four prevalent revascularisation strategies
with/without cardiopulmonary bypass interventions in CABG surgery. Methods
and analysis We will search on PubMed, Embase, Cochrane Library, Web of
Science and ClinicalTrials.gov for randomised controlled trials and
observational cohort studies comparing outcomes of CABG surgery under
conventional on-pump, off-pump, on-pump beating heart and minimal
extracorporeal circulation technology. All English articles published
before 30 November 2022 will be considered. The primary outcome will be
30-day mortality. The secondary outcomes will be various early and late
adverse events after CABG surgery. The Revised Cochrane Risk of Bias Tool
and Newcastle-Ottawa Scale will be used to assess the quality of included
articles. A random-effects pairwise meta-analysis will be performed to
report the head-to-head comparison. Then, the network meta-analysis will
be performed using a Bayesian framework with random-effects models. Ethics
and dissemination This research does not require the approval of an ethics
committee as it relies on reviewing literature and does not involve
dealing with humans or animals. The findings of this review will be
published in a peer-reviewed journal. PROSPERO registration number
CRD42023381279. Copyright © Author(s) (or their employer(s))
2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights
and permissions. Published by BMJ.

<52>
Accession Number
2026561391
Title
Data standards for transcatheter aortic valve implantation: The European
Unified Registries for Heart Care Evaluation and Randomised Trials
(EuroHeart).
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 9(5) (pp
529-536), 2023. Date of Publication: 01 Aug 2023.
Author
Aktaa S.; Batra G.; James S.K.; Blackman D.J.; Ludman P.F.; Mamas M.A.;
Abdel-Wahab M.; Angelini G.D.; Czerny M.; Delgado V.; De Luca G.; Agricola
E.; Foldager D.; Hamm C.W.; Iung B.; Mangner N.; Mehilli J.; Murphy G.J.;
Mylotte D.; Parma R.; Petronio A.S.; Popescu B.A.; Sondergaard L.; Teles
R.C.; Sabate M.; Terkelsen C.J.; Testa L.; Wu J.; Maggioni A.P.; Wallentin
L.; Casadei B.; Gale C.P.
Institution
(Aktaa, Blackman, Gale) Leeds Institute of Cardiovascular and Metabolic
Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom
(Aktaa, Wu, Gale) Leeds Institute for Data Analytics, University of Leeds,
Leeds LS2 9JT, United Kingdom
(Aktaa, Blackman, Gale) Department of Cardiology, Leeds Teaching Hospitals
NHS Trust, Leeds LS1 3EX, United Kingdom
(Batra, James, Wallentin) Department of Medical Sciences Cardiology and
Uppsala Clinical Research Center, Uppsala University, Uppsala 38 751 85,
Sweden
(Ludman) Institute of Cardiovascular Sciences, University of Birmingham,
Birmingham B15 2SQ, United Kingdom
(Mamas) Keele Cardiovascular Research Group, Keele University, Stoke on
Trent ST5 5BG, United Kingdom
(Abdel-Wahab) Heart Center Leipzig, University of Leipzig, Leipzig 04109,
Germany
(Angelini) Bristol Heart Institute, Bristol University, Bristol BS8 1TH,
United Kingdom
(Czerny) Department of Cardiovascular Surgery, Faculty of Medicine,
Albert-Ludwigs-University of Freiburg, University Heart Center Freiburg,
Freiburg 79189, Germany
(Delgado) Heart Institute; Department of Cardiology, Cardiovascular
Imaging Section, Hospital University Germans Trias i Pujol, Badalona
08916, Spain
(De Luca) Clinical and Experimental Cardiology Unit, AOU Sassari, Sassari
07100, Italy
(Agricola) Cardiovascular Imaging Unit, San Raffaele Hospital, Milan,
Vita-Salute University, San Raffaele, Milan 20132, Italy
(Foldager) ESC Patient Forum, Denmark
(Hamm) Medical Clinic I, University of Giessen, Giessen 35390, Germany
(Hamm) Kerckhoff Heart Center, Bad Nauheim 61231, Germany
(Iung) Cardiology Department, Bichat Hospital, APHP and Universite
Paris-Cite, Paris 75006, France
(Mangner) Heart Centre Dresden, Department of Internal Medicine and
Cardiology, Technische Universitaet, Dresden 01069, Germany
(Mehilli) Department: Medizinische Klinik I, Landshut-Achdorf Hospital,
Landshut 84036, Germany
(Mehilli) Klinikum der Universitat Munchen,
Ludwig-Maximilians-Universitat, Munich 80539, Germany
(Mehilli) German Centre for Cardiovascular Research (DZHK), Munich Heart
Alliance, Munich 80539, Germany
(Murphy) NIHR Biomedical Research Unit, University of Leicester, Leicester
LE1 7RH, United Kingdom
(Mylotte) Department of Cardiology, University Hospital and National
University of Ireland Galway, Galway H91 YR71, Ireland
(Parma) Department of Cardiology and Structural Heart Diseases, Medical
University of Silesia, Katowice 40-055, Poland
(Petronio) Cardiothoracic and Vascular Dpt. University of Pisa, Pisa
56126, Italy
(Popescu) Department of Cardiology, University of Medicine and Pharmacy
Carol Davila -Euroecolab, Emergency Institute for Cardiovascular Diseases,
Bucharest 050474, Romania
(Sondergaard) Department of Cardiology, Rigshospitalet, Copenhagen
University Hospital, Copenhagen 2100, Denmark
(Teles) Centro de Documentacao, Centro Hospitalar de Lisboa Ocidental,
Nova Medical School, Hospital de Santa Cruz, Lisbon 1169056, Portugal
(Sabate) Department of Interventional Cardiology, Cardiovascular
Institute, Hospital Clinic, Institut d'Investigacions Biomediques August
Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain
(Terkelsen) Aarhus University Hospital and the Danish Heart Foundation
8200, Denmark
(Testa) IRCCS San Donato Hospital, Milan 20097, Italy
(Casadei) ANMCO Research Center-Heart Care Foundation, Florence 50121,
Italy
Publisher
Oxford University Press
Abstract
Aims: Standardized data definitions are necessary for the quantification
of quality of care and patient outcomes in observational studies and
randomised controlled trials (RCTs). The European Unified Registries for
Heart Care Evaluation and Randomised Trials (EuroHeart) project of the
European Society of Cardiology (ESC) aims to create pan-European data
standards for cardiovascular diseases and interventions, including
transcatheter aortic valve implantation (TAVI). Methods and Results:
We followed the EuroHeart methodology for cardiovascular data standard
development. A Working Group of 29 members representing 12 countries was
established and included a patient representative, as well as experts in
the management of valvular heart disease from the European Association of
Percutaneous Cardiovascular Interventions (EAPCI), the European
Association of Cardiovascular Imaging (EACVI) and the Working Group on
Cardiovascular Surgery. We conducted a systematic review of the literature
and used a modified Delphi method to reach consensus on a final set of
variables. For each variable, the Working Group provided a definition,
permissible values, and categorized the variable as mandatory (Level 1) or
additional (Level 2) based on its clinical importance and feasibility. In
total, 93 Level 1 and 113 Level 2 variables were selected, with the level
1 variables providing the dataset for registration of patients undergoing
TAVI on the EuroHeart IT platform. Conclusion(s): This document
provides details of the EuroHeart data standards for TAVI processes of
care and in-hospital outcomes. In the context of EuroHeart, this will
facilitate quality improvement, observational research, registry-based
RCTs and post-marketing surveillance of devices, and pharmacotherapies.
One-sentence summary: The EuroHeart data standards for transcatheter
aortic valve implantation (TAVI) are a set of internationally agreed data
variables and definitions that once implemented will facilitate
improvement of quality of care and outcomes for patients receiving
TAVI. Copyright © 2022 The Author(s). Published by Oxford
University Press on behalf of the European Society of Cardiology.

<53>
[Use Link to view the full text]
Accession Number
2026555827
Title
STICH3C: Rationale and Study Protocol.
Source
Circulation: Cardiovascular Interventions. 16(8) (pp 487-497), 2023. Date
of Publication: 01 Aug 2023.
Author
Fremes S.E.; Marquis-Gravel G.; Gaudino M.F.L.; Jolicoeur E.M.; Bedard S.;
Masterson Creber R.; Ruel M.; Vervoort D.; Wijeysundera H.C.; Farkouh
M.E.; Rouleau J.-L.
Institution
(Fremes, Vervoort, Wijeysundera) Schulich Heart Centre, Sunnybrook Health
Sciences Centre, University of Toronto, ON, Canada
(Marquis-Gravel, Jolicoeur, Rouleau) Montreal Heart Institute, University
of Montreal, QC, Canada
(Gaudino, Jolicoeur) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York City, NY, United States
(Masterson Creber) Division of Health Informatics, Weill Cornell Medicine,
New York City, NY, United States
(Bedard) Centre d'Excellence sur le Partenariat Avec les Patients et le
Public, Montreal, QC, Canada
(Ruel) Division of Cardiac Surgery, University of Ottawa, Heart Institute,
ON, Canada
(Farkouh) Division of Cardiology, Peter Munk Cardiac Centre, Toronto
General Hospital, ON, Canada
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Coronary artery bypass grafting (CABG) is the recommended mode
of revascularization in patients with ischemic left ventricular
dysfunction (iLVSD) and multivessel disease. However, contemporary
percutaneous coronary intervention (PCI) outcomes have improved with the
integration of novel technologies and refinement of revascularization
strategies, and PCI is often used in clinical practice in this population.
There is a lack of evidence from randomized trials comparing contemporary
state-of-the-art PCI versus CABG for the treatment of iLVSD and
multivessel disease. This was the impetus for the STICH3C trial (Canadian
CABG or PCI in Patients With Ischemic Cardiomyopathy), described here.
 METHOD(S): The STICH3C trial is a prospective, unblinded,
international, multicenter trial with an expected sample size of 754
participants from =45 centers. Patients with multivessel/left main
coronary artery disease and iLVSD with left ventricular ejection fraction
<=40% considered by the local Heart Team appropriate for and amenable to
revascularization by both modes of revascularization will be randomized in
a 1:1 ratio to state-of-the-art PCI or CABG. RESULT(S): The primary
end point is the composite of death from any cause, stroke, spontaneous
myocardial infarction, urgent repeat revascularization, or heart failure
readmission, summarized as a time-to-event outcome. The key hierarchical
end point is time to death and frequency of hospitalizations for heart
failure. The key safety outcome is a composite of major adverse events.
Disease-specific quality-of-life and health economics measures will be
compared between groups. Participants will be followed for a median of 5
years, with a minimum follow-up of 4 years. CONCLUSION(S): STICH3C
will directly inform patients, clinicians, and international practice
guidelines about the efficacy and safety of CABG versus PCI in patients
with iLVSD. The results will provide novel and broad evidence, including
clinical events, health status, and economic assessments, to guide care
for patients with iLVSD and severe coronary artery disease. REGISTRATION:
URL: https://clinicaltrials.gov/; Unique identifier:
NCT05427370. Copyright © 2023 Lippincott Williams and Wilkins.
All rights reserved.

<54>
Accession Number
2025615595
Title
Delayed Ventricular Septal Rupture Repair After Myocardial Infarction: An
Updated Review.
Source
Current Problems in Cardiology. 48(10) (no pagination), 2023. Article
Number: 101887. Date of Publication: October 2023.
Author
Arsh H.; Pahwani R.; Arif Rasool Chaudhry W.; Khan R.; Khenhrani R.R.;
Devi S.; Malik J.
Institution
(Arsh) Department of Medicine, THQ Hospital, Pasrur, Pakistan
(Pahwani) Department of Medicine, Jinnah Sindh Medical University,
Karachi, Pakistan
(Arif Rasool Chaudhry) Department of Surgery, Cavan General Hospital,
Cavan, Ireland
(Khan) Department of Neurosurgery, Sherwan Rural Health Center, Sherwan,
Pakistan
(Khenhrani, Devi) Department of Medicine, Liaquat University of Medical
and Health Sciences, Jamshoro, Pakistan
(Malik) Department of Cardiovascular Research, Cardiovascular Analytics
Group, Islamabad, Pakistan
Publisher
Elsevier Inc.
Abstract
Ventricular septal rupture (VSR) is a rare but serious complication that
can occur after myocardial infarction (MI) and is associated with
significant morbidity and mortality. The optimal management approach for
VSR remains a topic of debate, with considerations including early versus
delayed surgery, risk stratification, pharmacological interventions,
minimally invasive techniques, and tissue engineering. The pathophysiology
of VSR involves myocardial necrosis, inflammatory response, and enzymatic
degradation of the extracellular matrix (ECM), particularly mediated by
matrix metalloproteinases (MMPs). These processes lead to structural
weakening and subsequent rupture of the ventricular septum.
Hemodynamically, VSR results in left-to-right shunting, increased
pulmonary blood flow, and potentially hemodynamic instability. The early
surgical repair offers the advantages of immediate closure of the defect,
prevention of complications, and potentially improved outcomes. However,
it is associated with higher surgical risk and limited myocardial recovery
potential during the waiting period. In contrast, delayed surgery allows
for a period of myocardial recovery, risk stratification, and optimization
of surgical outcomes. However, it carries the risk of ongoing
complications and progression of ventricular remodeling. Risk
stratification plays a crucial role in determining the optimal timing for
surgery and tailoring treatment plans. Various clinical factors, imaging
assessments, scoring systems, biomarkers, and hemodynamic parameters aid
in risk assessment and guide decision-making. Pharmacological
interventions, including vasopressors, diuretics, angiotensin-converting
enzyme inhibitors, beta-blockers, antiplatelet agents, and antiarrhythmic
drugs, are employed to stabilize hemodynamics, prevent complications,
promote myocardial healing, and improve outcomes in VSR patients.
Advancements in minimally invasive techniques, such as percutaneous device
closure, and tissue engineering hold promise for less invasive
interventions and better outcomes. These approaches aim to minimize
surgical morbidity, optimize healing, and enhance patient recovery. In
conclusion, the management of VSR after MI requires a multidimensional
approach that considers various aspects, including risk stratification,
surgical timing, pharmacological interventions, minimally invasive
techniques, and tissue engineering. Copyright © 2023 Elsevier
Inc.

<55>
Accession Number
2025579437
Title
Meta-Analysis of the Prognostic Significance of Carotid Artery Stenosis in
Patients Who Underwent Transcatheter Aortic Valve Implantation.
Source
American Journal of Cardiology. 200 (pp 225-231), 2023. Date of
Publication: 01 Aug 2023.
Author
Vella A.; Roux O.; Antiochos P.; Monney P.; Maurizi N.; Skalidis I.;
Fournier S.; Eeckhout E.; Roguelov C.; Oestreicher S.; Kirsch M.; Muller
O.; Lu H.
Institution
(Vella) Service of Cardiology, Geneva University Hospital and University
of Geneva, Geneva, Switzerland
(Roux) HerzHirslanden Group, Herzzentrum im Park AG, Zurich, Switzerland
(Antiochos, Monney, Maurizi, Skalidis, Fournier, Eeckhout, Roguelov,
Muller, Lu) Service of Cardiology, Lausanne University Hospital and
University of Lausanne, Lausanne, Switzerland
(Oestreicher) Service of Internal Medicine, Lausanne University Hospital
and University of Lausanne, Lausanne, Switzerland
(Kirsch) Service of Cardiovascular Surgery, Lausanne University Hospital
and University of Lausanne, Lausanne, Switzerland
Publisher
Elsevier Inc.
Abstract
Stroke is a known complication of both transcatheter aortic valve
implantation (TAVI) and carotid artery stenosis (CAS). Whether CAS is a
predictor of worse prognosis after TAVI is unclear. We performed a
meta-analysis to assess the impact of CAS on the incidence of
neurovascular complications and mortality after TAVI. We searched
PubMed/MEDLINE and EMBASE databases from inception to January 2023. CAS
was defined by >=50% stenosis of at least 1 carotid artery. Studies
comparing CAS versus non-CAS TAVI populations were included. Patients'
baseline characteristics and 30-day clinical outcomes were extracted. End
points included the 30-day incidence of neurovascular complications
(stroke or transient ischemic attack) and 30-day all-cause mortality. We
identified six studies, totaling 6,763 patients in the CAS group and
23,861 patients in the non-CAS group. Patients with CAS had a higher
prevalence of hypertension, diabetes mellitus, dyslipidemia, previous
myocardial infarction, coronary artery bypass graft, peripheral artery
disease, previous neurovascular disease, and chronic kidney disease. There
was no significant difference in the rates of 30-day neurovascular
complications between CAS and non-CAS groups (relative risk 1.23, 95%
confidence interval 0.63 to 2.40, p = 0.54). CAS was associated with a
higher risk of 30-day all-cause mortality (relative risk 1.28, 95%
confidence interval 1.12 to 1.47, p <0.001), not found in a sensitivity
analysis. In conclusion, patients with CAS presented with a significantly
higher co-morbidity burden. CAS was not associated with an increased risk
of 30-day neurovascular complications. 30-day mortality was higher in the
CAS group but that may be a surrogate of the heavy co-morbidity burden of
patients with CAS. Copyright © 2023 The Author(s)

<56>
Accession Number
2025248464
Title
Prevention of surgical site infections: a personal odyssey.
Source
Journal of Hospital Infection. 138 (pp 85-88), 2023. Date of Publication:
August 2023.
Author
Kluytmans J.
Institution
(Kluytmans) Department of Medical Microbiology, University Medical Center
Utrecht, Utrecht University, Utrecht, Netherlands
Publisher
W.B. Saunders Ltd

<57>
Accession Number
2025141075
Title
Prognostic Value of Post-PCI Angiography-Derived Fractional Flow Reserve:
A Systematic Review and Meta-Analysis of Cohort Studies.
Source
Journal of Personalized Medicine. 13(8) (no pagination), 2023. Article
Number: 1251. Date of Publication: August 2023.
Author
Terentes-Printzios D.; Gkini K.-P.; Oikonomou D.; Gardikioti V.;
Aznaouridis K.; Dima I.; Tsioufis K.; Vlachopoulos C.
Institution
(Terentes-Printzios, Gkini, Oikonomou, Gardikioti, Aznaouridis, Dima,
Tsioufis, Vlachopoulos) First Department of Cardiology, National and
Kapodistrian University of Athens, Medical School, Hippokration Hospital,
114 Vasilissis Sofias St, Athens 11527, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
The post-percutaneous coronary intervention (post-PCI) fractional flow
reserve (FFR) can detect suboptimal PCI or residual ischemia and
potentially lead to fewer adverse clinical outcomes. We sought to
investigate the predictive value of the angiography-derived FFR for
adverse cardiovascular events in patients after PCI. We conducted a
comprehensive search of electronic databases, MEDLINE, EMBASE, and the
Cochrane Library, for studies published until March 2023 that investigated
the prognostic role of angiography-derived fractional flow reserve values
after PCI. We investigated the best predictive ability of the post-PCI
angiography-derived FFR and relative risk (RR) estimates with 95%
confidence intervals (CIs) between post-PCI angiography-derived FFR values
and adverse events. Thirteen cohort studies involving 6961 patients (9719
vascular lesions; mean follow-up: 2.2 years) were included in this
meta-analysis. The pooled HR of the studies using specific cut-off points
for post-PCI angiography-derived FFR was 4.13 (95% CI, 2.92-5.82) for
total cardiovascular events, while the pooled HRs for target vessel
revascularization, cardiac death, target vessel myocardial infarction, and
target lesion revascularization were 6.87 (95% CI, 4.93-9.56), 6.17 (95%
CI, 3.52-10.80), 3.98 (95% CI, 2.37-6.66) and 6.27 (95% CI, 3.08-12.79),
respectively. In a sensitivity analysis of three studies with 1789
patients assessing the predictive role of the post-PCI angiography-derived
FFR as a continuous variable, we found a 58% risk reduction for future
adverse events per 0.1 increase in the post-PCI angiography-derived FFR
value. In conclusion, post-PCI angiography-derived FFR is an effective
tool for predicting adverse cardiovascular events and could be potentially
used in decision making, both during PCI and in the long-term
follow-up. Copyright © 2023 by the authors.

<58>
Accession Number
2025140185
Title
Liquid Metal-Based Flexible Bioelectrodes for Management of
In-Stent-Restenosis: Potential Application.
Source
Biosensors. 13(8) (no pagination), 2023. Article Number: 795. Date of
Publication: August 2023.
Author
Zhang X.; Li L.; Deng Z.
Institution
(Zhang, Li, Deng) Key Laboratory of Cryogenics, Technical Institute of
Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China
(Zhang, Deng) School of Future Technology, University of Chinese Academy
of Sciences, Beijing 100049, China
(Li) Plastic Surgery Hospital, Chinese Academy of Medical Sciences,
Beijing 100144, China
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Although vascular stents have been widely used in clinical practice, there
is still a risk of in-stent restenosis after their implantation. Combining
conventional vascular stents with liquid metal-based electrodes with
impedance detection, irreversible electroporation, and blood pressure
detection provides a new direction to completely solve the restenosis
problem. Compared with conventional rigid electrodes, liquid metal-based
electrodes combine high conductivity and stretchability, and are more
compliant with the implantation process of vascular stents and remain in
the vasculature for a long period of time. This perspective reviews the
types and development of conventional vascular stents and proposes a novel
stent that integrates liquid metal-based electrodes on conventional
vascular stents. This vascular stent has three major functions of
prediction, detection and treatment, and is expected to be a new
generation of cardiovascular implant with intelligent sensing and
real-time monitoring. Copyright © 2023 by the authors.

<59>
Accession Number
2025062950
Title
Impact of Obesity on Atrial Electrophysiological Substrate.
Source
Journal of Cardiovascular Development and Disease. 10(8) (no pagination),
2023. Article Number: 342. Date of Publication: August 2023.
Author
Schram Serban C.; de Groot N.M.S.
Institution
(Schram Serban, de Groot) Department of Cardiology, Erasmus University
Medical Center, Rotterdam 3015 GD, Netherlands
(de Groot) Department of Microelectronics, Circuits and Systems, Faculty
of Electrical Engineering, Mathematics and Computer Sciences, Delft
University of Technology, Delft 2628 CD, Netherlands
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
(1) Background. Obesity is a well-established worldwide recognised risk
factor for atrial fibrillation (AF). Prior review papers reported on the
associations between obesity and AF development, but not on the relation
between obesity and atrial electrophysiology. We therefore conducted a
systematic review to describe the current knowledge of the characteristics
of the atrial electrophysiological substrate in obese individuals and how
they relate to the development of AF. (2) Methods. A search was conducted
in Pubmed, Embase, and the Cochrane Library for publications evaluating
the impact of obesity on atrial electrophysiology, electrical substrates,
and their relation to the development of AF. (3) Results. A systematic
literature search retrieved 477 potential publications based on the
inclusion criteria; 76 full-text articles were selected for the present
systematic review. The literature demonstrated that obesity predisposes to
not only a higher AF incidence but also to more extensive atrial
electrophysiological abnormalities increasing susceptibility to AF
development. (4) Conclusion. Obesity may predispose to an overall increase
in atrial electropathology, consisting of an increase in the slowing of
the conduction, conduction block, low-voltage areas, and complex
fractionated electrograms. To determine the impact of obesity-induced
atrial electrical abnormalities on the long-term clinical outcome, further
prospective studies are mandatory. Copyright © 2023 by the
authors.

<60>
Accession Number
2024862699
Title
A Systematic Review of Short-Term Outcomes of Minimally Invasive
Thoracoscopic Surgery for Lung Cancer after Neoadjuvant Systemic Therapy.
Source
Cancers. 15(15) (no pagination), 2023. Article Number: 3908. Date of
Publication: August 2023.
Author
Sedighim S.; Frank M.I.; Heutlinger O.; Lee C.; Hachey S.J.; Keshava H.B.
Institution
(Sedighim, Lee, Keshava) Department of General Surgery, Irvine School of
Medicine, University of California, 3800 Chapman Ave, Suite, 6200, Orange,
CA 92868, United States
(Frank, Heutlinger) Irvine School of Medicine, University of California,
Orange, CA 92868, United States
(Hachey) Department of Molecular and Cell Biology, Irvine School of
Biological Sciences, University of California, Orange, CA 92868, United
States
(Keshava) Division of Thoracic Surgery, Irvine School of Medicine,
University of California, Orange, CA 92868, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Minimally invasive surgeries for non-small cell lung cancers
(NSCLCs) such as video-assisted thoracoscopic surgeries (VATSs) and
robotic-assisted thoracoscopic surgeries (RATSs) have become standard of
care for patients needing surgical resection in early stages. The role for
neoadjuvant systemic therapy has increased with patients receiving
neoadjuvant systemic chemotherapy and immunotherapy. However, there has
been some equipoise over the intraoperative and overall outcomes for these
patients. Here, we review the current data regarding outcomes of patients
undergoing minimally invasive thoracic surgical resection after systemic
chemotherapy, immunotherapy, or both. Method(s): A systematic
literature review of randomized controlled trials and observational
studies presenting data on patients with NSCLC that underwent neoadjuvant
systemic therapy followed by minimally invasive surgery was performed
assessing complications, conversion rates, and lymph node yield.
 Result(s): Our search strategy and review of references resulted in
239 publications to screen with 88 full texts assessed and 21 studies
included in our final review. VATS had a statistically significant higher
lymph node yield in five studies. The reported conversion rates ranged
from 0 to 54%. Dense adhesions, bleeding, and difficult anatomy were the
most common reported reasons for conversion to open surgeries. The most
common complications between both groups were prolonged air leak,
arrythmia, and pneumonia. VATS was found to have significantly fewer
complications in three papers. Conclusion(s): The current literature
supports VATS as safe and feasible for patients with NSCLC after
neoadjuvant systemic treatment. Surgeons should remain prepared to convert
to open surgeries in those patients with dense adhesions and bleeding
risk. Copyright © 2023 by the authors.

<61>
Accession Number
2024858500
Title
Comparison of the effects of one-level and bi-level pre-incisional erector
spinae plane block on postoperative acute pain in video-assisted
thoracoscopic surgery; a prospective, randomized, double-blind trial.
Source
BMC Anesthesiology. 23(1) (no pagination), 2023. Article Number: 270. Date
of Publication: December 2023.
Author
Zengin E.N.; Zengin M.; Yigit H.; Sazak H.; Sekerci S.; Alagoz A.
Institution
(Zengin, Yigit, Sekerci) Ankara Bilkent City Hospital, Anesthesiology and
Reanimation Clinic, Ministry of Health, Ankara, Turkey
(Zengin) Ankara Etlik City Hospital, Anesthesiology and Reanimation
Clinic, Ministry of Health, Ankara, Turkey
(Sazak, Alagoz) University of Health Sciences, Ankara Ataturk Sanatorium
Training and Research Hospital, Ankara, Turkey
Publisher
BioMed Central Ltd
Abstract
Background: This prospective, randomized, double-blind trial aimed to
compare the postoperative analgesic efficacy of One-Level pre-incisional
erector spinae plane block (ESPB) and Bi-Level pre-incisional ESPB in
patients undergoing video-assisted thoracic surgery (VATS).
 Method(s): This pilot trial was conducted between April 2022 and
February 2023 with sixty patients. The patients were randomly divided into
two groups. In One-Level ESPB Group (n = 30) block was performed at the
thoracal(T)5 level with the 30 ml 0.25% bupivacaine. In the Bi-Level ESPB
Group (n = 30) block was performed at T4 and T6 levels by using 15 ml of
0.25% bupivacaine for each level. In the postoperative period, 50 mg
dexketoprofen every 12 h and 1 g paracetamol every 8 h were given
intravenously (IV). Patient-controlled analgesia (PCA) prepared with
morphine was applied to the patients. 0.5 mg/kg of tramadol was
administered via IV for rescue analgesia. Visual analog scale (VAS) scores
were recorded in the postoperative 1st, 2nd,
4th, 12th, 24th, and 48th
-hours. The need for additional analgesics and side effects were recorded.
In two groups, patients' demographics and postoperative hemodynamic data
were recorded. Result(s): VAS scores at resting were statistically
significantly higher at the 1st (p: 0.002) and 4th
-hour (p: 0.001) in the One-Level ESPB. When the groups were evaluated in
terms of VAS coughing scores, the 4th -hour (p: 0.001) VAS
coughing scores results were found to be statistically significantly
higher in the One-Level ESPB group. In terms of VAS values evaluated
during follow-up, the rates of VAS coughing score > 3 values were found to
be statistically significantly lower in the Bi-Level ESPB group (p:
0.011). There was no statistically significant difference between the
groups in terms of side effects, morphine consumption, and additional
analgesic use (p > 0.05). Conclusion(s): Adequate analgesia was
achieved in the early postoperative period in the group treated with
Bi-Level ESPB with similar morphine consumption and side effects. This may
be an advantage, especially in the early postoperative period when the
pain is quite intense. Copyright © 2023, BioMed Central Ltd.,
part of Springer Nature.

<62>
Accession Number
2022256795
Title
Surgical and non-surgical management of thoracic and cervical
paraganglioma.
Source
Annales d'Endocrinologie. 84(4) (pp 466-471), 2023. Date of Publication:
August 2023.
Author
Araujo-Castro M.; Redondo Lopez S.; Pascual-Corrales E.; Polo Lopez R.;
Alonso-Gordoa T.; Molina-Cerrillo J.; Moreno Mata N.; Caballero Silva U.;
Barbera Durban R.
Institution
(Araujo-Castro, Pascual-Corrales) Neuroendocrinology Division, Department
of Endocrinology & Nutrition & IRYCIS, Hospital Universitario Ramon y
Cajal & Universidad de Alcala, Madrid, Spain
(Redondo Lopez) Department of Vascular Surgery, Hospital Universitario
Ramon y Cajal, Madrid, Spain
(Polo Lopez, Barbera Durban) Department of Otorhinolaryngology, Hospital
Universitario Ramon y Cajal, Madrid, Spain
(Alonso-Gordoa, Molina-Cerrillo) Department of Medical Oncology, Hospital
Universitario Ramon y Cajal & IRYCIS, Madrid, Spain
(Moreno Mata, Caballero Silva) Department of Thoracic Surgery, Hospital
Universitario Ramon y Cajal, Madrid, Spain
Publisher
Elsevier Masson s.r.l.
Abstract
Thoracic and cervical paragangliomas (PGLs) are rare neuroendocrine tumors
arising from chromaffin cells of the neural crest progenitors located
outside the adrenal gland. We describe our current protocol as a
multidisciplinary team for the management of cervical and thoracic PGLs.
Surgery is generally considered the treatment of choice as it offers the
best chance for cure. For resection of thoracic PGLs, video-assisted
thoracoscopic surgery (VATS) is the main surgical approach, while open
thoracotomy is preferred in case of tumors > 6 cm, lacking confirmation of
a plane of separation with adjacent structures, or with technical
difficulties during VATS. In cervical PGLs, the surgical approach should
be individualized according to location, mainly based on the
Glasscock-Jackson and the Fisch-Mattox classifications. Surgery is the
treatment of choice for most cervical and thoracic PGLs, but radiotherapy
or observation could be more suitable options in unresectable cervical and
thoracic PGLs or when resection has been incomplete. Copyright ©
2022 Elsevier Masson SAS

<63>
Accession Number
2024135454
Title
Intraoperative suggestions to prevent postoperative delirium in patients
undergoing transaortic valvular replacement: a randomized
placebo-controlled trial.
Source
Aging Clinical and Experimental Research. 35(9) (pp 1865-1872), 2023. Date
of Publication: September 2023.
Author
Kaufmann C.; Zech N.; Brandt F.; Hilker M.; Debl K.; Creutzenberg M.;
Zeman F.; Graf B.M.; Sinner B.
Institution
(Kaufmann, Zech, Brandt, Creutzenberg, Graf, Sinner) Department of
Anesthesiology, University Hospital Regensburg, Regensburg, Germany
(Hilker) Department of Cardiothoracic Surgery, University Hospital
Regensburg, Regensburg, Germany
(Debl) Department of Cardiology, University Hospital Regensburg,
Regensburg, Germany
(Zeman) Department of Medical Biostatistics, University Hospital
Regensburg, Regensburg, Germany
(Sinner) Department of Anesthesia and Intensive Care, Medical University
Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Postoperative delirium (POD) is a serious complication
following anaesthesia and surgery and significantly influences
postoperative outcome especially in the elderly population. Intraoperative
music and positive suggestions influence postoperative outcomes by
attenuating analgesic demand and increasing patient satisfaction.
 Aim(s): Here, we examined the effect of intraoperative music and
positive suggestions on the development of POD in aged patients undergoing
transcatheter aortic valve replacement (TAVR) procedure under general
anaesthesia. Method(s): For this randomized placebo-controlled study,
eligible patients without cognitive deficit, indicated by a MMSE < 10
points, were anesthetized using remifentanil and sevoflurane. Anaesthetic
depth was guide with bispectral index. An audiotape with positive
suggestions was applied from a MP3 player via headphones. POD, pain and
PONV was assessed. CAM-ICU and Nu-DESC were done twice daily for the first
5 days. Result(s): Of 140 patients 118 patients could be analysed (57
male, 80.6 +/- 5.1 years). POD was diagnosed in 16 patients (12.7%). POD
was significantly more often observed in male (12, 21.1%) than in female
(4, 6.6%, p = 0.02) and in patients with a low MMSE (23.6 +/- 4.5 vs. 26.8
+/- 2.8, p = 0.001). Anaesthetic depth did not influence the incidence of
POD. Intraoperative music and suggestions did not affect the rate of POD,
pain, analgesic requirement or PONV. Discussion(s): In patients
undergoing TAVR male sex and low MMSE scoring are associated with an
increase in POD. Conclusion(s): Intraoperative music and positive
suggestions do not influence the incidence of POD in this patient group.
Study registration: DRKS: 00024444, start of registration: 4.02.202, final
registration: 17.09.2021 Copyright © 2023, The Author(s).

<64>
Accession Number
2023241858
Title
Enteral access and reflux management in neonates with severe
univentricular congenital heart disease: literature review and proposed
algorithm.
Source
European Journal of Pediatrics. 182(8) (pp 3375-3383), 2023. Date of
Publication: August 2023.
Author
Avasarala V.; Aitharaju V.; Encisco E.M.; Rymeski B.; Ponsky T.A.;
Huntington J.T.
Institution
(Avasarala, Aitharaju, Ponsky) Department of Surgery, Northeast Ohio
Medical University, Rootstown, OH, United States
(Encisco, Ponsky, Huntington) Department of Pediatric Surgery, Akron
Children's Hospital, 215 West Bowery Street, Level 6, Akron, OH 44308,
United States
(Encisco, Rymeski, Ponsky) Division of Pediatric General and Thoracic
Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,
United States
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Neonates with severe congenital heart disease undergoing surgical repair
may face various complications, including failure to thrive. Feeding tube
placement and fundoplication are often performed to combat poor growth in
neonates. With the variety of feeding tubes available and controversy
surrounding when fundoplication is appropriate, there is no current
protocol to determine which intervention is necessary for this patient
population. We aim to provide an evidence-based feeding algorithm for this
patient population. Initial searches for relevant publications yielded 696
publications; after review of these studies and inclusion of additional
studies through external searches, a total of 38 studies were included for
qualitative synthesis. Many of the studies utilized did not directly
compare the different feeding modalities. Of the 38 studies included, five
studies were randomized control trials, three studies were literature
reviews, one study was an online survey, and the remaining twenty-nine
studies were observational. There is no current evidence to suggest that
this specific patient population should be treated differently regarding
enteral feeding. We propose an algorithm to assist optimal feeding for
neonates with congenital heart disease. Conclusion(s): Nutrition
remains a vital component of the care of neonates with congenital heart
disease; determining the optimal feeding strategy for these patients can
be approached like other neonates. Copyright © 2023, The
Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part
of Springer Nature.

<65>
Accession Number
2022705825
Title
Comparison of intracardiac echocardiography with transesophageal
echocardiography for left atrial appendage occlusion: an updated
systematic review and meta-analysis.
Source
Journal of Interventional Cardiac Electrophysiology. 66(6) (pp 1337-1340),
2023. Date of Publication: September 2023.
Author
Krishan S.; Hashim L.; Javed L.; Gomez-Perez J.; Muhammad R.; Gondal J.;
Sacco J.; Clifton S.; Khattab M.; Munir M.B.; DeSimone C.V.; Deshmukh A.;
Stavrakis S.; Asad Z.U.A.
Institution
(Krishan, Hashim, Javed, Gomez-Perez, Gondal, Sacco, Khattab, Stavrakis,
Asad) Department of Medicine, University of Oklahoma Health Sciences
Center, 800 Stanton L. Young Blvd, AAT 5400, Oklahoma City, OK 73104,
United States
(Muhammad) Oklahoma State University College of Osteopathic Medicine,
Tulsa, OK, United States
(Clifton) Robert M. Bird Health Sciences Library, University of Oklahoma
Health Sciences Center, Oklahoma City, OK, United States
(Munir) Department of Cardiovascular Medicine, Section of
Electrophysiology, University of California Davis, Davis, CA, United
States
(DeSimone, Deshmukh) Department of Cardiovascular Medicine, Mayo Clinic,
Rochester, MN, United States
Publisher
Springer

<66>
Accession Number
2020421673
Title
Outcomes of catheter ablation of atrial tachyarrhythmia guided exclusively
by activation mapping.
Source
Journal of Interventional Cardiac Electrophysiology. 66(6) (pp 1383-1389),
2023. Date of Publication: September 2023.
Author
Zhang X.; Li W.; Lin A.; Zou F.; Marazzato J.; Varrias D.; Nagraj S.; Wang
Y.-C.; Seo J.; Della Rocca D.G.; Levine E.; Santangeli P.; Lakkireddy D.;
Natale A.; Di Biase L.
Institution
(Zhang, Lin, Zou, Marazzato, Levine, Di Biase) Montefiore Medical Center,
Albert Einstein College of Medicine, Bronx, NY, United States
(Li, Varrias, Nagraj, Wang, Seo) New York City Health + Hospitals/Jacobi
Medical Center, Albert Einstein College of Medicine, Bronx, NY, United
States
(Marazzato) Department of Medicine and Surgery, University of Insubria,
Varese, Italy
(Della Rocca, Natale, Di Biase) Texas Cardiac Arrhythmia Institute, St.
David's Medical Center, Austin, TX, United States
(Santangeli) Hospital of the University of Pennsylvania, Philadelphia, PA,
United States
(Lakkireddy) Kansas City Heart Rhythm Institute, HCA Midwest Health,
Kansas City, MO, United States
Publisher
Springer
Abstract
Introduction: Complex atrial tachyarrhythmias (CATs) are commonly observed
in patients with prior catheter ablation or cardiac surgery. These
arrhythmias are challenging to map and ablate. Historically, entrainment
mapping was utilized to characterize CAT. With the advent of
high-definition mapping (HDM), full visualization of the CAT circuit is
possible which may obviate the need for entrainment mapping.
 Method(s): We sought to investigate the outcomes of catheter ablation
of CAT guided only by HDM. Consecutive patients who underwent CAT ablation
from 2017 to 2021 were included in our study (excluding right atrial
tachyarrhythmias). Patients were sorted by the type of mapping performed.
Group I consisted of patients where HDM alone was utilized with no attempt
of entrainment. Group II consisted of patients where both entrainment and
HDM were utilized. Result(s): A total of 67 patients were included in
our study, with 40 patients in HDM group (I) and 27 patients in
entrainment group (II). No statistically significant difference regarding
1-year freedom from atrial arrhythmias was found between the two groups
(80% vs 77.8%, p = 0.819). Four CATs were terminated by entrainment during
procedure versus none in the HDM-only group (p = 0.011).
 Conclusion(s): CAT ablation with HDM alone yielded similar 1-year
freedom from atrial arrhythmias compared to ablation with HDM and
entrainment. Entrainment combined with HDM was associated with higher
undesired CAT interruption rate. Further validation is needed with
randomized control trials. Copyright © 2022, The Author(s), under
exclusive licence to Springer Science+Business Media, LLC, part of
Springer Nature.

<67>
Accession Number
2018949577
Title
Double-lung versus heart-lung transplantation for end-stage
cardiopulmonary disease: a systematic review and meta-analysis.
Source
Surgery Today. 53(9) (pp 1001-1012), 2023. Date of Publication: September
2023.
Author
Yan H.-J.; Zheng X.-Y.; Huang H.; Xu L.; Tang H.-T.; Wang J.-J.; Li C.-H.;
Zhang S.-X.; Fu S.-Y.; Wen H.-Y.; Tian D.
Institution
(Yan, Tian) Department of Thoracic Surgery, West China Hospital, Sichuan
University, 37 Guo Xue Xiang, Chengdu 610041, China
(Yan, Zheng, Huang, Xu, Tang, Wang, Li, Zhang, Fu, Tian) Heart and Lung
Transplant Research Laboratory, Affiliated Hospital of North Sichuan
Medical College, Nanchong 637000, China
(Wen) Department of Cardiothoracic Intensive Care Unit, Affiliated
Hospital of North Sichuan Medical College, Nanchong 637000, China
Publisher
Springer
Abstract
We compared posttransplant outcomes following double-lung transplantation
(DLTx) and heart-lung transplantation (HLTx), based on a search of PubMed,
Cochrane Library, and Embase, from inception to March 8, 2022, for studies
that report outcomes of these procedures. We then performed a
meta-analysis of baseline characteristics and posttransplant outcomes.
Subgroup analyses were implemented according to indication, publication
year, and center. This study was registered on PROSPERO (number
CRD42020223493). Ten studies were included in this meta-analysis,
involving 1230 DLTx patients and 1022 HLTx patients. The DLTx group was
characterized by older donors (P = 0.04) and a longer allograft ischemia
time (P < 0.001) than the HLTx group. The two groups had comparable
1-year, 3-year, 5-year, 10-year survival rates (all P > 0.05), with
similar results identified in subgroup analyses. We found no significant
differences in 1-year, 5-year, and 10-year chronic lung allograft
dysfunction (CLAD)-free survival, length of intensive care unit stay and
hospital stay, length of postoperative ventilation, in-hospital mortality,
or surgical complications between the groups (all P > 0.05). Thus, DLTx
provides similar posttransplant survival to HLTx for end-stage
cardiopulmonary disease. These two procedures have a comparable risk of
CLAD and other posttransplant outcomes. Copyright © 2022, The
Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.

<68>
Accession Number
641852049
Title
5-Year haemodynamic performance of three aortic bioprostheses. A
randomized clinical trial.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 64(2) (no pagination),
2023. Date of Publication: 01 Aug 2023.
Author
Montero Cruces L.; Carnero Alcazar M.; Perez Camargo D.; Cobiella Carnicer
J.; Campelos Fernandez P.; Reguillo Lacruz F.J.; Maroto Castellanos L.C.
Institution
(Montero Cruces, Carnero Alcazar, Perez Camargo, Cobiella Carnicer,
Campelos Fernandez, Reguillo Lacruz, Maroto Castellanos) Department of
Cardiovascular Surgery, Clinico San Carlos Hospital, Madrid, Spain
Publisher
NLM (Medline)
Abstract
OBJECTIVES: The Carpentier Perimount (CP) Magna Ease, the Crown
Phospholipid Reduction Treatment (PRT) and the Trifecta bovine pericardial
valves have been widely used worldwide. The primary end point of this
study was to compare the haemodynamic performance quantified by in vivo
echocardiograms of these 3 aortic prostheses. METHOD(S): The
"BEST-VALVE" (comparison of 3 contemporary cardiac bioprostheses: mid-term
valve haemodynamic performance) was a single-centre randomized clinical
trial to compare the haemodynamic and clinical outcomes of the
aforementioned bioprostheses. The 5-year results are assessed in this
manuscript. RESULT(S): A total of 154 patients were included. The CP
Magna Ease (n=48, 31.2%), Crown PRT (n=51, 32.1%) and Trifecta (n=55,
35.7%) valves were compared. Significant differences were observed among
the 3 bioprostheses 5 years after the procedure. The following
haemodynamic differences were found between the CP Magna Ease and the
Crown PRT bioprostheses [mean aortic gradient: 12.3 mmHg (interquartile
range {IQR} 7.8-17.5) for the CP Magna Ease vs 15mmHg (IQR 10.8-31.9) for
the Crown PRT, P<0.001] and between the CP Magna Ease and the Trifecta
prostheses [mean aortic gradient: 12.3 mmHg (IQR 7.8-17.5) for the CP
Magna Ease vs 14.7mmHg (IQR 8.2-55) for the Trifecta, P<0.001], with a
better haemodynamic performance of the CP Magna Ease. The cumulative
incidence of severe structural valve degeneration was 9.5% in the Trifecta
group at 6years of follow-up. The 1-, 3- and 5-year survival from
all-cause mortality was 91.5%, 83.5% and 74.8%, respectively (log rank
P=0.440). Survival from the composite event at the 1-, 3- and 5-year
follow-up was 92.8%, 74.6% and 59%, respectively (log rank P=0.299).
 CONCLUSION(S): We detected significant differences between the 3
bioprostheses; the CP Magna Ease had the best haemodynamic performance at
the 5-year follow-up. Copyright © The Author(s) 2023. Published
by Oxford University Press on behalf of the European Association for
Cardio-Thoracic Surgery. All rights reserved.

<69>
Accession Number
2026692303
Title
Effectiveness of virtual reality on anxiety and pain management in
patients undergoing cardiac procedures: A protocol for systematic review
and meta-analysis.
Source
Open Heart. 10(1) (no pagination), 2023. Article Number: 002305. Date of
Publication: 30 Jun 2023.
Author
Bashir Z.; Misquith C.; Has P.; Bukhari S.
Institution
(Bashir) Department of Medicine, Warren Alpert Medical School of Brown
University, Providence, RI, United States
(Misquith) Public Health and Research Support Library, Brown University,
Providence, RI, United States
(Has) Lifespan Biostatistics, Epidemiology and Research Design, Rhode
Island Hospital, Providence, RI, United States
(Bukhari) Department of Medicine, Temple University, Philadelphia, PA,
United States
Publisher
BMJ Publishing Group
Abstract
Introduction Anxiety and pain associated with cardiac procedures can lead
to worse outcomes and poor satisfaction. Virtual reality (VR) can offer an
innovative approach to a more informative experience that may enhance
procedural understanding and reduce anxiety. It may also provide a more
enjoyable experience by controlling procedure-related pain and improving
satisfaction. Previous studies have shown benefits of VR-related therapies
in improving anxiety related to cardiac rehabilitation and different
surgical procedures. We aim to evaluate the effectiveness of VR technology
in comparison to the standard of care in reducing anxiety and pain related
to cardiac procedures. Methods and analysis This systematic review and
meta-analysis protocol is structured according to the Preferred Reporting
for Systematic Review and Meta-analysis-Protocol (PRISMA-P) guidelines. A
comprehensive search strategy will be used to search the online databases
for randomised controlled trials (RCTs) on VR, cardiac procedures,
anxiety, and pain. Risk of bias will be analysed using revised Cochrane
risk of bias tool for RCTs. Effect estimates will be reported as
standardised mean differences with a 95% CI. Random effect model will be
used to generate effect estimates if heterogeneity is significant (I 2
>60%), otherwise fixed effect model will be used. A p value of <0.05 will
be taken as statistically significant. Publication bias will be reported
using Egger's regression test. Statistical analysis will be performed
using Stata SE V.17.0 and RevMan5. Ethics and dissemination There will be
no direct involvement of the patient or the public in the conception,
design, data collection, and analysis of this systematic review and
meta-analysis. Results of this systematic review and meta-analysis will be
disseminated via journal articles. PROSPERO registration number CRD
42023395395. Copyright © 2023 Open Heart

<70>
Accession Number
2026436776
Title
Clinical Outcomes After Caval Valve Implantation for Severe Symptomatic
Tricuspid Regurgitation: A Meta-Analysis.
Source
American Journal of Cardiology. 205 (pp 84-86), 2023. Date of Publication:
15 Oct 2023.
Author
Badwan O.Z.; Skoza W.; Mirzai S.; Bansal A.; Braghieri L.; Karmali R.H.;
Nero N.; Harb S.C.; Puri R.; Kapadia S.
Institution
(Badwan, Skoza, Mirzai, Braghieri, Karmali) Departments of Internal
Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic,
Cleveland, Ohio, United States
(Bansal, Harb, Puri, Kapadia) Departments of Cardiovascular Medicine,
Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland,
Ohio, United States
(Nero) Medical Library, Cleveland Clinic Floyd D. Loop Alumni Library,
Cleveland, Ohio, United States
Publisher
Elsevier Inc.

<71>
Accession Number
2025434956
Title
Evaluation of the Effect of New Multimodal Analgesia Regimen for Cardiac
Surgery: A Prospective, Randomized Controlled, Single-Center Clinical
Study [Response to Letter].
Source
Drug Design, Development and Therapy. 17 (pp 2457-2460), 2023. Date of
Publication: 2023.
Author
Jin L.; Guo K.
Institution
(Jin, Guo) Department of Anesthesia, Zhongshan Hospital, Fudan University,
Shanghai, China
Publisher
Dove Medical Press Ltd

<72>
[Use Link to view the full text]
Accession Number
2026676414
Title
Acute pain after serratus anterior plane or thoracic paravertebral blocks
for video-assisted thoracoscopic surgery: A noninferiority randomised
trial.
Source
European Journal of Anaesthesiology. 38 (pp S97-S105), 2021. Date of
Publication: 01 Aug 2021.
Author
Qiu Y.; Wu J.; Huang Q.; Lu Y.; Xu M.; Mascha E.J.; Yang D.; Ince I.;
Sessler D.I.
Institution
(Qiu, Wu, Huang, Lu, Xu) Department of Anesthesiology, Shanghai Chest
Hospital, Shanghai Jiao Tong University, Shanghai, China
(Qiu, Mascha, Yang, Ince, Sessler) The Department of Outcomes Research,
Anesthesiology Institute, Cleveland Clinic, China
(Wu) The Outcomes Research Consortium, China
(Mascha, Yang) The Department of Quantitative Health Sciences, Cleveland
Clinic, OH, United States
(Ince) The Department of Anesthesiology and Reanimation, Ataturk
University School of Medicine, Anaesthesiology Clinical Research Office,
Erzurum, Turkey
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUNDSerratus anterior plane blocks (SAPBs) and thoracic
paravertebral blocks (TPVBs) can both be used for video-assisted thoracic
surgery. However, it remains unknown whether the analgesic efficacy of a
SAPB is comparable to that of a TPVB.OBJECTIVEWe tested the primary
hypothesis that SAPBs provide noninferior analgesia compared with TPVBs
for video-assisted thoracic surgery.DESIGNA noninferiority randomised
trial.SETTINGShanghai Chest Hospital, between August 2018 and November
2018.PATIENTSNinety patients scheduled for video-assisted thoracic
lobectomy or segmentectomy were randomised. Patients were excluded if they
were unable to perform the visual analogue pain scale, or surgery was
converted to thoracotomy.INTERVENTIONSBlocks were performed after
induction of general anaesthesia. The three groups were paravertebral
blocks (n = 30); serratus anterior plane blocks (n = 29); and general
anaesthesia alone (n = 30).PRIMARY OUTCOME MEASURESVisual analogue pain
scores (0 to 10 cm) at rest and while coughing, and Prince-Henry pain
scores (0 to 4 points) were used to assess postoperative analgesia at 2,
24 and 48 h after surgery. We assessed the noninferiority of SAPBs with
TPVBs on all three primary pain outcomes using a delta of 1 cm or one
point as appropriate.RESULTSThe mean difference (95% confidence intervals)
in visual analogue scores between the SAPBs and TPVBs was -0.04 (-0.10 to
0.03) cm at rest, -0.22 (-0.43 to -0.01) cm during coughing and -0.10
(-0.25 to 0.05) for Prince-Henry pain scores. As the upper limit of the
confidence intervals were less than 1 (all P < 0.001), noninferiority was
claimed for all three primary outcomes. Compared with general anaesthesia
alone, the VAS scores at rest and while coughing, and the Prince-Henry
pain scores for the two blocks were significantly lower during the initial
2 h after surgery.CONCLUSIONSSerratus anterior plane blocks are quicker
and easier to perform than paravertebral blocks and provide comparable
analgesia in patients having video-assisted thoracic surgery. Both blocks
provided analgesia that was superior to general anaesthesia alone during
the initial 2 h after surgery.TRIAL REGISTRATIONChinese Clinical Trial
Registry, identifier: ChiCTR1800017671. Copyright © 2021
Lippincott Williams and Wilkins. All rights reserved.

<73>
Accession Number
2025193934
Title
Sex differences in permanent pacemaker implantation after transcatheter
aortic valve replacement: a systematic review and meta-analysis.
Source
Expert Review of Cardiovascular Therapy. (no pagination), 2023. Date of
Publication: 2023.
Author
Rivera F.B.; Cha S.W.; Aparece J.P.; Gonzales J.S.T.; Salva W.F.C.;
Bantayan N.R.B.; Carado G.P.; Sharma V.; Al-Abcha A.; Co M.L.; Collado
F.M.S.; Volgman A.S.
Institution
(Rivera) Department of Medicine, Lincoln Medical Center, New York, NY,
United States
(Cha, Aparece, Gonzales, Salva) Cebu Institute of Medicine, Cebu,
Philippines
(Bantayan) University of the Philippines College of Medicine, Manila,
Philippines
(Carado) University of the East Ramon Magsaysay Memorial Medical Center,
Quezon, Philippines
(Sharma) Department of Cardiology, University of Iowa Hospitals and
Clinics, Lowa City, IA, United States
(Al-Abcha) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
(Co) Section of Clinical Cardiac Electrophysiology, Thomas Jefferson
University, Philadelphia, PA, United States
(Collado, Volgman) Division of Cardiology, Rush University Medical Center,
Chicago, IL, United States
Publisher
Taylor and Francis Ltd.
Abstract
Background: There is limited evidence on the effect of sex on permanent
pacemaker implantation (PPMI) after transcatheter aortic valve replacement
(TAVR). The primary objective of this meta-analysis was to determine the
role of sex among patients requiring PPMI post-TAVR. Method(s): A
literature search was conducted using the SCOPUS, MEDLINE, and CINAHL
databases for studies published until October 2022. Eligible studies
included published randomized controlled trials (RCTs) and Observational
Cohort Studies (OCS) articles that reported PPMI as an outcome of
pacemaker status following TAVR. This study was performed per the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Guidelines. Publication bias was estimated using a Funnel plot
and Egger's test. Data were pooled using a random-effects model. The
primary endpoint was the sex difference in PPMI after TAVR, with odds
ratios and 95% confidence intervals (CIs) extracted. Result(s): Data
was obtained from 63 studies, and a total of 79,655 patients were
included. The cumulative PPMI rate was 15.5% (95% CI, 13.6%-17.7%). The
pooled analysis revealed that while there were more females than males
undergoing TAVR (51.6%, 95% CI 50.4%-52.8%), males have a 14.5% higher
risk for post-TAVR PPMI than females (OR 1.145, 95% CI 1.047-1.253, P <
0.01). Conclusion(s): Males are more likely to experience PPMI after
TAVR than females. Further research needs to be done to better explain
these observed differences in outcomes. Copyright © 2023 Informa
UK Limited, trading as Taylor & Francis Group.

<74>
Accession Number
642148804
Title
Standardised Exercise Prescription for Patients with Chronic Coronary
Syndrome and/or Heart Failure: A Consensus Statement from the EXPERT
Working Group.
Source
Sports medicine (Auckland, N.Z.). (no pagination), 2023. Date of
Publication: 30 Aug 2023.
Author
Hansen D.; Beckers P.; Neunhauserer D.; Bjarnason-Wehrens B.; Piepoli
M.F.; Rauch B.; Voller H.; Corra U.; Garcia-Porrero E.; Schmid J.-P.;
Lamotte M.; Doherty P.; Reibis R.; Niebauer J.; Dendale P.; Davos C.H.;
Kouidi E.; Spruit M.A.; Vanhees L.; Cornelissen V.; Edelmann F.; Barna O.;
Stettler C.; Tonoli C.; Greco E.; Pedretti R.; Abreu A.; Ambrosetti M.;
Braga S.S.; Bussotti M.; Faggiano P.; Takken T.; Vigorito C.; Schwaab B.;
Coninx K.
Institution
(Hansen, Dendale) Heart Centre Hasselt, Jessa Hospital, Hasselt, Belgium
(Hansen, Dendale, Spruit) UHasselt, BIOMED (Biomedical Research Institute)
and REVAL (Rehabilitation Research Centre) (REVAL/BIOMED), Hasselt
University, Agoralaan Building A, Diepenbeek 3590, Belgium
(Beckers) Department of Cardiology, Antwerp University Hospital, Edegem,
Belgium
(Beckers) Translational Pathophysiological Research, Antwerp University,
Antwerp, Belgium
(Neunhauserer) Sport and Exercise Medicine Division, Department of
Medicine, University of Padova, Padua, Italy
(Bjarnason-Wehrens) Department of Preventive and Rehabilitative Sport and
Exercise Medicine, Institute for Cardiology and Sports Medicine, German
Sports University, Cologne, Germany
(Piepoli) Clinical Cardiology, IRCCS Policlinico San Donato, Milan, Italy
(Piepoli) Department of Biomedical Sciences for Health, University of
Milan, Milan, Italy
(Rauch) Institut fur Herzinfarktforschung Ludwigshafen, Ludwigshafen am
Rhein/Stiftung Institut fur Herzinfarktforschung Ludwigshafen,
Ludwigshafen am Rhein/Zentrum fur Ambulante Rehabilitation, Trier, Germany
(Voller) Department of Cardiology, Klinik am See, Rudersdorf, Germany
(Voller) Center of Rehabilitation Research, University of Potsdam,
Potsdam, Germany
(Corra) Cardiologic Rehabilitation Department, Istituti Clinici
Scientifici Salvatore Maugeri, SPA, SB, Scientific Institute of di Veruno,
IRCCS, Veruno, NO, Italy
(Garcia-Porrero) Cardiology Service of Complejo Hospitalario,
Universitario de Leon, Leon, Spain
(Schmid) Department of Cardiology, Clinic Barmelweid, Barmelweid,
Switzerland
(Lamotte) CUB Erasme Hospital, Brussels, Belgium
(Doherty) Department of Health Sciences, University of York, York, United
Kingdom
(Reibis) Cardiological Outpatient Clinics at the Park Sanssouci, Potsdam,
Germany
(Niebauer) Institute of Sports Medicine, Prevention and Rehabilitation,
Research Institute of Molecular Sports Medicine and Rehabilitation, Ludwig
Boltzmann Institute for Digital Health and Prevention, Paracelsus Medical
University Salzburg, Salzburg, Austria
(Davos) Cardiovascular Research Laboratory, Biomedical Research
Foundation, Academy of Athens, Athens, Greece
(Kouidi) Laboratory of Sports Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece
(Spruit) Department of Research & Education; CIRO+, Centre of Expertise
for Chronic Organ Failure, Horn/Department of Respiratory Medicine,
Maastricht University Medical Centre, NUTRIM School of Nutrition and
Translational Research in Metabolism, Maastricht, The Netherlands
(Vanhees, Cornelissen) Research Group of Cardiovascular Rehabilitation,
Department of Rehabilitation Sciences, Faculty of Kinesiology and
Rehabilitation Sciences, KU Leuven, Leuven, Belgium
(Vanhees, Cornelissen) Department Rehabilitation Sciences, University
Leuven, Leuven, Belgium
(Edelmann) Department of Cardiology, Angiology and Intensive Care,
Charite-Universitaetsmedizin Berlin, Campus Virchow Klinikum, Berlin,
Germany
(Barna) Family Medicine Department, National O.O. Bogomolets Medical
University, Kiev, Ukraine
(Stettler) Division of Endocrinology, Diabetes and Clinical Nutrion,
University Hospital/Inselspital, Bern, Switzerland
(Tonoli) Movement Control and Neuroplasticity Research Group, Department
of Movement Sciences, Faculty of Movement and Rehabilitation Sciences, KU
Leuven, Leuven, Belgium
(Greco) CS, Fuscaldo, Italy
(Pedretti, Braga) Cardiovascular Department, IRCCS MultiMedica, Milan,
Italy
(Abreu) Centre of Cardiovascular RehabilitationCardiology Department,
Centro Universitario Hospitalar Lisboa Norte & Faculdade de Medicina da
Universidade Lisboa/Instituto Saude Ambiental & Instituto Medicina
Preventiva, Faculdade Medicina da Universidade Lisboa/CCUL/CAML, Lisbon,
Portugal
(Ambrosetti) Cardiovascular Rehabilitation Unit, Le Terrazze Clinic,
Cunardo, Italy
(Bussotti) Unit of Cardiorespiratory Rehabilitation, IRCCS, Institute of
Milan, Milan, Italy
(Faggiano) Cardiovascular Department, Fondazione Poliambulanza, Brescia,
Italy
(Takken) Division of Pediatrics, Child Development & Exercise Center,
Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, Netherlands
(Vigorito) Department of Translational Medical Sciences, Internal Medicine
and Cardiac Rehabilitation, University of Naples Federico II, Naples,
Italy
(Schwaab) Curschmann Clinic, Rehabilitation Center for Cardiology,
Vascular Diseases and Diabetes, University of Lubeck, Timmendorfer
Strand/Medical Faculty, Lubeck, Germany
(Coninx) UHasselt, Faculty of Sciences, Hasselt University, Hasselt,
Belgium
Publisher
NLM (Medline)
Abstract
Whereas exercise training, as part of multidisciplinary rehabilitation, is
a key component in the management of patients with chronic coronary
syndrome (CCS) and/or congestive heart failure (CHF), physicians and
exercise professionals disagree among themselves on the type and
characteristics of the exercise to be prescribed to these patients, and
the exercise prescriptions are not consistent with the international
guidelines. This impacts the efficacy and quality of the intervention of
rehabilitation. To overcome these barriers, a digital training and
decision support system [i.e. EXercise Prescription in Everyday practice &
Rehabilitative Training (EXPERT) tool], i.e. a stepwise aid to exercise
prescription in patients with CCS and/or CHF, affected by concomitant risk
factors and comorbidities, in the setting of multidisciplinary
rehabilitation, was developed. The EXPERT working group members reviewed
the literature and formulated exercise recommendations (exercise training
intensity, frequency, volume, type, session and programme duration) and
safety precautions for CCS and/or CHF (including heart transplantation).
Also, highly prevalent comorbidities (e.g. peripheral arterial disease) or
cardiac devices (e.g. pacemaker, implanted cardioverter defibrillator,
left-ventricular assist device) were considered, as well as indications
for the in-hospital phase (e.g. after coronary revascularisation or
hospitalisation for CHF). The contributions of physical fitness,
medications and adverse events during exercise testing were also
considered. The EXPERT tool was developed on the basis of this evidence.
In this paper, the exercise prescriptions for patients with CCS and/or CHF
formulated for the EXPERT tool are presented. Finally, to demonstrate how
the EXPERT tool proposes exercise prescriptions in patients with CCS
and/or CHF with different combinations of CVD risk factors, three patient
cases with solutions are presented. Copyright © 2023. The
Author(s), under exclusive licence to Springer Nature Switzerland AG.

<75>
Accession Number
642148616
Title
Down the Rabbit Hole: Reviewing the Evidence for Primary Prevention of
Cardiovascular Disease in People with Obesity.
Source
European journal of preventive cardiology. (no pagination), 2023. Date of
Publication: 30 Aug 2023.
Author
Stumpf M.A.M.; Cercato C.; de Melo M.E.; Santos R.D.; Mancini M.C.
Institution
(Stumpf, Cercato, de Melo, Mancini) Obesity Unit, Division of
Endocrinology and Metabolism, University of Sao Paulo Medical School
Hospital, Sao Paulo, Brazil
(Santos) Lipid Clinic Heart Institute (InCor), University of Sao Paulo
Medical School Hospital, Sao Paulo, Brazil
(Santos) Academic Research Organization, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
Publisher
NLM (Medline)
Abstract
Obesity is a prevalent chronic disorder and a well-known risk factor for
cardiovascular disease. However, the evidence of treating obesity for
primary prevention of major cardiovascular events is still scarce and
controversial. In this review, we provided a comprehensive description of
the current evidence in treating obesity regarding cardiovascular
protection. Bariatric surgery appears to be the most robust method to
reduce events in people without established cardiovascular disease. High
compliance to lifestyle interventions can further reduce cardiovascular
risk. Concerning pharmacological therapies, a post-hoc analysis from
SUSTAIN-6 and a meta-analysis from STEP trials suggest that semaglutide, a
GLP-1 receptor agonist, could reduce cardiovascular events in people
without established cardiovascular disease. The first study addressed
specifically a high-risk population with diabetes and, the second, low or
intermediary-risk individuals without diabetes. Tirzepatide, a novel dual
GIP/GLP-1 agonist, although not yet tested in specific cardiovascular
outcomes trials, could be an alternative since it induces loss in weight
similar to the achieved by bariatric surgery. Therefore, extrapolated data
in distinct baseline cardiovascular risk populations suggest that these
two drugs could be used in primary prevention with the aim of preventing
cardiovascular events, but the grade of this evidence is still low.
Specifically designed studies are needed to address this specific
topic. Copyright © The Author(s) 2023. Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved. For permissions, please e-mail:
journals.permissions@oup.com.

<76>
Accession Number
642147318
Title
Optimal antiplatelet strategy following coronary artery bypass grafting: a
meta-analysis.
Source
Heart (British Cardiac Society). (no pagination), 2023. Date of
Publication: 30 Aug 2023.
Author
Agrawal A.; Kumar A.; Majid M.; Badwan O.; Arockiam A.D.; El Dahdah J.;
Syed A.B.; Schleicher M.; Reed G.W.; Cremer P.C.; Griffin B.P.; Menon V.;
Wang T.K.M.
Institution
(Agrawal, Kumar, Majid, Badwan, Arockiam, El Dahdah, Syed, Reed, Cremer,
Griffin, Menon, Wang) Department of Cardiovascular Medicine, Cleveland
Clinic, Cleveland, OH, United States
(Schleicher) Floyd D. Loop Alumni Library, Cleveland Clinic, Cleveland,
OH, United States
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Coronary artery bypass grafting (CABG) is an established
revascularisation strategy for multivessel and left main coronary artery
disease. Although aspirin is routinely recommended for patients with CABG,
the optimal antiplatelet regimen after CABG remains unclear. We evaluated
the efficacies and risks of different antiplatelet regimens (dual (DAPT)
versus single (SAPT), and dual with clopidogrel (DAPT-C) versus dual with
ticagrelor or prasugrel (DAPT-T/P)) after CABG. METHOD(S): We
followed Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines and performed a comprehensive literature search
using PubMed, Ovid Medline, Ovid Embase and Cochrane Central Register of
Controlled Trials. Data were extracted and pooled using random-effects
models and Review Manager (V.5.4). RESULT(S): Among the 2970 article
abstracts screened, 215 full-text articles were reviewed and 38 studies
totaling 77 447 CABG patients were included for analyses. DAPT compared
with SAPT was associated with significantly lower all-cause mortality (OR
0.65 with 95% CI 0.50 to 0.86; p=0.002), cardiovascular mortality (OR
0.53, 95% CI 0.33 to 0.84; p=0.008), and major adverse cardiac and
cerebrovascular events (MACCE) (OR 0.68, 95% CI 0.51 to 0.91; p=0.01), but
higher rates of major (OR 1.30, 95% CI 1.08 to 1.56; p=0.007) and minor
bleeding (OR 1.87, 95% CI 1.28 to 2.74; p=0.001) after CABG. DAPT-T/P
compared with DAPT-C was associated with significantly lower all-cause (OR
0.43, 95% CI 0.29 to 0.65; p<=0.0001) and cardiovascular mortality (OR
0.44, 95% CI 0.24 to 0.80; p=0.008), and no differences on other
cardiovascular or bleeding outcomes after CABG. CONCLUSION(S): In
patients with CABG, DAPT compared with SAPT and DAPT-T/P compared with
DAPT-C were associated with reduction in all-cause and cardiovascular
mortality, especially in patients with acute coronary syndrome.
Additionally, DAPT was associated with reduction in MACCE, but higher
rates of major and minor bleeding. An individualised approach to choosing
antiplatelet regimen is necessary for patients with CABG based on
ischaemic and bleeding risks. Copyright © Author(s) (or their
employer(s)) 2023. No commercial re-use. See rights and permissions.
Published by BMJ.

<77>
Accession Number
2026553753
Title
Combination prophylactic amiodarone with beta-blockers versus
beta-blockers in atrial fibrillation after cardiac surgery: A
systematic-review and meta-analysis.
Source
Heart and Lung. 62 (pp 256-263), 2023. Date of Publication: 01 Nov 2023.
Author
Polintan E.T.; Monsalve R.; Menghrajani R.H.; Sirilan K.Y.; Nayak S.S.;
Abdelmaseeh P.; Patarroyo-Aponte G.; Lo K.B.; Dani S.S.
Institution
(Polintan) Department of Internal Medicine, SSM-Health St. Mary's
Hospital, St. Louis, MO, United States
(Monsalve) College of Medicine, Our Lady of Fatima University, Valenzuela
City, Philippines
(Menghrajani, Sirilan) Department of Internal Medicine, Lincoln Medical
Center, Bronx, NY, United States
(Nayak) Division of Hospital Medicine, Department of Internal Medicine,
Yale New Haven Bridgeport Hospital, Bridgeport, CT, United States
(Abdelmaseeh) Department of Medicine, Christiana Care Hospital, Delaware,
United States
(Patarroyo-Aponte) Division of Pulmonary, Critical Care and Sleep
Medicine, Department of Internal Medicine, McGovern Medical School, The
University of Texas Health Science Center at Houston, Houston, TX, United
States
(Lo) Department of Medicine, Einstein Medical Center, Sidney Kimmel
College of Medicine Thomas Jefferson University, Philadelphia, PA, United
States
(Dani) Department of Cardiology, Lahey Hospital & Medical Center,
Burlington, MA, United States
Publisher
Elsevier Inc.
Abstract
Background: Guideline recommendations regarding the preferred preventive
measures for postoperative atrial fibrillation (POAF) are unclear, nor
have we found any review articles addressing the combination of amiodarone
and beta-blockers for the prevention of POAF. Objective(s): To
investigate the efficacy and safety of combination beta-blockers and
amiodarone in the prevention of POAF while also comparing the use of
amiodarone and beta-blockers individually. Method(s): We used Pubmed
as the primary resource. POAF incidence was the primary outcome of this
study. The secondary outcomes were hospital length of stay (LOS), ICU LOS,
treatment-related drug discontinuation (TRDD), and mortality. The
random-effects model assessed all pooled outcomes with 95% confidence
intervals. Statistical significance was set at p<=0.05. Result(s):
The amiodarone subgroup of POAF incidence saw a Risk Ratio (RR) of 0.81
[0.63, 1.06], p=0.12, while the combination subgroup resulted in a RR of
0.63 [0.49, 0.80], p <0.001. TRDD for the amiodarone subgroup resulted in
a RR of 0.68 [0.25, 1.82], p=0.44, while the combination subgroup saw a RR
of 0.84 [0.57, 1.23], p=0.36. For mortality, the amiodarone subgroup
resulted in a RR of 0.97 [0.48, 1.98], p=0.93, while the combination
subgroup resulted in a RR of 1.04 [0.27, 4.05], p=0.96. Both hospital and
ICU LOS saw no significant difference between treatment arms for both the
combination subgroup and amiodarone alone. Except for the incidence of
postoperative atrial fibrillation (POAF) in the combination prophylaxis
group, most of the measured outcomes did not meet the optimized
information size (OIS) that was estimated. Conclusion(s): Combination
prophylaxis with amiodarone and beta-blockers significantly lowered risks
of POAF incidence in comparison to beta-blockers alone while also having
comparative mortality and TRDD outcomes. Copyright © 2023
Elsevier Inc.

<78>
Accession Number
2026484312
Title
The effect of nanocurcumin on the incidence of atrial fibrillation, and
markers of inflammation and oxidative stress level after coronary artery
bypass graft surgery: A randomized, double-blind, placebo-controlled
clinical study.
Source
Avicenna Journal of Phytomedicine. 12(5) (pp 503-513), 2022. Date of
Publication: October 2022.
Author
Alhashemi S.H.; Mohammadpour A.H.; Heidari R.; Nikoo M.H.; Nemati M.H.;
Vazin A.
Institution
(Alhashemi, Vazin) Department of Clinical Pharmacy, School of Pharmacy,
Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of
(Mohammadpour) Department of Clinical Pharmacy, School of Pharmacy,
Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Mohammadpour) Pharmaceutical Research Center, Pharmaceutical Technology
Institute, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic
Republic of
(Heidari) Pharmaceutical Sciences Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
(Nikoo) Department of Cardiology, Medical School, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
(Nikoo) Non-Communicable Diseases Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
(Nemati) Department of Cardiac Surgery, Medical School, Shiraz University
of Medical Sciences, Shiraz, Iran, Islamic Republic of
Publisher
Mashhad University of Medical Sciences
Abstract
Objective: Postoperative atrial fibrillation (POAF) is the most frequent
dysrhythmias observed following coronary artery bypass graft (CABG)
surgery. Several studies have shown the beneficial effects of curcumin on
cardiovascular diseases; however, there is no clinical trial to examine
its effect on POAF. This randomized, double-blind, placebo-controlled
clinical study was designed to evaluate the prophylactic effects of a
nano-formulation of curcumin (SinaCurcuminTM) versus placebo on POAF and
levels of biomarkers of inflammation and oxidative stress in patients
undergoing CABG surgery. Material(s) and Method(s): A total of 234
eligible patients were randomized to receive 240 mg curcumin
nano-formulation or placebo three days prior to the surgery and on the
first four postoperative days. The occurrence of POAF was monitored for at
least 96 hr after the surgery. Also, C-reactive protein (hs-CRP),
malondialdehyde (MDA) and glutathione (GSH) levels were assessed at
baseline and the end of the study. Result(s): Analyses were done in
the intention-to-treat population. No significant difference was observed
in the occurrence of POAF between the treatment (9.5%) and placebo (11.5%)
groups. Also, curcumin intervention did not alter serum concentration of
the hs-CRP, MDA, or GSH in comparison with placebo. Conclusion(s): In
conclusion, it seems that perioperative treatment with SinaCurcuminTM did
not prevent POAF after CABG surgery. Copyright © 2022 Mashhad
University of Medical Sciences. All rights reserved.

<79>
Accession Number
2025445990
Title
Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients
with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized
Controlled Trial.
Source
Current Vascular Pharmacology. 21(3) (pp 211-217), 2023. Date of
Publication: 2023.
Author
Xu J.; Zhu L.; Xie Y.; Zhang M.; Xiao Z.; Su R.; Wen T.; Liu L.
Institution
(Xu, Zhu, Xie, Zhang, Xiao, Su, Liu) Department of Cardiovascular
Medicine, The Second Xiangya Hospital, Central South University, Hunan
410011, China
(Xu, Zhu, Xie, Zhang, Xiao, Su, Liu) Research Institute of Blood Lipid and
Atherosclerosis, Central South University, Hunan 410011, China
(Xu, Zhu, Xie, Zhang, Xiao, Su, Liu) Modern Cardiovascular Disease
Clinical Technology Research Center of Hunan Province, Hunan 410011, China
(Xu, Zhu, Xie, Zhang, Xiao, Su, Liu) Cardiovascular Disease Research
Center of Hunan Province, Hunan 410011, China
(Wen) Department of Emergency Medicine, Second Xiangya Hospital, Central
South University, Hunan 410011, China
(Wen) Emergency Medicine and Difficult Diseases Institute, Second Xiangya
Hospital, Central South University, Hunan 410011, China
Publisher
Bentham Science Publishers
Abstract
Background: Hypertriglyceridemia, is commonly found in patients with
diabetes. Xuezhikang, an extract of red yeast rice, is effective in
reducing cardiovascular events in Chinese patients with diabetes and
coronary heart disease (CHD). Xuezhikang has been reported to
significantly decrease the level of triglycerides (TG), a potential causal
risk factor for myocardial infarction. On the basis of a similar reduction
in low-density lipoprotein cholesterol, this study will evaluate the
effect of xuezhikang on TG levels compared with pravastatin in patients
with type 2 diabetes mellitus (T2DM) and dyslipidemia. Method(s):
This is an open-label, multicenter, randomized controlled study to assess
the effects of xuezhikang (1.2 g/day) and pravastatin (20 mg/day) on TG
and other blood lipid parameters in patients with T2DM and dyslipidemia. A
total of 114 patients will be enrolled and randomly assigned 1:1 to
receive xuezhikang or pravastatin treatment for 6 weeks. Result(s):
The primary outcome measure is the change from baseline in fasting TG
levels after 6 weeks. The change from baseline in other fasting and
postprandial lipid parameters, and glucose profiles at 1, 2, and 4 h after
a nutritious breakfast will also be explored. Conclusion(s): This
study will evaluate the effect of a 6-week treatment with xuezhikang
compared with pravastatin on fasting and postprandial TG levels and other
blood lipid parameters in patients with T2DM and dyslipidemia without
atherosclerotic cardiovascular disease (ASCVD). The results will provide
more information on optimizing the lipid control of patients with diabetes
in the primary prevention of ASCVD. Trial Registration: Chinese Clinical
Trial Registry, ChiCTR2100046704. Registered 27 May 2021. Copyright
© 2023 The Author(s). Published by Bentham Science Publisher.

<80>
Accession Number
2024482550
Title
Association between nonalcoholic fatty liver disease and atrial
fibrillation and other clinical outcomes: a meta-analysis.
Source
Journal of Investigative Medicine. 71(6) (pp 591-602), 2023. Date of
Publication: August 2023.
Author
Jaiswal V.; Ang S.P.; Huang H.; Momi N.K.; Hameed M.; Naz S.; Batra N.;
Ishak A.; Doshi N.; Gera A.; Sharath M.; Waleed M.S.; Raj N.; Aguilera
Alvarez V.H.
Institution
(Jaiswal, Raj) JCCR Cardiology, Uttar Pradesh, Varanasi, India
(Jaiswal, Hameed, Ishak, Gera) Department of Research and Academic
Affairs, Larkin Community Hospital, South Miami, FL, United States
(Ang) Division of Internal Medicine, Rutgers Health/Community Medical
Center, Toms River, NJ, United States
(Huang) Royal College of Surgeons in Ireland, Dublin, Ireland
(Momi) Christian Medical College and Hospital, Punjab, Ludhiana, India
(Naz) The University of Texas, MD Anderson Cancer Center, Houston, TX,
United States
(Batra) Department of Internal Medicine, Beaumont Hospital, Royal Oak, MI,
United States
(Doshi) Department of Medicine, Pravara Institute of Medical Science,
Maharashtra, Ahmednagar, India
(Sharath) Bangalore Medical College and Research Institute, Karnataka,
Bengaluru, India
(Waleed) Lower Bucks Hospital, Bristol, PA, United States
(Raj) B.P Koirala Institute of Health Science, Dharan, Nepal
(Aguilera Alvarez) Autonomous University of Baja California, Mexicali, CA,
United States
Publisher
SAGE Publications Inc.
Abstract
The association between nonalcoholic fatty liver disease (NAFLD) with
cardiovascular and cerebrovascular outcomes, as well as their clinical
impact, has yet to be established in the literature. This meta-analysis
aims to evaluate the association between the NAFLD patients and the risk
of atrial fibrillation (AF), heart failure (HF), stroke, cardiovascular
mortality (CVM), and revascularization incidence. We performed a
systematic literature search using PubMed, Embase, Scopus, and Cochrane
libraries for relevant articles from inception until August 2022. A total
of 12 cohort studies with 18,055,072 patients (2,938,753 NAFLD vs
15,116,319 non-NAFLD) were included in our analysis. The mean age of the
NAFLD patients group and the non-NAFLD group was comparable (55.68 vs
55.87). The most common comorbidities among the NAFLD patients group
included hypertension (38% vs 24%) and diabetes mellitus (14% vs 8%). The
mean follow-up duration was 6.26 years. The likelihood of AF (risk ratio
(RR), 1.42 (95% CI 1.19, 1.68), p < 0.001), HF (RR, 1.43(95% CI 1.03,
2.00), p < 0.001), stroke (RR, 1.26(95% CI 1.16, 1.36), p < 0.001),
revascularization (RR, 4.06(95% CI 1.44, 11.46), p = 0.01), and CVM (RR,
3.10(95% CI 1.43, 6.73), p < 0.001) was significantly higher in the NAFLD
patients group compared to that of the non-NAFLD group. However, all-cause
mortality was comparable between both the groups of patients (RR, 1.30
(95% CI 0.63, 2.67), p = 0.48). In conclusion, the patients with NAFLD are
at increased risk of AF, HF, and CVM. Copyright © 2023 American
Federation for Medical Research.

<81>
Accession Number
2024388532
Title
Vascular access for transcatheter aortic valve replacement: A network
meta-analysis.
Source
Journal of Cardiology. 82(4) (pp 227-233), 2023. Date of Publication:
October 2023.
Author
Yokoyama Y.; Sakata T.; Mikami T.; Misumida N.; Scotti A.; Takagi H.;
Sugiura T.; Kuno T.; Latib A.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Sakata) Cardiovascular Research Institute, Icahn School of Medicine at
Mount Sinai, New York, NY, United States
(Mikami) Department of Neurology, Tufts Medical Center, Medford and
Somerville, MA, United States
(Misumida) Division of Cardiovascular Medicine, Gill Heart and Vascular
Institute, University of Kentucky, Lexington, United States
(Scotti, Kuno, Latib) Department of Cardiology, Montefiore Medical Center,
Albert Einstein College of Medicine, Bronx, NY, United States
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shimizu, Shizuoka, Japan
(Sugiura) Department of Cardiothoracic & Vascular Surgery, Montefiore
Medical Center, Albert Einstein College of Medicine, Bronx, New York,
United States
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Background: The choice of an alternative access for transcatheter aortic
valve replacement (TAVR) remains controversial when transfemoral (TF)
access is not feasible. Method(s): We conducted a network
meta-analysis to compare the outcomes of TAVR via various peripheral
vascular accesses. MEDLINE and EMBASE were searched through July 2022 to
identify studies that investigated outcomes in patients who underwent TAVR
via TF, trans-subclavian (Tsc), transcarotid (TC), or transcaval (Tcav)
access. A network meta-analysis was conducted via random-effects model.
Outcomes of interest were major or life-threatening bleeding, stroke,
major vascular complication, and 30-day mortality. Result(s): No
randomized trial was identified. Our analysis included 33 observational
studies that enrolled a total of 43,455 patients who underwent TAVR via TF
(n = 36,202), Tsc (n = 3869), TC (n = 3066), or Tcav (n = 318) access. The
risk of major or life-threatening bleeding was higher via Tsc compared
with TF [odds ratio (OR); 95 % confidence interval (CI) =1.51 (1.03-2.23),
p = 0.034]. The risk of stroke was higher via Tsc compared with TF and
Tcav [OR (95 % CI) =2.00 (1.14-3.52), p = 0.018, OR (95 % CI) =2.43
(1.03-5.74), p = 0.044, respectively]. The risk of major vascular
complications was lower via TC compared with Tsc, and Tcav and higher with
Tcav compared with TF and Tsc. 30-day mortality was higher via Tsc
compared with TF. Tsc was associated with higher risk of major or
life-threatening bleeding compared with TF, and higher risk of stroke
compared to TF and Tcav. Tcav had the highest risk of major vascular
complications. Conclusion(s): In patients who underwent TF, Tsc, TC,
or Tcav TAVR, Tsc had a higher rate of stroke compared to TF and Tcav, and
major or life-threatening bleeding compared to TF. The rate of major
vascular complications in Tcav was the highest among the four
approaches. Copyright © 2023 Elsevier Ltd

<82>
Accession Number
2024278697
Title
Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic
Review With Meta-Analysis for Comparison to Methylene Blue.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 37(9) (pp 1757-1772),
2023. Date of Publication: September 2023.
Author
Brokmeier H.M.; Seelhammer T.G.; Nei S.D.; Gerberi D.J.; Mara K.C.;
Wittwer E.D.; Wieruszewski P.M.
Institution
(Brokmeier, Nei, Wieruszewski) Department of Pharmacy, Mayo Clinic,
Rochester, MN
(Seelhammer, Wittwer, Wieruszewski) Department of Anesthesiology, Mayo
Clinic, Rochester, MN
(Gerberi) Mayo Medical Libraries, Mayo Clinic, Rochester, MN
(Mara) Department of Quantitative Health Sciences, Division of Clinical
Trials and Biostatistics, Mayo Clinic, Rochester, MN
Publisher
W.B. Saunders
Abstract
Hydroxocobalamin inhibits nitric oxide-mediated vasodilation, and has been
used in settings of refractory shock. However, its effectiveness and role
in treating hypotension remain unclear. The authors systematically
searched Ovid Medline, Embase, EBM Reviews, Scopus, and Web of Science
Core Collection for clinical studies reporting on adult persons who
received hydroxocobalamin for vasodilatory shock. A meta-analysis was
performed with random-effects models comparing the hemodynamic effects of
hydroxocobalamin to methylene blue. The Risk of Bias in Nonrandomized
Studies of Interventions tool was used to assess the risk of bias. A total
of 24 studies were identified and comprised mainly of case reports (n =
12), case series (n = 9), and 3 cohort studies. Hydroxocobalamin was
applied mainly for cardiac surgery vasoplegia, but also was reported in
the settings of liver transplantation, septic shock, drug-induced
hypotension, and noncardiac postoperative vasoplegia. In the pooled
analysis, hydroxocobalamin was associated with a higher mean arterial
pressure (MAP) at 1 hour than methylene blue (mean difference 7.80, 95% CI
2.63-12.98). There were no significant differences in change in MAP (mean
difference -4.57, 95% CI -16.05 to 6.91) or vasopressor dosage (mean
difference -0.03, 95% CI -0.12 to 0.06) at 1 hour compared to baseline
between hydroxocobalamin and methylene blue. Mortality was also similar
(odds ratio 0.92, 95% CI 0.42-2.03). The evidence supporting the use of
hydroxocobalamin for shock is limited to anecdotal reports and a few
cohort studies. Hydroxocobalamin appears to positively affect hemodynamics
in shock, albeit similar to methylene blue. Copyright © 2023
Elsevier Inc.

<83>
Accession Number
2023848459
Title
Improved mortality and haemodynamics with milrinone in cardiogenic shock
due to acute decompensated heart failure.
Source
ESC Heart Failure. 10(4) (pp 2577-2587), 2023. Date of Publication: August
2023.
Author
Rodenas-Alesina E.; Luis Scolari F.; Wang V.N.; Brahmbhatt D.H.;
Mihajlovic V.; Fung N.L.; Otsuki M.; Billia F.; Overgaard C.B.; Luk A.
Institution
(Rodenas-Alesina, Luis Scolari, Wang, Brahmbhatt, Mihajlovic, Fung,
Otsuki, Billia, Overgaard, Luk) Ted Rogers Centre for Heart Research,
Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
(Rodenas-Alesina, Luis Scolari, Wang, Brahmbhatt, Mihajlovic, Billia,
Overgaard, Luk) Department of Medicine, Division of Cardiology, University
of Toronto, Toronto, ON, Canada
(Brahmbhatt) National Heart & Lung Institute, Imperial College London,
London, United Kingdom
(Overgaard) Southlake Regional Health Centre, Newmarket, ON, Canada
Publisher
John Wiley and Sons Inc
Abstract
Aims: Studies in cardiogenic shock (CS) often have a heterogeneous
population of patients, including those with acute myocardial infarction
and acute decompensated heart failure (ADHF-CS). The therapeutic profile
of milrinone may benefit patients with ADHF-CS. We compared the outcomes
and haemodynamic trends in ADHF-CS receiving either milrinone or
dobutamine. Methods and Results: Patients presenting with ADHF-CS
(from 2014 to 2020) treated with a single inodilator (milrinone or
dobutamine) were included in this study. Clinical characteristics,
outcomes, and haemodynamic parameters were collected. The primary endpoint
was 30 day mortality, with censoring at the time of transplant or left
ventricular assist device implantation. A total of 573 patients were
included, of which 366 (63.9%) received milrinone and 207 (36.1%) received
dobutamine. Patients receiving milrinone were younger, had better kidney
function, and lower lactate at admission. In addition, patients receiving
milrinone received mechanical ventilation or vasopressors less frequently,
whereas a pulmonary artery catheter was more frequently used. Milrinone
use was associated with a lower adjusted risk of 30 day mortality (hazard
ratio = 0.52, 95% confidence interval 0.35-0.77). After
propensity-matching, the use of milrinone remained associated with a lower
mortality (hazard ratio = 0.51, 95% confidence interval 0.27-0.96). These
findings were associated with improved pulmonary artery compliance, stroke
volume, and right ventricular stroke work index. Conclusion(s): The
use of milrinone compared with dobutamine in patients with ADHF-CS is
associated with lower 30 day mortality and improved haemodynamics. These
findings warrant further study in future randomized controlled
trials. Copyright © 2023 The Authors. ESC Heart Failure published
by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

<84>
Accession Number
2026632719
Title
Outcomes of Concomitant Coronary Artery Bypass Grafting in Patients With
Infective Endocarditis: A Systematic Review and Meta-Analysis.
Source
American Journal of Cardiology. 205 (pp 354-359), 2023. Date of
Publication: 15 Oct 2023.
Author
Caldonazo T.; Kirov H.; Doenst T.; Tasoudis P.; Moschovas A.; Faerber G.;
Treml R.E.; Sa M.P.; Mukharyamov M.; Diab M.
Institution
(Caldonazo, Kirov, Doenst, Faerber, Mukharyamov, Diab) Departments of
Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany
(Tasoudis) Division of Cardiothoracic Surgery, The University of North
Carolina at Chapel Hill, Chapel Hill, NC, United States
(Moschovas) Department of Cardiothoracic Surgery, University Hospital
Wurzburg, Wurzburg, Germany
(Treml) Departments of Anesthesiology and Intensive Care Medicine,
Friedrich-Schiller-University Jena, Jena, Germany
(Sa) Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
(Sa) UPMC Heart and Vascular Institute, University of Pittsburgh Medical
Center, Pittsburgh, PA, United States
(Diab) Department of Cardiac Surgery, Herz- und Kreislaufzentrum,
Rotenburg an der Fulda, Germany
Publisher
Elsevier Inc.
Abstract
It is current practice to perform concomitant coronary artery bypass
grafting (CABG) in patients with infective endocarditis who have relevant
coronary artery disease. However, CABG may add complexity to the
operation. We performed a systematic review and a meta-analysis of studies
that presented outcomes from patients who underwent valve surgery because
of infective endocarditis with or without concomitant CABG. Three
databases were assessed. Perioperative mortality was the primary outcome.
Long-term mortality and postoperative stroke were the secondary outcomes.
Inverse variance method and random model were performed. Five studies with
a total of 5,408 patients were included. Mean follow-up was 8.2 years.
Just 1 study addressed exclusively patients with documented coronary
artery disease. Perioperative mortality did not differ between patients
with or without concomitant CABG (odds ratio 1.53, 95% confidence interval
0.52 to 4.48, p = 0.44). Long-term mortality did not differ between
patients who received and those who did not receive concomitant CABG (odds
ratio 1.79, confidence interval 0.88 to 3.65, p = 0.11). Only 1 study from
a multicenter registry reported data on the occurrence of postoperative
stroke, which demonstrated that its incidence after adjustment was 26% in
patients with concomitant CABG versus 21% in patients without concomitant
CABG (p = 0.003). The results suggest that in endocarditis patients,
adding CABG to valve surgery does not affect perioperative or long-term
mortality. Data available on the impact of concomitant CABG on neurologic
outcomes are limited to a retrospective multicenter registry and suggest
that concomitant CABG may be associated with higher postoperative
stroke. Copyright © 2023 The Authors

<85>
Accession Number
2026432966
Title
Pleural effusion secondary to endometriosis: A systematic review.
Source
American Journal of the Medical Sciences. 366(4) (pp 296-304), 2023. Date
of Publication: October 2023.
Author
Porcel J.M.; Sancho-Marquina P.; Monteagudo P.; Bielsa S.
Institution
(Porcel, Sancho-Marquina, Monteagudo, Bielsa) Pleural Medicine Unit,
Department of Internal Medicine, Arnau de Vilanova University Hospital
Hospital, IRBLleida, Universitat de Lleida, Lleida, Spain
Publisher
Elsevier B.V.
Abstract
Background: Endometriosis-associated pleural effusion is a rare occurrence
with poorly defined clinical characteristics. Method(s): A systematic
review was performed to examine all articles on endometriosis-associated
pleural effusion extracted from 4 databases (PubMed, Embase, Web of
Science and Scopus) from inception until November 2022. Result(s): A
total of 142 articles (isolated cases and small retrospective series)
involving 176 patients (median age 33 years) with endometriosis-associated
pleural effusion were included. The most frequent symptoms were dyspnea
(67%), chest pain (55%) and abdominal pain (40%). Pleural effusion was
predominantly unilateral (89%), right-sided (88.5%) and massive (56%).
Ascites was evident in 42% of the cases. Pleural fluid had a bloody
appearance in 99% of cases and always met the exudate criteria. Pleural
fluid cytology identified only 9% of the patients, with pleural biopsy
being the most common diagnostic procedure (74%). Most patients were
treated with hormones (76%), thoracic surgery (60%) and abdominal surgery
(27%). Effusion recurrence was observed in 26% of cases after a median
follow-up of 1 year. Conclusion(s): The presence of right-sided
hemorrhagic pleural effusion in a young woman warrants an assessment for
the possibility of endometriosis. Despite conventional treatment, effusion
recurs in approximately a quarter of patients. Copyright © 2023
Southern Society for Clinical Investigation

<86>
Accession Number
2025175675
Title
Randomized comparison of effects of two different remifentanil dose on
surgical conditions during endoscopic sinus surgery.
Source
BMC Anesthesiology. 23(1) (no pagination), 2023. Article Number: 292. Date
of Publication: December 2023.
Author
Jeong J.H.; Park C.W.; Yoon Y.J.; Lee D.J.; Cho S.Y.
Institution
(Jeong) Department of Otorhinolaryngology, Hanyang University Guri
Hospital, Guri-Si, Gyeonggi-Do, South Korea
(Park, Yoon, Lee, Cho) Department of Anesthesiology and Pain Medicine,
Hanyang University Guri Hospital, 249-1, Gyomun-Dong, Guri-Si, Gyeonggi-Do
471-701, South Korea
Publisher
BioMed Central Ltd
Abstract
Background: The combination of propofol and remifentanil results in better
surgical field conditions during endoscopic sinus surgery than inhalation
anesthesia. This study compared surgical field conditions between two
groups receiving low or high concentration of remifentanil and hemodynamic
variables using non-invasive cardiac monitoring. Method(s):
Fifty-four patients between ASA I or II, were randomly assigned to either
the high-concentration remifentanil group (HR), effect-site concentration
of 8 ng/mL or the low-concentration remifentanil group(LR), effect-site
concentration of 4 ng/mL. Surgical condition was evaluated using the
Boezaart Surgical Field Grading Scale presented by Boezaart. Cardiac
output was measured using non-invasive cardiac monitoring (CSN-1901).
 Result(s): In terms of surgical conditions, the HR group showed
significantly lower values than the LR group (p = 0.021) at 90 min after
the start of surgery. Heart rate was significantly lower in the HR group
than the LR group at 30, 60, and 90 min after the start of surgery (30
min; p = 0.005, 60 min; p = 0.002, 90 min; p = 0.001). There was a
statistically significant decrease of cardiac output in the HR group
compared to the LR group immediately after endotracheal intubation and at
30, 60, and 90 min after the start of surgery (Base; P = 0.222,
Intubation; P = 0.016, 30 min; p = 0.014, 60 min; P = 0.012, 90 min; P =
0.008). However, in the case of stroke volume, there was no significant
difference between the two groups in all measurements. Conclusion(s):
When comparing the HR group and the LR group, the surgical condition was
improved at 90 min after the start of surgery. MAP was lower in the HR
group and this was a result of reduction in cardiac output primarily
attributed to the decrease in heart rate rather than a decrease in stroke
volume. Trial registration: Clinical Trial Registry of the Republic of
Korea (KCT0006453). Copyright © 2023, BioMed Central Ltd., part
of Springer Nature.

<87>
Accession Number
2025159834
Title
Effect of right anterolateral thoracotomy versus median sternotomy on
postoperative wound tissue repair in patients with congenital heart
disease: A meta-analysis.
Source
International Wound Journal. (no pagination), 2023. Date of Publication:
2023.
Author
He R.; Zhang K.; Zhou C.; Pei C.
Institution
(He, Zhang, Zhou, Pei) Maternal and Child Health Hospital of Hubei
Province, Wuhan, China
Publisher
John Wiley and Sons Inc
Abstract
Right anterolateral thoracotomy (RAT) and median sternotomy (MS) are two
major methods for treatment of congenital cardiac disease. But there are
various types of surgery that provide a better operative outcome for the
patient. Therefore, we carried out a meta-analysis to investigate the
effects of these two methods in the treatment of wound tissue,
hospitalization and so on, to find out which surgery method could provide
the best short-term effect. In this research, we chose an English
controlled trial from 2003 to 2022 to evaluate the influence of right
anterolateral thoracotomy and median sternotomy on the short-term outcome
of Cardiopulmonary bypass (CPB), time of operation, time spent in the
hospital, and the time of scar formation. Our findings suggest that the
RAT method was associated with a shorter surgical scars for congenital
heart disease operations compared to MS with respect to post-operation
scars (WMD, 3.55; 95% CI, 0.04, 7.05; p = 0.05). The RAT method is better
suited to the needs of patients who care about their injuries.
Nevertheless, in addition to other surgery related factors which might
affect post-operative wound healing, we discovered that MS took a shorter
time to perform CPB compared with RAT surgery (WMD, - 1.94; 95% CI, -3.39,
-0.48; p = 0.009). Likewise, when it comes to the time taken to perform
surgery, MS needs less operational time compared to RAT methods (WMD,
-12.84; 95% CI, -25.27, -0.42; p = 0.04). On the other hand, the time
needed for MS to recover was much longer compared to the RAT (WMD, 0. 60;
95% CI, 0.02, 1.18; p = 0.04). This indicates that while RAT is
advantageous in terms of shortening the duration of post-operative scar,
it also increases the time needed for surgical operations and
CPB. Copyright © 2023 The Authors. International Wound Journal
published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.

<88>
Accession Number
2024699862
Title
Dual elevated remnant cholesterol and C-reactive protein in myocardial
infarction, atherosclerotic cardiovascular disease, and mortality.
Source
Atherosclerosis. 379 (no pagination), 2023. Article Number: 117141. Date
of Publication: August 2023.
Author
Doi T.; Langsted A.; Nordestgaard B.G.
Institution
(Doi, Langsted, Nordestgaard) Department of Clinical Biochemistry,
Copenhagen University Hospital, Herlev and Gentofte, Borgmester Ib Juuls
Vej 73, Herlev 2730, Denmark
(Doi, Langsted, Nordestgaard) The Copenhagen General Population Study,
Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester
Ib Juuls Vej 73, Herlev 2730, Denmark
(Doi, Langsted, Nordestgaard) Institute of Clinical Medicine, Faculty of
Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B,
Copenhagen 2200, Denmark
Publisher
Elsevier Ireland Ltd
Abstract
Background and aims: Elevated remnant cholesterol and low-grade
inflammation each cause atherosclerotic cardiovascular disease (ASCVD);
however, it is unknown whether joint elevation of both factors confers the
highest risk. We tested the hypothesis that dual elevated remnant
cholesterol and low-grade inflammation marked by elevated C-reactive
protein is associated with the highest risk of myocardial infarction,
ASCVD, and all-cause mortality. Method(s): The Copenhagen General
Population Study randomly recruited white Danish individuals aged 20-100
years in 2003-2015 and followed them for a median 9.5 years. ASCVD was
cardiovascular mortality, myocardial infarction, stroke, and coronary
revascularization. Result(s): In 103,221 individuals, we observed
2,454 (2.4%) myocardial infarctions, 5,437 (5.3%) ASCVD events, and 10,521
(10.2%) deaths. The hazard ratios increased with each of stepwise higher
remnant cholesterol and stepwise higher C-reactive protein. In individuals
with the highest tertile of both remnant cholesterol and C-reactive
protein compared to individuals with the lowest tertile of both, the
multivariable adjusted hazard ratios were 2.2 (95%CI:1.9-2.7) for
myocardial infarction, 1.9 (1.7-2.2) for ASCVD, and 1.4 (1.3-1.5) for
all-cause mortality. Corresponding values for only the highest tertile of
remnant cholesterol were 1.6 (1.5-1.8), 1.4 (1.3-1.5), and 1.1 (1.0-1.1),
and those for only the highest tertile of C-reactive protein were 1.7
(1.5-1.8), 1.6 (1.5-1.7), and 1.3 (1.3-1.4), respectively. There was no
statistical evidence for interaction between elevated remnant cholesterol
and elevated C-reactive protein on risk of myocardial infarction (p =
0.10), ASCVD (p = 0.40), or all-cause mortality (p = 0.74).
 Conclusion(s): Dual elevated remnant cholesterol and C-reactive
protein confers the highest risk of myocardial infarction, ASCVD, and
all-cause mortality, that is, compared to either of these two factors
individually. Copyright © 2023 The Authors

<89>
Accession Number
2026578155
Title
Long-Term Outcomes and Toxicity in Esophageal Cancer Patients after
Neoadjuvant or Definitive Concurrent Chemotherapy with Proton Beam
Therapy.
Source
International Journal of Radiation Oncology Biology Physics. Conference:
ASTRO 2023. San Diego United States. 117(2 Supplement) (pp e280-e281),
2023. Date of Publication: 01 Oct 2023.
Author
Abana C.O.; Carriere P.P.; Damen P.; van Rossum P.S.N.; Bravo P.L.; Wei
X.; Pollard J.M.; Nitsch P.L.; Murphy M.B.; Hofstetter W.; Liao Z.; Lin
S.H.
Institution
(Abana, Carriere, Liao, Lin) Department of Radiation Oncology, The
University of Texas MD Anderson Cancer Center, Houston, TX, United States
(Damen) Department of Radiation Oncology, The University Medical Center
Utrecht, Utrecht University, Utrecht, Netherlands
(van Rossum) Department of Radiation Oncology, Amsterdam University
Medical Center, Amsterdam, Netherlands
(Bravo, Wei) Department of Radiation Oncology Clinical Research, The
University of Texas MD Anderson Cancer Center, Houston, TX, United States
(Pollard, Nitsch) Department of Radiation Physics, The University of Texas
MD Anderson Cancer Center, Houston, TX, United States
(Murphy) Department of Gastrointestinal Medical Oncology, The University
of Texas, MD Anderson Cancer Center, Houston, TX, United States
(Hofstetter) Department of Thoracic and Cardiovascular Surgery, The
University of Texas MD Anderson Cancer Center, Houston, TX, United States
Publisher
Elsevier Inc.
Abstract
Purpose/Objective(s): Proton-beam therapy (PT) is increasingly utilized
over three dimensional-conformal radiation therapy (3D-CRT) and intensity
modulated radiation therapy (IMRT) photon irradiation for the treatment of
various malignancies due to better toxicity reduction. We investigated the
long-term outcomes and toxicity in esophageal cancer (EC) patients treated
with PT as part of their neoadjuvant concurrent chemoradiation followed by
surgery (nCRT) or definitive concurrent chemoradiation (dCRT) treatment
regimen. Materials/Methods: All consecutively treated, American Joint
Committee on Cancer 7th edition clinical stage I-IV EC patients
from 2006 to 2022 were retrospectively analyzed. Standard RT dose for most
patients was 50.4 Gy/28 fractions. nCRT patients had surgery within 4
months post-RT. Kaplan-Meier method was used to determine overall survival
(OS), locoregional recurrence-free survival (LRRFS) and distant
metastatic-free survival (DMFS). Acute and chronic RT-related toxicities
were graded with Common Terminology Criteria for Adverse Events version
4.0. Result(s): There were 510 EC PT patients: 204 (40%) had nCRT and
306 (60%) had dCRT. Most lesions were located in the lower esophagus, of
adenocarcinoma histology and treated with passive scatter PT. Overall
median follow-up was 72 months. Median, 3- and 5-year OS for all patients
were 43 months, 54.1% and 44.9%, respectively. Median LRRFS and DMFS were
not reached. Esophagitis was the most common grade >=3 (G3+) toxicity (59
patients; 28.9%, including a G4 and a G5 toxicity), followed by nausea (29
patients; 14.2%) and esophageal stricture (26 patients, 12.7%). With nCRT,
median, 3- and 5-year OS were 80 months, 64.7% and 56.1%, respectively,
while the median LRRFS and DMFS were not reached again. Their most common
G3+ toxicity was esophagitis in 14 patients (6.9%) followed by nausea (8
patients; 3.9%). An nCRT patient developed G4 RT pneumonitis. Pathological
complete response (pCR) was observed in 58 patients (28.4%).
Surgery-related pulmonary, cardiac and gastrointestinal complications were
reported in 38 (18.6%), 40 (19.6%) and 43 (21.1%) patients, respectively.
dCRT patients had a median follow-up of 65 months, and median, 3- and
5-year OS of 32 months, 46.7% and 37.0%, respectively. Although the median
LRRFS was not reached, the median DMFS was 74 months. The most observed
dCRT G3+ toxicity was esophagitis (45 patients, 22.1%: including both G4
and G5 patients) and then esophageal stricture (23 patients, 11.3%). A
dCRT patient developed G4 fistula. Conclusion(s): To our knowledge,
this is the largest single-institutional study on EC long-term outcomes
and toxicity using PT. Our cohort reveals good outcomes and mostly mild
CRT-related toxicities. Trimodality nCRT with protons demonstrates
excellent outcomes relative to the CROSS trial (49.4 months) with
identical pCR rate (29% in CROSS) and similar toxicity profile. nCRT with
protons should be studied rigorously in the current randomized phase III
trial NRG GI006. Copyright © 2023

<90>
Accession Number
2025141087
Title
Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary
Management.
Source
Diagnostics. 13(16) (no pagination), 2023. Article Number: 2698. Date of
Publication: August 2023.
Author
Carsote M.; Terzea D.; Vasilescu F.; Cucu A.-P.; Ciuche A.; Nistor C.
Institution
(Carsote) Department of Endocrinology, Carol Davila University of Medicine
and Pharmacy, Bucharest 020021, Romania
(Carsote) Department of Endocrinology, C.I. Parhon National Institute of
Endocrinology, Bucharest 020021, Romania
(Terzea) Department of Pathology, C.I. Parhon National Institute of
Endocrinology, Bucharest 020021, Romania
(Vasilescu) Department of Pathology, Dr. Carol Davila Central Military
Emergency University Hospital, Bucharest 020021, Romania
(Cucu, Ciuche, Nistor) Thoracic Surgery Department, Dr. Carol Davila
Central Military, Emergency University Hospital, Bucharest 020021, Romania
(Ciuche, Nistor) Department 4-Cardio-Thoracic Pathology, Thoracic Surgery
II Discipline, Carol Davila University of Medicine and Pharmacy, Bucharest
020021, Romania
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
We aimed to overview the most recent data on sternal metastases from a
multidisciplinary approach (diagnosis strategies, outcome, and
histological reports). This narrative review based on a PubMed search
(between January 2020 and 22 July 2023) using key words such as "sternal",
"manubrium", and "metastasis" within the title and/or abstract only
included original papers that specifically addressed secondary sternal
spreading of cancer in adults, for a total of 48 original articles (14
studies and 34 single case reports). A prior unpublished case in point is
also introduced (percutaneous incisional biopsy was used to address a 10
cm sternal tumour upon first admission on an apparently healthy male). The
studies (n = 14) may be classified into one of three groups: studies
addressing the incidence of bone metastases (including sternum) amid
different primary cancers, such as prostate cancer (N = 122 with bone
metastases, 83% of them with chest wall metastases), head and neck cancers
(N = 3620, 0.8% with bone metastases, and 10.34% of this subgroup with
sternum involvement); and glioblastoma (N = 92 with bone metastases, 37%
of them with non-vertebral metastases, including the sternum); assessment
cohorts, including breast cancer (N = 410; accuracy and sensitivity of
PET/CT vs. bone scintigraphy is superior with concern to sternum
spreading) and bone metastases of unknown origin (N = 83, including a
subgroup with sternum metastases; some features of PET/CT help the
differentiation with multiple myeloma); and cohorts with various
therapeutic approaches, such as palliative arterial embolization (N = 10),
thymic neuroendocrine neoplasia (1/5 detected with sternum metastases),
survival rates for sternum metastases vs. non-sternum chest wall
involvement (N = 87), oligo-metastatic (sternal) breast cancer (3 studies,
N = 16 for all of them), oligo-metastatic head and neck cancer (N = 81),
conformal radiotherapy (N = 24,215, including an analysis on sternum
spreading), and EBRT followed by MR-HIFU (N = 6). Core data coming from
the isolated case reports (N = 34) showed a female to male ratio of 1.6;
the females' ages were between 34 and 80 (mean of 57.28) and the males'
ages varied between 33 and 79 (average of 58.78) years. The originating
tumour profile revealed that the most frequent types were mammary (N = 8,
all females) and thyroid (N = 9, both women and men), followed by bladder
(N = 3), lung (N = 2), and kidney (N = 2). There was also one case for
each of the following: adenoid cystic carcinoma of the jaw, malignant
melanoma, caecum MiNEN, a brain and an extracranial meningioma, tongue
carcinoma, cholangiocarcinoma, osteosarcoma, and hepatocellular carcinoma.
To our knowledge, this is the most complex and the largest analysis of
prior published data within the time frame of our methods. These data open
up new perspectives of this intricate, dynamic, and challenging domain of
sternum metastases. Awareness is a mandatory factor since the patients may
have a complex multidisciplinary medical and/or surgical background or
they are admitted for the first time with this condition; thus, the
convolute puzzle will start from this newly detected sternal lump.
Abbreviations: N = number of patients; n = number of studies; PET/CT =
positron emission tomography/computed tomography; EVRT = external beam
radiotherapy; MR-HIFU = magnetic resonance-guided high-intensity focused
ultrasound; MiNEN = mixed neuroendocrine-non-neuroendocrine
tumour. Copyright © 2023 by the authors.

<91>
Accession Number
2026658165
Title
American Society of ExtraCorporeal Technology: Development of Standards
and Guidelines for Pediatric and Congenital Perfusion Practice (2019).
Source
Journal of Extra-Corporeal Technology. 52(4) (pp 319-326), 2020. Date of
Publication: 01 Dec 2020.
Author
Oldeen M.E.; Angona R.E.; Hodge A.; Klein T.
Institution
(Oldeen) Division of Cardiovascular-Thoracic Surgery, Ann & Robert H.
Lurie Children's Hospital of Chicago, Chicago, IL, United States
(Angona) Strong Memorial Hospital, University of Rochester Medical Center,
Box Surg/Cardiac, Rochester, NY, United States
(Hodge) Cardiothoracic Surgery, The Heart Center, Nationwide Children's
Hospital, Columbus, OH, United States
(Klein) Cincinnati Children's Hospital Medical Center, Cincinnati, OH,
United States
Publisher
EDP Sciences
Abstract
The development of standards and guidelines by professional societies
offers clinicians guidance toward providing evidence-based care. The
ultimate goals of standards and guidelines are to standardize care and
improve patient safety and outcomes while also minimizing risk. The
American Society of ExtraCorporeal Technology (AmSECT) currently offers
perfusionists several clinical resources, primarily the Standards and
Guidelines for Perfusion Practice; however, no document exists specific to
pediatric perfusion. Historically, the development of a pediatric-specific
document has been limited by available scientific evidence because of
smaller patient populations, sample sizes, and variable techniques among
congenital perfusionists. In the current setting of evolving clinical
practices and increasingly complex cardiac operations, a subcommittee of
pediatric perfusionists developed the Standards and Guidelines for
Pediatric and Congenital Perfusion Practice. The development process
included a comprehensive literature review for supporting evidence to
justify new recommendations or updates to the existing AmSECT Adult
Standards and Guidelines document. Multiple revisions incorporating
feedback from the community led to a finalized document accepted by the
AmSECT member and made available electronically in May 2019. The Standards
and Guidelines for Pediatric and Congenital Perfusion Practice is an
essential tool for pediatric perfusionists, serves as the backbone for
institutionally based protocols, promotes improved decision-making, and
identifies opportunities for future research and collaboration with other
disciplines. The purpose of this article is to summarize the process of
development, the content, and recommended utilization of AmSECT's
Standards and Guidelines for Pediatric and Congenital Perfusion Practice.
AmSECT recommends adoption of the Standards and Guidelines for Pediatric
and Congenital Perfusion Practice to reduce practice variation and enhance
clinical safety. Copyright © 2020 AMSECT.

<92>
Accession Number
2026658164
Title
Sleep Quality after Coronary Artery Bypass Graft Surgery: Comparing
Pulsatile and Nonpulsatile Pump Flow.
Source
Journal of Extra-Corporeal Technology. 52(4) (pp 314-318), 2020. Date of
Publication: 01 Dec 2020.
Author
Mirmohammadsadeghi A.; Jahannama N.; Mirmohammadsadeghi M.
Institution
(Mirmohammadsadeghi, Jahannama, Mirmohammadsadeghi) Chamran Heart Center,
Isfahan University of Medical Sciences (IUMS), Isfahan, Iran, Islamic
Republic of
Publisher
EDP Sciences
Abstract
Poor postoperative sleep quality is a common problem in patients
undergoing coronary artery bypass graft surgery (CABG). The purpose of
this study was to compare the effect of pulsatile and nonpulsatile pump
flow on sleep quality of these patients. In this clinical trial, 52
patients undergoing on pump CABG surgery with the roller pump were
randomly divided into two equal groups of 26 patients: group 1 using
pulsatile pump flow and group 2 nonpulsatile pump flow while the heart was
arrested. Sleep score of both groups was evaluated by Pittsburgh Sleep
Quality Index questionnaire 2 days before operation and 1 month after
operation, and they were compared with each other. Analysis was performed
with SPSS software version 22 (SPSS for Windows Inc., Chicago, IL) using
the independent t-test, chi-square test, and Fisher exact test. Both
groups were the same in demographic characteristics and risk factors such
as age, gender, diabetes mellitus, hypertension, hyperlipidemia, smoking,
body mass index, and preoperative ejection fraction. Operation data showed
no difference between two groups considering cardiopulmonary bypass time
and cardiac arrest time. Preoperative sleep quality score of both groups
had no significant difference (p =.84). One month postoperative sleep
quality score of the pulsatile group was significantly better than that of
the nonpulsatile group (p =.04). Using pulsatile flow cardiopulmonary
bypass can effectively decrease postoperative sleep disorders in
comparison to nonpulsatile flow. Copyright © 2020 AMSECT.

<93>
Accession Number
2026677782
Title
Expert Systematic Review on the Choice of Conduits for Coronary Artery
Bypass Grafting: Endorsed by the European Association for Cardio-Thoracic
Surgery (EACTS) and The Society of Thoracic Surgeons (STS).
Source
Annals of Thoracic Surgery. (no pagination), 2023. Date of Publication:
2023.
Author
Gaudino M.; Bakaeen F.G.; Sandner S.; Aldea G.S.; Arai H.; Chikwe J.;
Firestone S.; Fremes S.E.; Gomes W.J.; Bong-Kim K.; Kisson K.; Kurlansky
P.; Lawton J.; Navia D.; Puskas J.D.; Ruel M.; Sabik J.F.; Schwann T.A.;
Taggart D.P.; Tatoulis J.; Wyler von Ballmoos M.
Institution
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York-Presbyterian Hospital, New York, NY, United States
(Bakaeen) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Cleveland, OH, United States
(Sandner) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Aldea) Division of Cardiothoracic Surgery, University of Washington
School of Medicine, Seattle, WA, United States
(Arai) Department of Cardiovascular Surgery, Graduate School of Medical
and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo,
Japan
(Chikwe) Department of Cardiac Surgery, Smidt Heart Institute,
Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Firestone, Kisson) The Society of Thoracic Surgeons, Chicago, IL, United
States
(Fremes) Schulich Heart Centre, Sunnybrook Health Sciences Centre, and the
Institute of Health Policy Management and Evaluation, University of
Toronto, Toronto, ON, Canada
(Gomes) Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo
Hospital, Escola Paulista de Medicina, Universidade Federal de Sao Paulo
(Unifesp), SP, Sao Paulo, Brazil
(Bong-Kim) Cardiovascular Center, Myong-ji Hospital, Gyeong-gi-do, South
Korea
(Kurlansky) Division of Cardiac Surgery, Department of Surgery, Columbia
University, New York, NY, United States
(Lawton) Division of Cardiac Surgery, Department of Surgery, Johns Hopkins
University, Baltimore, MD, United States
(Navia) Department of Cardiac Surgery, ICBA Instituto Cardiovascular,
Buenos Aires, Argentina
(Puskas) Department of Cardiovascular Surgery, Mount Sinai Saint Luke's,
New York, NY, United States
(Ruel) Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada
(Sabik) Department of Surgery, University Hospitals Cleveland Medical
Center, Cleveland, OH, United States
(Schwann) Division of Cardiac Surgery, Baystate Health, Springfield, MA,
United States
(Taggart) Department of Cardiac Surgery, John Radcliffe Hospital,
University of Oxford, Oxford, United Kingdom
(Tatoulis) Department of Cardiothoracic Surgery, Royal Melbourne Hospital,
University of Melbourne, Melbourne, Australia
(Wyler von Ballmoos) Division of Cardiothoracic Surgery, Houston Methodist
DeBakey Heart & Vascular Center, Houston, TX, United States
Publisher
Elsevier Inc.

<94>
Accession Number
2026303788
Title
Serratus anterior and pectoralis plane blocks for robotically assisted
mitral valve repair: a randomised clinical trial. Comment on Br J Anaesth
2023; 130: 786-94.
Source
British Journal of Anaesthesia. (no pagination), 2023. Date of
Publication: 2023.
Author
Xue F.S.; Gao X.; Li C.W.
Institution
(Xue, Gao, Li) Department of Anesthesiology, Beijing Friendship Hospital,
Capital Medical University, Beijing, China
Publisher
Elsevier Ltd

<95>
Accession Number
642138643
Title
Early Left Atrial Venting versus Conventional Treatment for Left
Ventricular Decompression during Venoarterial Extracorporeal Membrane
Oxygenation Support: The EVOLVE-ECMO Randomised Clinical Trial.
Source
European journal of heart failure. (no pagination), 2023. Date of
Publication: 29 Aug 2023.
Author
Park H.; Yang J.H.; Ahn J.-M.; Kang D.-Y.; Lee P.H.; Kim T.O.; Choi K.H.;
Kang P.J.; Jung S.-H.; Yun S.-C.; Park D.-W.; Lee S.-W.; Park S.-J.; Kim
M.-S.
Institution
(Park, Ahn, Kang, Lee, Kim, Park, Lee, Park, Kim) Division of Cardiology,
Department of Internal Medicine, Asan Medical Center Heart Institute,
University of Ulsan College of Medicine, Seoul, South Korea
(Park) Division of Cardiology, Department of Medicine, Gangneung Asan
Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
(Yang, Choi) Division of Cardiology, Department of Internal Medicine,
Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea
(Kang, Jung) Department of Thoracic and Cardiovascular Surgery, Asan
Medical Center, University of Ulsan College of Medicine, Seoul, South
Korea
(Yun) Department of Clinical Epidemiology and Biostatistics, Asan Medical
Center, University of Ulsan College of Medicine, Seoul, South Korea
Publisher
NLM (Medline)
Abstract
AIMS: Few studies have reported data on the optimal timing of left
ventricular (LV) unloading during venoarterial extracorporeal membrane
oxygenation (VA-ECMO) for cardiac arrest or shock. This study evaluated
the feasibility of an early LV unloading strategy compared with a
conventional strategy in VA-ECMO. METHODS AND RESULTS: Between December
2018 and August 2022, 60 patients at two institutions were randomised in a
1:1 ratio to receive early (n=30) or conventional (n=30) LV unloading
strategies. The early LV unloading strategy was defined as LV unloading
performed at the time of VA-ECMO insertion. LV unloading was performed
using a percutaneous transseptal left atrial cannulation via the femoral
vein incorporated into the ECMO venous circuit. The early and conventional
LV unloading groups included 29 (96.7%) and 23 (76.7%) patients,
respectively (median time from VA-ECMO insertion to LV unloading: 48.4h,
interquartile range 47.8-96.5h). The groups showed no significant
differences in the rate of VA-ECMO weaning as the primary endpoint (70.0%
vs. 76.7%; relative risk, 0.91; 95% confidence interval, 0.67-1.24;
P=0.386) and survival to discharge (53.3% vs. 50.0%, P=0.796). However,
the pulmonary congestion score index at 48h after LV unloading was
significantly improved only in the early LV unloading group (2.0+/-0.7 vs.
1.7+/-0.6 at baseline vs. at 48h; P=0.008). CONCLUSION(S): Compared
with the conventional approach, early LV unloading did not improve the
VA-ECMO weaning rate, despite the rapid improvement in pulmonary
congestion. Therefore, the results of this study do not support the
application of this strategy after VA-ECMO insertion. Copyright This
article is protected by copyright. All rights reserved.

<96>
Accession Number
642138076
Title
Oesophagopleural fistula after pneumonectomy: A systematic review and case
series.
Source
Annals of the Royal College of Surgeons of England. (no pagination),
2023. Date of Publication: 29 Aug 2023.
Author
Phelan L.; Layton G.R.; Lee E.H.; Hallle-Smith J.; Bishay E.; Griffiths
E.A.
Institution
(Phelan, Hallle-Smith, Bishay, Griffiths) University Hospitals Birmingham
NHS Foundation Trust, United Kingdom
(Layton) University Hospitals of Leicester NHS Trust, United Kingdom
(Lee) University of Birmingham Medical School, United Kingdom
(Griffiths) Institute of Cancer and Genomic Sciences, College of Medical
and Dental Sciences, University of Birmingham, United Kingdom
Publisher
NLM (Medline)
Abstract
INTRODUCTION: There is a paucity of data on the optimal management of
oesophagopleural fistula (OPF) following pneumonectomy. The current
published literature is limited to case reports and small case series.
Although rare, OPF can have a significant impact on both the morbidity and
mortality of patients. METHOD(S): Two cases of OPF managed at our
institution were reported. A systematic review was then conducted in line
with Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidance concerning OPF following pneumonectomy. Demographic, operative
and management data were analysed. FINDINGS: Systematic review-identified
data pertaining to 59 patients from 31 papers was collated. Median patient
age was 59.5 years with pneumonectomy performed typically for malignancy
(68%) or tuberculosis (19%). Median time from pneumonectomy to a diagnosis
of OPF was 12.5 months. Twenty-five per cent of the patients had a
synchronous bronchopleural fistula. Management of OPF in this setting is
heterogenous. Conservative management was often reserved for asymptomatic
or unfit patients. The remainder underwent endoscopic or surgical
correction of the fistulae or a combination of the two with varying
outcomes. Median follow-up was 18 months. All-cause mortality was 31%
(18/59) with a median duration from pneumonectomy to death of 35 days
(range 1-1,095). CONCLUSION(S): Major heterogeneity of management for
this rare complication hinders the introduction of standardised guidance
of post-pneumonectomy OPF. Surgical and endoscopic intervention is
feasible and can be successful in specialist centres. Adopting an
multidisciplinary team approach involving both oesophagogastric and
thoracic surgery teams and the introduction of a registry database of
postoperative complications are likely to yield optimal outcomes.

<97>
Accession Number
642137615
Title
Effect of colchicine on perioperative atrial fibrillation and myocardial
injury after non-cardiac surgery in patients undergoing major thoracic
surgery (COP-AF): an international randomised trial.
Source
Lancet (London, England). (no pagination), 2023. Date of Publication: 25
Aug 2023.
Author
Conen D.; Ke Wang M.; Popova E.; Chan M.T.V.; Landoni G.; Cata J.P.;
Reimer C.; McLean S.R.; Srinathan S.K.; Reyes J.C.T.; Grande A.M.; Tallada
A.G.; Sessler D.I.; Fleischmann E.; Kabon B.; Voltolini L.; Cruz P.;
Maziak D.E.; Gutierrez-Soriano L.; McIntyre W.F.; Tandon V.;
Martinez-Tellez E.; Guerra-Londono J.J.; DuMerton D.; Wong R.H.L.; McGuire
A.L.; Kidane B.; Roux D.P.; Shargall Y.; Wells J.R.; Ofori S.N.; Vincent
J.; Xu L.; Li Z.; Eikelboom J.W.; Jolly S.S.; Healey J.S.; Devereaux P.J.
Institution
(Conen, McIntyre, Jolly, Devereaux) Population Health Research Institute,
Hamilton, ON, Canada; Department of Medicine, McMaster University,
Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and
Impact, McMaster University, Hamilton, ON, Canada
(Ke Wang, Ofori, Xu, Eikelboom, Healey) Population Health Research
Institute, Hamilton, ON, Canada; Department of Medicine, McMaster
University, Hamilton, ON, Canada
(Popova) Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain;
Centro Cochrane Iberoamericano, Barcelona, Spain
(Chan) Chinese University of Hong Kong, Hong Kong Special Administrative
Region, Shatin, China
(Landoni) Department of Anesthesia and Intensive Care, IRCCS San Raffaele
Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute
University San Raffaele, Milan, Italy
(Cata, Guerra-Londono) Department of Anesthesiology and Perioperative
Medicine, University of Texas MD Anderson Cancer Center, Houston, TX,
United States
(Reimer) Department of Anesthesiology, Queen's University, Kingston Health
Sciences Centre, Kingston, ON, Canada
(McLean) Vancouver Acute Department of Anesthesia and Perioperative
Medicine, Vancouver General Hospital, Vancouver, BC, Canada
(Srinathan, Kidane) Department of Surgery, University of Manitoba,
Winnipeg, MB, Canada
(Reyes, Martinez-Tellez) Department of Thoracic Surgery, Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain
(Grande, Roux) Hospital Universitario Ramon y Cajal, Madrid, Spain
(Tallada) Department of Anesthesiology, Vall d'Hebron Hospital
Universitari, Barcelona, Spain
(Sessler) Department of Outcomes Research, Cleveland Clinic, Cleveland,
OH, United States
(Fleischmann, Kabon) Department of Anesthesia, Intensive Care Medicine and
Pain Medicine, Medical University of Vienna, Vienna, Austria
(Voltolini) Thoracic Surgery Unit, University Hospital Careggi, Florence,
Italy
(Cruz) Service of Anesthesiology and Reanimation, General University
Hospital Gregorio Maranon, Madrid, Spain
(Maziak) Division of Thoracic Surgery, Department of Surgery, Ottawa
Hospital, University of Ottawa, Ottawa, ON, Canada
(Gutierrez-Soriano) Anesthesiology Department, Anesthesiology Research
Group, Fundacion Cardioinfantil-Instituto de Cardiologia, Bogota, Colombia
(Tandon) Department of Medicine, McMaster University, Hamilton, ON, Canada
(DuMerton) Kingston Health Sciences Centre, Kingston, ON, Canada
(Wong) Division of Cardiothoracic Surgery, Department of Surgery, Chinese
University of Hong Kong, Hong Kong Special Administrative Region, China
(McGuire) Division of Thoracic Surgery, Vancouver General Hospital,
Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
(Shargall) Division of Thoracic Surgery, Department of Surgery, Faculty of
Health Sciences, McMaster University, Hamilton, ON, Canada
(Wells, Vincent, Li) Population Health Research Institute, Hamilton, ON,
Canada
Publisher
NLM (Medline)
Abstract
BACKGROUND: Higher levels of inflammatory biomarkers are associated with
an increased risk of perioperative atrial fibrillation and myocardial
injury after non-cardiac surgery (MINS). Colchicine is an
anti-inflammatory drug that might reduce the incidence of these
complications. METHOD(S): COP-AF was a randomised trial conducted at
45 sites in 11 countries. Patients aged 55 years or older and undergoing
major non-cardiac thoracic surgery were randomly assigned (1:1) to receive
oral colchicine 0.5 mg twice daily or matching placebo, starting within 4
h before surgery and continuing for 10 days. Randomisation was done with
use of a computerised, web-based system, and was stratified by centre.
Health-care providers, patients, data collectors, and adjudicators were
masked to treatment assignment. The coprimary outcomes were clinically
important perioperative atrial fibrillation and MINS during 14 days of
follow-up. The main safety outcomes were a composite of sepsis or
infection, and non-infectious diarrhoea. The intention-to-treat principle
was used for all analyses. This trial is registered with
ClinicalTrials.gov, NCT03310125. FINDINGS: Between Feb 14, 2018, and June
27, 2023, we enrolled 3209 patients (mean age 68 years [SD 7], 1656
[51.6%] male). Clinically important atrial fibrillation occurred in 103
(6.4%) of 1608 patients assigned to colchicine, and 120 (7.5%) of 1601
patients assigned to placebo (hazard ratio [HR] 0.85, 95% CI 0.65 to 1.10;
absolute risk reduction [ARR] 1.1%, 95% CI -0.7 to 2.8; p=0.22). MINS
occurred in 295 (18.3%) patients assigned to colchicine and 325 (20.3%)
patients assigned to placebo (HR 0.89, 0.76 to 1.05; ARR 2.0%, -0.8 to
4.7; p=0.16). The composite outcome of sepsis or infection occurred in 103
(6.4%) patients in the colchicine group and 83 (5.2%) patients in the
placebo group (HR 1.24, 0.93-1.66). Non-infectious diarrhoea was more
common in the colchicine group (134 [8.3%] events) than the placebo group
(38 [2.4%]; HR 3.64, 2.54-5.22). INTERPRETATION: In patients undergoing
major non-cardiac thoracic surgery, administration of colchicine did not
significantly reduce the incidence of clinically important atrial
fibrillation or MINS but increased the risk of mostly benign
non-infectious diarrhoea. FUNDING: Canadian Institutes of Health Research,
Accelerating Clinical Trials Consortium, Innovation Fund of the
Alternative Funding Plan for the Academic Health Sciences Centres of
Ontario, Population Health Research Institute, Hamilton Health Sciences,
Division of Cardiology at McMaster University, Canada; Hanela Foundation,
Switzerland; and General Research Fund, Research Grants Council, Hong
Kong. Copyright © 2023 Elsevier Ltd. All rights reserved.

<98>
Accession Number
642137389
Title
A Nationwide Evaluation of Cardiothoracic Resident Research Productivity.
Source
The Annals of thoracic surgery. (no pagination), 2023. Date of
Publication: 26 Aug 2023.
Author
Narahari A.K.; Patel P.D.; Chandrabhatla A.S.; Wolverton J.; Lantieri
M.A.; Sarkar A.; Mehaffey J.H.; Wagner C.M.; Ailawadi G.; Pagani F.D.;
Likosky D.S.
Publisher
NLM (Medline)
Abstract
BACKGROUND: Evaluating the research productivity of cardiothoracic (CT)
surgery residents during their training and early career is crucial for
tracking their academic development. To this end, the training pathway of
residents and the characteristics of their program in relation to their
productivity was evaluated. METHOD(S): Alumni lists from integrated
6-year thoracic surgery (I-6) and traditional thoracic surgery residency
programs were collected. A Python script was utilized to search PubMed for
publications and the iCite database for citations from each trainee.
Publications over a 20-year time span were stratified by the year of
publication in relation to the trainee's graduation from thoracic surgery
residency. Trainees were analyzed by training program type, institutional
availability of a cardiothoracic T32 training grant, and protected
academic development time. RESULT(S): A total of 741 CT graduates
(I-6: 70, Traditional: 671) spanning 1971-2021 from 57 programs published
over 23,000 manuscripts. I-6 trainees published significantly more
manuscripts during medical school and residency compared to traditional
trainees. Trainees at institutions with CT T32 training grants published
significantly more manuscripts than those at non-T32 institutions (13 vs.
9; p = 0.0048). I-6 trainees publish more manuscripts at programs with
dedicated academic development time compared to trainees at programs
without protected time (22 vs. 9; p = 0.004). CONCLUSION(S): I-6
trainees publish significantly more manuscripts during medical school and
residency compared to their traditional colleagues. Trainees at
institutions with T32 training grants and dedicated academic development
time publish a higher number of manuscripts than trainees without those
opportunities. Copyright © 2023. Published by Elsevier Inc.

EPICORE Embase Updates

Saturday, September 9, 2023

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me